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Abstract 
Amyotrophic Lateral Sclerosis (ALS) is the most common adult onset motor neuron (MN) 
disorder, characterised by muscle wasting due to MN death. Astrocytes play an important 
role in disease progression in the SOD1G93A transgenic mouse model and patients of ALS. 
Although astrocytes display a selective toxicity to MN, the toxic factor(s) have not been 
identified. We hypothesise that differential gene expression in SOD1-ALS astrocytes will 
reveal targets for therapeutic intervention. Microarray analysis was performed upon Laser 
Capture Microdissected astrocytes isolated from spinal cord of symptomatic (90 day) and 
late-stage (120 day) SOD1G93A mice and non-transgenic (NTg) littermates, and from post-
mortem human SOD1-ALS and control spinal cord. Functional studies were performed using 
enzymatic activity assays and immunohistochemistry upon spinal cord and in vitro validation 
studies were performed using murine neonatal cultures of astrocytes, microglia and 
embryonic MNs and “i-astrocytes” directly converted from human ALS fibroblasts. In murine 
astrocytes annotation clustering analysis showed increased expression of lysosomal 
transcripts which were validated by qPCR . Using functional experiments, we have found 
significantly higher activity of the lysosomal enzyme β-hexosamindase in the spinal cord of 
SOD1G93A mice. Immune response and phagocytic pathways are also enriched within both 
datasets, and phagocytosis assays using fluorescently labelled NSC34 cell debris show that 
SOD1G93A astrocytes engulf significantly higher amounts of neuronal debris compared to NTg 
controls, highlighting an increased reactivity of astrocytes at symptom onset. Human SOD1-
astrocytes show down-regulation of transcripts involved in tight junction formation such as 
ZO-2, Claudin-5 and Occludin, and we hypothesise that ALS-astrocytes contribute to the 
breakdown in blood-brain-barrier (BBB) integrity seen in ALS. qPCR confirmed differential 
expression of BBB-influencing genes such as claudin-5, junctional adhesion molecule 2 and 
transforming growth factor beta-2. Model BBBs made with i-astrocytes from human 
patients co-cultured with endothelia show significantly lower transendothelial electrical 
resistance and dextran-permeability values pointing to an astrocyte role in increased BBB 
permeability during disease. These studies show the breadth of behaviours displayed by 
astrocytes during ALS disease progression and will provide an important guide for future 
therapeutic intervention. 
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CHAPTER 1 
Introduction 
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1. Introduction 
1.1 Motor neuron disease 
Motor neurons are cells which convey electrical information from the motor cortex to 
the musculature to bring about movement. Motor neurons can be divided into upper 
and lower motor neurons, depending upon which part of the central nervous system 
(CNS) their cell bodies are contained within. In general, information regarding 
movement is sent along upper motor neurons which originate in the motor cortex, 
through the brainstem and into the spinal cord via the corticospinal tract. These 
neurons communicate with lower motor neurons which originate in the brainstem and 
the ventral horn of the spinal cord and project to the musculature.  
Motor neuron disease encompasses a group of neurodegenerative conditions which 
feature a progressive loss of motor neurons leading to loss of muscular movement. 
Several conditions exist, dependent upon the site of onset and subsequent 
neurodegeneration (Al-Chalabi and Hardiman, 2013). For example, degeneration of 
upper motor neurons with unaffected lower motor neurons is termed primary lateral 
sclerosis (PLS); degeneration of lower motor neurons with unaffected upper motor 
neurons is termed progressive muscular atrophy (PMA) and degeneration of both 
upper and lower motor neurons is termed amyotrophic lateral sclerosis (ALS). These 
disorders exist on a spectrum whereby PLS and PMA exist at the extremes and ALS 
features differing proportions of upper and lower motor neuron involvement. Motor 
neuron disease also includes progressive bulbar palsy (a.k.a. bulbar ALS), which 
features degeneration of upper and/or lower motor neurons supplying the muscles 
responsible for speech and swallowing.  
1.2 Amyotrophic lateral sclerosis 
Amyotrophic lateral sclerosis was first described by Jean Martin Charcot in 1869 and is 
the most common of the motor neuron diseases (Cooper-Knock et al., 2013). The 
progressive loss of motor neurons and thus muscular movement leads to death, 
typically from respiratory muscle failure, within 2-3 years of symptom onset. ALS 
occurs in approximately 2 per 100,000 population with incidence enhanced by factors 
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such as: increasing age; gender (~1.5:1 male to female ratio); and genetic susceptibility 
– where ~5-10% of ALS cases are caused by genetic mutations (Table 1.1) (Al-Chalabi 
and Hardiman, 2013). ALS caused by these genetic mutations is termed familial ALS 
(fALS) whereas the remaining ~90-95% of ALS cases have no known family history and 
are known as sporadic ALS (sALS). sALS patients may also have mutations in some of 
the key causative genes, but their disease occurrence may also be due to 
environmental factors such as smoking, exercise and exposure to certain toxins (Al-
Chalabi and Hardiman, 2013). Currently, the drug riluzole (trade name Rilutek) is the 
only treatment which exerts a neuroprotective effect in ALS, and extends life by 2-3 
months on average (Miller et al., 2007). 
ALS is classified using the El Escorial criteria (Brooks, 1994) which lay down the disease 
symptoms that are required, supportive, compatible or that rule out disease diagnosis 
(Ince et al., 1998a). For example, the required symptoms for ALS diagnosis are the 
presence of upper and lower motor neuron signs and evidence of disease  progression. 
The El Escorial criteria have been updated since they were first established. For 
example the Awaji-Shima recommendations proposed a larger involvement of 
electrophysiology data in diagnosis, and have subsequently led to a more consistent 
set of patients entering clinical trials (Costa et al., 2012). ALS progression is measured 
using the revised ALS functional rating scale (ALSFRS-R) which consists of 12 questions 
regarding the regions of the body that might be affected by the disease (Rutkove, 
2015). Although 2-3 years is the median survival of patients with ALS, the speed of 
disease progression is variable. Rapid progression is predicted by bulbar site of onset 
and asymmetrical (i.e. predominantly left or right-sided) degeneration with mixed 
upper and lower motor neuron involvement (Wijesekera et al., 2009). Other factors 
associated with rapid disease progression are: higher age of onset, short duration from 
first symptom to diagnosis and whether or not there is cognitive impairment (Al-
Chalabi and Hardiman, 2013).  
With reference to cognitive impairment, ALS is now known to exist on a spectrum with 
fronto-temporal dementia (FTD), with variable cognitive involvement depending upon 
the ALS subtype (Giordana et al., 2011). FTD is the second most common form of 
dementia after Alzheimer’s disease (AD) leading to neuronal death in the frontal and  
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temporal lobes of the brain. FTD shares pathological features with ALS such as protein 
inclusions and also shares some of the same causative genes. 
1.3 Genetic Subtypes of ALS 
Although 90-95% of ALS cases have no known hereditary cause, mutations or 
expansions in several genes are now known to cause or increase vulnerability to ALS 
(Table 1.1). The first discovered gene which when mutated gave rise to ALS was the 
gene coding for Cu/Zn superoxide dismutase 1 (SOD1) (Rosen et al., 1993). The most 
common ALS-linked genes include FUS (Kwiatkowski et al., 2009, Vance et al., 2009) 
and TARDBP (Sreedharan et al., 2008) which encode proteins involved in RNA 
processing. In 2011, a non-coding expansion consisting of GGGGCC repeats in 
chromosome 9 open reading frame 72 (C9ORF72) was identified as accounting for up 
to 50% of fALS and a significant proportion of sALS (up to 8%) cases (Renton et al., 
2011, DeJesus-Hernandez et al., 2011). The involvement of cognitive deficits is variable 
depending upon the genetic subtype of ALS, for example SOD1-ALS features nearly no 
involvement of FTD whereas C9ORF72-ALS cases feature up to 50% FTD involvement 
(Byrne et al., 2012).  
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Table 1.1 Major genes conferring susceptibility to ALS. FTD = fronto-temporal dementia. Data obtained from the ALSoD database 
(http://alsod.iop.kcl.ac.uk/) 
ALS 
subtype 
Gene affected Gene symbol Chromosomal locus Proportion 
of fALS 
(approx.) 
Reference 
ALS1 superoxide dismutase 1 SOD1 21q22 20% (Rosen et al., 1993) 
ALS2 alsin ALS 2q33 Rare (Yang et al., 2001) 
ALS3 Unknown  18q21  (Hand et al., 2002) 
ALS4 senataxin SETX 9q34 Rare (Chen et al., 2004) 
ALS5 spatacsin SPG11 15q15-q21 Rare (Orlacchio et al., 2010) 
ALS6 fused in sarcoma FUS 16p11.2 4% (Kwiatkowski et al., 2009, Vance et al., 
2009) 
ALS7 Unknown  20-ptel-p13 Rare (Sapp et al., 2003) 
ALS8 vesicle associated membrane protein 2B VAPB 20q13.3 <1% (Nishimura et al., 2004) 
ALS9 angiogenin ANG 14q11.2 1% (Greenway et al., 2006) 
ALS10 TAR DNA binding protein TARDBP 1p36.2 5% (Sreedharan et al., 2008) 
ALS11 Polyphosphoinositide phosphatase FIG4 6q21 <1% (Chow et al., 2009) 
ALS12 optineurin OPTN 10p13 <1% (Maruyama et al., 2010) 
ALS 13 ataxin 2 ATXN2 12q23-q24.1  (Elden et al., 2010) 
ALS 14 valosin-containing protein VCP 9p13  (Johnson et al., 2010) 
ALS 15 ubiquilin 2 UBQLN2 Xp11.21  (Deng et al., 2011) 
ALS 16 sigma non-opioid intracellular receptor 1 SIGMAR1 9p13  (Al-Saif et al., 2011) 
ALS 17 chromatin modifying protein 2B CHMP2B 3p12.1 <1% (Skibinski et al., 2005, Cox et al., 2010) 
ALS 18 profilin 1 PFN1 17p13.3  (Wu et al., 2012a) 
ALS 19 v-erb-b2 avian erythroblastic leukemia viral 
oncogene homolog 4 
ERBB4 2q33.3-q34  (Takahashi et al., 2013) 
ALS 20 heterogeneous nuclear ribonucleoprotein 
A1 
HNRNPA1 12q13.1  (Kim et al., 2013) 
ALS 21 matrin 3 MATR3 5q31.2  (Johnson et al., 2014) 
ALS- chromosome 9 open reading frame 72 C9ORF72 9q21-22 40-50% (Renton et al., 2011, DeJesus-Hernandez 
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ALS 
subtype 
Gene affected Gene symbol Chromosomal locus Proportion 
of fALS 
(approx.) 
Reference 
FTD1 et al., 2011) 
ALS-
FTD2 
coiled-coil-helix-coiled-coil-helix domain 
containing 10 
CHCHD10 22q11.23  (Bannwarth et al., 2014) 
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1.3.1 Superoxide dismutase 1 
Superoxide dismutase 1 (SOD1), mutations in which are the cause of ~20% of familial 
ALS (fALS) (Rosen et al., 1993), was the first and is therefore the most well-
characterised of the ALS-linked genes. Mutant SOD1 is widely used for transgenic 
animal models of the disease such as the SOD1G93A mouse (Gurney et al., 1994) and the 
SOD1G93R zebrafish (Ramesh et al., 2010). These models allow for detailed study of 
motor neurons and the surrounding glia during disease progression. At least 150 
different mutations in SOD1 are known to cause ALS, with all mutations being 
dominant apart from the N86S and D90A mutations which are also found to be 
recessive in Scandinavia (Turner and Talbot, 2008). Toxicity from mutant SOD1 is 
assumed to be through a toxic gain of function, rather than a loss of enzyme activity, 
as knockdown or inactivation of the enzyme does not result in motor neuron death 
(Reaume et al., 1996). In addition mutations that confer 100% disumutase activity such 
as G37R and those that confer no dismutase activity such as H46D/H48Q both lead to 
motor neuron loss (Wong et al., 1995, Wang et al., 2002). The dismutase-inactive mice 
also showed ubiquitinated inclusions in the spinal cord and aggregates containing high-
molecular weight SOD1. This supports hypotheses that SOD1 misfolding and 
aggregation may play a role in ALS pathogenesis (Hart, 2006). However the motor 
neurons in SOD1 knockout mice are more sensitive to injury and SOD1 null mice also 
display increased amounts of denervation (Shefner et al., 1999), meaning that a loss of 
activity cannot be completely dismissed.  
Interestingly, disease course is variable dependent upon the SOD1 mutation, with the 
A4V mutation (the most common in the U.S.A.) showing an aggressive disease course 
(Cudkowicz et al., 1997) whereas the D90A mutation (the most common in the world) 
shows a slow disease course (Andersen et al., 1995). Correspondingly, animal models 
based upon different SOD1 mutations show phenotypically different disease 
progressions (Lobsiger et al., 2007, Turner and Talbot, 2008, Pan et al., 2012). 
Nevertheless, these models have provided invaluable insights into the mechanisms 
that lead to motor neuron death during ALS. Finally, there is evidence to suggest that 
wild-type SOD1 is involved in non SOD1-ALS. The knockdown of wild-type SOD1 in 
astrocytes derived from sALS patients is protective to co-cultured neurons (Haidet-
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Phillips et al., 2011), and misfolded SOD1 is seen in cases of familial ALS containing 
TARDBP and FUS mutations (Pokrishevsky et al., 2012). 
1.3.1.1 Mouse models of ALS based upon mutations in SOD1 
Mouse models containing mutations in SOD1 have been the most common model of 
ALS since mutations in the gene were found to cause disease. Gurney et al. (1994) 
were the first to develop a mouse model of ALS based upon a glycine to alanine 
substitution at position 93 of SOD1. To date this has been the most used model within 
ALS, however models based upon other mutations in SOD1 also exist. Commonly used 
models include the SOD1G37R model, which has full dismutase activity and an 
aggressive disease course (Wong et al., 1995), and the SOD1G85R and SOD1H46R models 
which show no dismutase activity (Bruijn et al., 1997, Wang et al., 2002). Despite being 
the most common mutations amongst SOD1-ALS patients, the SOD1A4V and SOD1D90A 
models are rarely used relative to the aforementioned mutations. When initially 
developed SOD1A4V mice did not show a phenotype and conversion to an ALS-like 
phenotype only occurs when the SOD1WT is also expressed in mice, suggesting that 
there may be a toxic effect of SOD1A4V upon SOD1WT (Deng et al., 2006). The SOD1D90A 
mouse model leads to a late-onset disease at around 12 months (Jonsson et al., 2006), 
in comparison to the 3 month disease onset of the SOD1G93A model, making it less 
amenable for experimentation. However the less aggressive disease course in this 
model may better represent the human condition. 
Although there are slight variations in disease onset and duration between models, 
this is representative of the heterogeneity in human SOD1-ALS already described, and 
all models display an ALS-like disease characterised by motor neuron degeneration and 
muscle wasting. These models have proven invaluable in the elucidation of the 
pathological mechanisms of ALS and the isolation of primary cells from these animals 
have allowed in vitro testing and drug-screening studies to be performed. Recent 
progress has been made in improving the consistency of disease onset and duration 
between SOD1G93A mice by inbreeding mice to remove background variability (Mead et 
al., 2011). This consistency in disease course means that fewer animals are now 
needed to model specific time points of disease.  
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1.4 Pathology of ALS 
The pathology of ALS is complex and consists of several disease mechanisms, most of 
which are able to influence one another. The situation is made more unclear due to 
different mechanisms being more or less important dependent upon the subtype of 
ALS. In addition to motor neurons, other cell types in the CNS known collectively as glia 
play important roles in disease pathogenesis. Some of the key pathological features of 
ALS are given below. 
1.4.1 ALS is a dying back axonopathy with impairment of axonal transport 
Evidence suggests that motor neuron death in ALS first begins at the distal end, i.e. 
towards the synaptic end of the axon, rather than at the cell body. Motor neurons in 
the SOD1G93A mouse model of ALS show a loss of synapses at the neuromuscular 
junction (NMJ) before symptom onset (Frey et al., 2000). Further studies revealed that 
denervation of the NMJ and loss of axons from the ventral root precede loss of motor 
neuron cell bodies in SOD1G93A mice (Fischer et al., 2004). In addition to a loss of 
synapses at NMJs preceding motor neuron death, this innervation is selectively lost at 
sites of fast-twitch muscle fibre innervation relative to slow-twitch muscle fibres 
(Hegedus et al., 2007). 
A contributing factor to the dying back aspect of neuronal death may be impairment in 
axonal transport. The so called “slow transport” of large structural components such as 
neurofilament proteins and cytoskeletal components is disrupted in mSOD1 mice long 
before symptomatic disease begins (Williamson and Cleveland, 1999) suggesting that 
axonal defects are an early part of the disease process. Real time in vivo imaging of 
axonal transport of the C-terminal fragment of tetanus toxin has also shown deficits in 
transport beginning at the pre-symptomatic point of disease (Bilsland et al., 2010). 
Surprisingly, when Legs at odd angles (Loa) mice containing a mutation in the 
microtubule binding protein dynein were crossed with SOD1G93A mice, a significant 
improvement in retrograde axonal transport was observed, along with an increase in 
motor neuron survival (Kieran et al., 2005). This counter-intuitive finding may mean 
that mutant SOD1G93A mediates its effects through interference with axonal transport. 
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1.4.2 Inclusions 
The majority of ALS cases are characterised by protein inclusions or aggregates 
occurring within the cytoplasm of both motor neurons and glial cells. The presence of 
ubiquitin within these inclusions is common (Leigh et al., 1988, Lowe et al., 1988) and 
ubiquitinated inclusions occur in different shapes such as compact inclusions or the 
more fibrous skein-like inclusions (Ince et al., 1998a). Ubiquitin is a small 8kDa protein 
which when added to other proteins targets them for degradation via the proteasome. 
In most genetic sub-types of ALS, the ubiquitinated protein within the inclusions is 
TAR-DNA binding protein 43 (TDP-43, endoded by the TARDBP gene) (Neumann et al., 
2006), which normally resides within the nucleus and plays a role in RNA processing. 
Another protein, optineurin, is also a common constituent of ubiquitinated and TDP-
43-containing inclusions in ALS (Maruyama et al., 2010). 
Mislocalisation of TDP-43 from the nucleus to the cytoplasm and its presence in 
protein aggregates is seen in nearly all ALS sub-types but is not found in SOD1-related 
ALS, where TDP-43-negative ubiquitinated hyaline inclusions are seen (Mackenzie et 
al., 2007, Robertson et al., 2007). Additionally, ALS caused by mutations in SOD1 or 
FUS contain inclusions of SOD1 or FUS respectively (Bruijn et al., 1997, Kwiatkowski et 
al., 2009, Vance et al., 2009).  
As well as inclusions containing these disease-linked proteins, the majority of ALS cases 
also contain inclusions known as bunina bodies. Bunina bodies are negative for TDP-43 
and ubiquitin in most cases that have been examined, and to date only the lysosomal 
cysteine protease inhibitor cystatin C and and the iron transport protein transferrin 
have been identified as bunina body constituents (Okamoto et al., 2008). Finally, ALS 
cases may contain inclusions of neurofilament protein (Ince et al., 1998b), which may 
have detrimental effects on neuronal structural integrity. The presence of inclusions in 
different genetic subtypes of ALS highlights the heterogeneity of disease mechanisms 
that can lead to a common disease course. As a further indication that ALS and FTD 
occur on a spectrum of disease pathology, TDP-43 aggregation is also a hallmark of FTD 
(Arai et al., 2006). 
  11 
1.4.3 Excitotoxicity 
Glutamate is the excitatory neurotransmitter used by motor neurons of the CNS. A 
classic pathological mechanism in ALS is over-stimulation of motor neurons by 
glutamate, known as excitotoxicity. Glutamate may build up in the synaptic cleft 
through loss or altered expression of glutamate transport mechanisms or through 
excessive glutamate release (Van Den Bosch et al., 2006) (see section 1.5.2.1). The two 
key glutamate receptors present upon motor neurons are N-methyl-d-aspartate 
receptor (NMDAr) and the α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid 
receptor (AMPAr). Motor neurons are thought to be especially susceptible to 
excitotoxic damage due to the low level expression of the AMPAr subunit GluR2, which 
normally confers a high level of calcium impermeability (Williams et al., 1997). In 
addition, motor neurons contain relatively low levels of calcium binding proteins which 
may lead to a lower calcium buffering capacity (Ince et al., 1993). Thus, excess 
glutamate stimulation can lead to calcium influx and disruption of calcium 
homeostasis, disrupting many signalling pathways within the cell (Ferraiuolo et al., 
2011b). The resulting influx of calcium leads to neuronal production of reactive oxygen 
species (ROS) from mitochondria and a feed-forward excitotoxic loop (Rao and Weiss, 
2004). This interaction is also seen in other neurodegenerative diseases; Aβ, the major 
component of amyloid plaques in Alzheimer’s disease, is seen to increase cellular ROS 
and decrease glycolysis, a driver of glutamate uptake (Schubert et al., 2009).  
To compound the damage from excitotoxicity, motor neurons in mSOD1 mice have 
intrinsically increased excitability upon depolarisation (Meehan et al., 2010). 
Interestingly, motor neurons of SOD1G93A mice show an increased amount of inhibitory 
synapses relative to excitatory synapses, suggesting that these cells are trying to limit 
excitotoxic damage (Avossa et al., 2006). With relevance to ALS being a dying back 
axonopathy, excitotoxic stimulation of motor neurons in culture leads to distal axonal 
swelling, accumulation of neurofilament proteins and loss of axons, suggesting that 
excitotoxicity is a key driver of motor neuron loss (King et al., 2007).  
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1.4.4 Oxidative stress and reactive oxygen species (ROS) 
Oxidative stress is caused by a build up of ROS within the cell. Sources of ROS can 
include the electron transport chain of mitochondria and ROS generation by reactive 
glial cells. Markers of oxidative stress are increased in patients with ALS; increased 
levels of 3-nitrotyrosine, a marker of peroxynitrite, is seen in the spinal cord and 
cerebrospinal fluid (CSF) (Beal et al., 1997, Tohgi et al., 1999). In addition, modification 
of proteins such as the astrocyte glutamate transporter EAAT2 by lipid peroxidation 
products is also seen (Pedersen et al., 1998), linking oxidative stress and excitotoxicity. 
Superoxide, nitric oxide, peroxynitrite, membrane lipid peroxidation and mitochondrial 
reactive oxygen species are all increased significantly over non-transgenic motor 
neurons in cultured murine SOD1G93A motor neurons (Kruman et al., 1999). ROS 
accumulation results in damage to mRNA (Chang et al., 2008), DNA (Fitzmaurice et al., 
1996) and protein (Shaw et al., 1995, Ferrante et al., 1997). Among the mRNA species 
particularly affected by ROS are those involved in the electron transport chain, 
providing a link to the mitochondrial dysfunction also commonly seen in ALS (Wong et 
al., 1995, Wiedemann et al., 2002, Chang et al., 2008). To compound this further, the 
expression of nuclear erythroid factor 2-related factor 2 (Nrf2), a regulator of genes 
involved in the oxidative stress response, is reduced in murine SOD1G93A cells and 
human ALS tissue (Kirby et al., 2005, Sarlette et al., 2008). 
Oxidative stress has received great attention due to the normal function of the SOD1 
enzyme as a remover of ROS. However, as previously mentioned, mutations in SOD1 
that lead to inactivation of dismutase activity still result in motor neuron degeneration, 
suggesting oxidative stress may be a secondary effect. Nevertheless, mouse models 
based upon mutations in TARDBP, which encodes the TDP-43 protein that is the major 
component of inclusions seen in the majority of ALS cases, have also been 
demonstrated to show markers of oxidative stress such as increased lipid peroxidation 
and decreased mitochondrial membrane potential (Duan et al., 2010). Thus oxidative 
stress is a feature of several genetic sub-types of ALS rather than just SOD1-ALS. 
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1.4.5 Mitochondrial damage 
Metabolic, and in particular mitochondrial, dysfunction is a key part of several 
neurodegenerative diseases including ALS. Mitochondria are the energy production 
machinery of the cell, but also play important roles in calcium buffering (linking 
mitochondrial stress and excitotoxicity) and apoptosis via the release of the pro-
apoptotic factor cytochrome c (Duffy et al., 2011). 
In ALS, mitochondrial degeneration and respiratory chain dysfunction is seen in human 
tissue and mutant SOD1 mouse models (Wiedemann et al., 2002, Wong et al., 1995). 
SOD1 is found associated with mitochondria in vivo (Higgins et al., 2002) and mutant 
SOD1 accumulates with high affinity at the outer mitochondrial membrane (Vande 
Velde et al., 2008). Mutant SOD1, but not SOD1WT, binds to the anti-apoptotic protein 
Bcl2 within mitochondria of the spinal cord, potentially increasing the vulnerability of 
neurons to apoptosis (Pasinelli et al., 2004). Mutant SOD1 selectively associates with 
mitochondria within the spinal cord and not in tissues such as muscle, liver and brain, 
providing another reason for selective motor neuronal vulnerability relative to other 
cell-types (Liu et al., 2004). 
Within neurons, mitochondria are highly motile, and move on microtubules along the 
neuronal axon (Ligon and Steward, 2000). In ALS, a breakdown in mitochondrial 
transport is observed, where there is a reduction in anterograde transport (away from 
the cell body) of mitochondria, leading to a lack of mitochondria in more distal parts of 
the axon (De Vos et al., 2007). Mitochondria are heavily concentrated at synapses to 
meet energy demands (Chang et al., 2006), thus the impaired trafficking of 
mitochondria could lead to faulty synaptic function and contribute to the dying back of 
motor neurons. Due to their role in many of the disease mechanisms already 
mentioned, mitochondria may be a good target for therapeutics. However, the small 
molecule drug olexisome, which previously extended survival in the SOD1G93A mouse 
(Bordet et al., 2007), failed phase III clinical trials in 2011, meaning that other 
therapeutic avenues will need to be explored.  
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1.4.6 Inflammation and immune response 
An aberrant immune response and inflammation are recognised as key features of ALS 
and include immune cell infiltration (Henkel et al., 2004), increased levels of 
chemokines (Kuhle et al., 2009), increased complement activity (Grewal et al., 1999, 
Goldknopf et al., 2006) and glial activation (Sargsyan et al., 2005, Hensley et al., 
2006)(see section 1.5). Whether these responses are beneficial or detrimental for 
motor neurons is not clear. Knockout of the pro-inflammatory cytokine IL-1β in 
SOD1G93A mice leads to increased survival time and decreased inflammation (Meissner 
et al., 2010), indicative of the negative role that inflammation can play. In contrast, the 
phagocytic activity of activated immune cells can clear debris allowing neuronal 
regeneration (Neumann et al., 2009). In further support of a beneficial role for 
inflammation, mice with a genetic background that leads to a slower, more benign 
disease course feature increased expression of immune transcripts in motor neurons 
(Nardo et al., 2013). Furthermore, knockdown of proliferating microglia, the immune 
cell of the CNS, using the thymidine kinase-ganciclovir system to conditionally ablate 
Cd11b+ cells, does not affect motor neuron survival in SOD1G93A mice indicating that 
dysregulated immune and inflammatory responses may not be a prime cause of motor 
neuron death in ALS (Gowing et al., 2008).  
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1.4.7 RNA processing 
Several ALS causing genes are involved in the processing of RNA or disrupt RNA 
processing during disease, including TARDBP (which encodes TDP-43), FUS, and 
C9ORF72. TDP-43, the main component of the inclusions seen in ALS, is a 
heterogeneous nuclear ribonucleoprotein (hnRNP) containing RNA recognition motifs 
(Buratti and Baralle, 2001) and binds to over 4000 RNA targets including those involved 
in the synaptic function, RNA processing and neuronal development (Sephton et al., 
2011). Similar to TDP-43, FUS contains an RNA binding motif and both mutated FUS 
and TDP-43 mislocalise to the cytoplasm instead of the nuclear localisation seen in 
control cases with wild-type TDP-43 and FUS (Kwiatkowski et al., 2009, Vance et al., 
2009). Such mislocalisation would lead to dysregulated expression of many genes. In 
contrast to TDP-43 and FUS, which have direct roles in mRNA processing, intronic 
expansions within C9ORF72 interfere with RNA species by direct binding and 
sequestration of RNA binding proteins within RNA foci (Walsh et al., 2014). This can 
result in abnormal splicing of the target mRNAs of these binding proteins. In addition, 
the presence of the C9ORF72 expansion upon one allele may lead to lower levels of 
functional C9ORF72 protein. The fact that TDP-43/FUS and C9ORF72 feature different 
mechanisms of disrupting normal RNA-processing increases its importance as a disease 
mechanism.  
Spinal muscular atrophy (SMA), another motor neuron disorder, is caused by 
mutations in the SMN1 gene (Lefebvre et al., 1995) which is involved in the 
construction of RNA processing proteins (Burghes and Beattie, 2009), again indicating 
that abnormal RNA processing is detrimental for motor neuron survival. Even, SOD1-
ALS, which does not contain mislocalisation of TDP-43, features transcriptional 
repression as seen in the NSC34 motor neuron like cell line expressing SOD1G93A (Kirby 
et al., 2005) and in laser captured motor neurons from the late-stage SOD1G93A mouse 
(Ferraiuolo et al., 2007).  
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1.5 Non-cell autonomy in ALS 
Not only do the above-mentioned pathological processes affect neurons, they also 
affect their glial neighbours. The CNS is comprised of multiple cell types, which can be 
subdivided into neurons and glia. Glia are by far the most numerous of these cells 
making up ~90% of human brain (He and Sun, 2007) and comprise three main cell-
types: astrocytes, oligodendrocytes and microglia. Astrocytes and oligodendrocytes are 
derived from a neural progenitor population which is ectodermal in origin whereas 
microglia, the immune effector cells of the CNS, are derived from mesoderm and are 
thought to develop from peripheral macrophages (Kettenmann and Ransom, 2005). 
The ALS disease process appears to affect all of the major cell types within the CNS, 
and all cells play a role in the eventual death of motor neurons. The process by which a 
diseased cell-type causes damage to another cell-type is termed non-cell autonomy. 
Non-cell autonomy is an important part of ALS, for example the expression of mutant 
SOD1 (mSOD1) in neurons alone is not sufficient for disease initiation (Pramatarova et 
al., 2001) suggesting that other CNS cells are essential for damage. It is now known 
that astrocytes, microglia and oligodendrocytes all play a role in motor neuron death 
and in multiple ALS pathogenic processes (Figure 1.1). 
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Figure 1.1 Key non-cell autonomous processes in SOD1-ALS. All glial cells undergo increased 
proliferation during disease progression. ROS are produced by dysfunctional mitochondria 
through mSOD1 association with the mitochondrial membrane. Normally, astrocytes respond 
to ROS by activation of the NRF2 transcription factor, its translocation to the nucleus, and 
subsequent transcription of antioxidant genes such as those involved in glutathione 
biosynthesis. However NRF2 is down-regulated in ALS. Astrocytes provide metabolic support to 
neurons through provision of glucose or lactate, the latter produced by glycolysis which may 
be affected by mitochondrial dysfunction. Glutamate is taken up by astrocytes from the 
extracellular space (ECS) and converted to glutamine for transport back to neurons (not 
shown). Astrocytic glutamate uptake through EAAT2 is fuelled by the aforementioned 
disrupted mitochondrial glycolysis, leading to lower glutamate uptake and increased glutamate 
concentrations in the ECS which cause excitotoxic damage via Ca2+ influx through ionotropic 
receptors. In ALS, EAAT2 expression is reduced, exacerbating excitotoxic damage. Microglial 
activation by mSOD1, heat shock proteins or other cellular breakdown products leads to 
secretion of TNF-α and IL1β and pro-inflammatory migroglial and astrocytic phenotypes. 
Oligodendrocytes lose the expression of MCT1, a lactate transporter important in providing 
metabolic support to the axon, and disruptions are seen in the myelin sheath. 
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1.5.1 Astrocytes 
Astrocytes are the most abundant cell in the central nervous system (CNS) and fulfil 
diverse roles including: maintenance of neuronal homeostasis, metabolic support, 
regulation of synaptic plasticity, clearance of neurotransmitters from synapses, 
interaction with microglia, and protection of nervous tissue when injury occurs. 
Astrocytes are characterised by a ramified morphology with many fine processes 
essential for performing the many functions listed above. Astrocytes are characterised 
by expression of proteins such as glial fibrillary acidic protein (GFAP), the calcium 
binding protein S100b, the cell surface glycoprotein CD44, aldehyde dehydrogenase 1 
family member L1 (ALDH1L1) and aquaporin 4 (AQP4), the expression of which varies 
according to astrocyte location and function. For over a decade, astrocytes have been 
regarded as part of “the tripartite synapse”, playing an essential role in synaptic 
signalling along with the pre-synaptic and post-synaptic neuron (Araque et al., 1999). 
Astrocytes form vast gap-junction connected syncitial networks through which they 
can dissipate signals and metabolites, and are integral parts of the blood brain barrier 
(BBB) and blood-spinal-cord-barrier (BSCB) (Blackburn et al., 2009). 
1.5.1.1 The provision and recycling of neurotransmitter 
Of particular importance to motor neurons, which use glutamate as the main 
excitatory neurotransmitter, astrocytes are important in removal of glutamate from 
the synaptic cleft. The two main astrocyte glutamate transporters are excitatory amino 
acid transporter 1 (EAAT1, a.k.a. GLAST in mice and rats) and EAAT2 (a.k.a. GLT-1 in 
mice and rats) (Pines et al., 1992, Storck et al., 1992). When GLAST and GLT1 were 
knocked down in wild-type rats, a severe deficit was seen with an excess of 
extracellular glutamate whereas knock down of the neuronal glutamate transporter 
EAAC1 did not alter extracellular glutamate levels (Rothstein et al., 1996). The 
imported glutamate is converted within astrocytes to the precursor glutamine by the 
astrocyte-specific enzyme glutamine synthetase (Norenberg and Martinez-Hernandez, 
1979). This glutamine is then safe to transport back to neurons without provoking 
excitation via glutamate receptors. Once inside the neuron, glutamine can be 
converted back to glutamate for use in neurotransmission (Bak et al., 2006). Astrocytes 
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are also involved in the recycling of the inhibitory neurotransmitter γ-aminobutyric 
acid (GABA), which is also derived from glutamine (Schousboe et al., 2004). 
1.5.1.2 Provision of energy substrate to neurons 
Perhaps the most important role of astrocytes is the provision of substrate to neurons 
for energy production. Since the suggestion that neurons use lactate generated 
through astrocytic glycolysis, termed the astrocyte-neuron lactate-shuttle (ANLS) 
(Pellerin and Magistretti, 1994), there has been considerable debate surrounding the 
preferred fuel source of neurons (Figure 1.2). Pellerin and Magistretti (1994) found 
that increased glutamate concentrations stimulated astrocytic Na+/glutamate co-
transport powered by aerobic glycolysis, demonstrated by increased lactate 
production by astrocytes in vitro. They hypothesised that this lactate could be utilised 
by neurons as an energy source through conversion to pyruvate and subsequent use in 
oxidative phosphorylation. This argument is not without controversy however; 
arguments against lactate as the preferential neuronal fuel source centre on findings 
that astrocytes are capable of higher rates and higher amounts of lactate uptake than 
neurons, whilst the opposite applies for glucose, and that modelling the ANLS requires 
using values not supported by the current literature (Simpson et al., 2007, Mangia et 
al., 2009).  
There now exist two different hypotheses of neuronal glucose metabolism: the 
classical pathway and the ANLS (Figure 1.2). The classical pathway proposes glucose to 
be taken up from the blood stream either into astrocytes through the glucose 
transporter GLUT-1 or directly into neurons from the extracellular space (ECS) through 
a neuronal glucose transporter such as GLUT-3. Glucose is then used in respiration and 
the lactate by-product is transported from neurons into astrocytes via 
monocarboxylate transporters (MCT-2 on neurons and MCT1 and 4 on astrocytes) 
where it diffuses through the syncytial network to the bloodstream. Lactate may also 
be transported into the ECS where it diffuses along its concentration gradient to the 
bloodstream. In the ANLS, glucose is taken up from the blood into astrocytes where it 
is used in glycolysis, a process which also fuels uptake of glutamate from the synaptic 
cleft. The lactate by-product is then transported to neurons where it can be converted 
to pyruvate and used in oxidative phosphorylation. Note that in the ANLS, glucose and 
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lactate may also diffuse directly between the bloodstream and neurons, however this 
process is thought to be secondary to the ANLS (Pellerin et al., 2007). 
 
 
Figure 1.2 The two competing hypotheses of neuronal glucose metabolism. The classical 
pathway proposes glucose to diffuse directly from the blood stream to neurons and through 
astrocytes. Neuronal lactate is then taken up by the astrocytic lactate transporters MCT1/4. In 
the ANLS, glucose is first metabolised in astrocytes to lactate and transported into neurons via 
the neuronal lactate transporter MCT-2. Blue arrows: Glucose movement; Red arrows: lactate 
movement; G: Glucose; L: Lactate; Gly: Glycolysis. 
 
1.5.1.3 Astrocytes are a key part of the blood brain barrier and blood spinal cord 
barrier 
The BBB is the cellular network lining the brain microvasculature, consisting of an 
endothelial cell lining surrounded by a layer of extracellular matrix known as the basal 
lamina (which contains pericytes and smooth muscle cells) onto which astrocytic 
endfeet project (Abbott et al., 2006). In contrast to endothelial cells of the periphery, 
the endothelia of the BBB and BSCB are joined by tight junctions, such that diffusion of 
most substances takes place transcellularly (i.e. through the cells rather than between 
them). Much transport of substrates is performed through endothelial transport 
proteins and astrocytes have been shown to modulate transport capabilities of the 
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endothelial network e.g. through up-regulating the glucose transporter GLUT-1 on 
endothelial cells in response to glucose deprivation (Regina et al., 2001). Astrocytes are 
able to signal across the syncytial network by the propagation of calcium waves 
(Cornell-Bell et al., 1990) which could signal neuronal metabolic demands to 
endothelial cells with resultant increase in substrate transport (Abbott et al., 2006).  
1.5.1.4 Heterogeneity of astrocytes in the CNS 
The generalisation of astrocytes as one group of cells is much too simplistic, as these 
cells appear to be as functionally heterogeneous as neurons. Ramon y Cajal, who first 
described astrocytes, noted the different morphologies of these cells from different 
brain regions (Zhang and Barres, 2010). An obvious morphological difference is that 
seen between white matter (a.k.a. fibrous) and grey matter (a.k.a. protoplasmic) 
astrocytes, where white matter astrocytes have clearly defined processes with little 
branching and grey matter astrocytes possess many fine processes with multiple 
branch points (Matyash and Kettenmann, 2010). The most commonly used marker of 
astrocytes, GFAP, is highly expressed in white matter astrocytes but much less in those 
of the grey matter (Cahoy et al., 2008), and is usually associated with astrocytic 
activation.  
The functional heterogeneity seen may reflect the different regions in which astrocytes 
develop. White matter astrocytes in the spinal cord show expression of different 
transcription factors based upon their location, perhaps reflecting their localisation 
with different neuronal subtypes (Hochstim et al., 2008). Oligodendrocyte 
transcription factor (OLIG2) is a transcription factor essential for oligodendrocyte and 
motor neuron development (Lu et al., 2002). In the P2 region of the developing spinal 
cord, the transcription factor T-Cell Acute Lymphocytic Leukemia 1 (TAL1 a.k.a. SCL) is 
required for the development of astrocytes rather than oligodendrocytes or 
interneurons via its repression of OLIG2 (Muroyama et al., 2005). However, OLIG2 
ablation only seems important for white matter astrocyte development but not for 
grey matter astrocytes (Cai et al., 2007), showing that astrocyte heterogeneity arises 
early in development.  
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Despite many similarities between astrocytes from rodents and humans, human 
astrocytes are much more complex and have been found to propagate calcium waves 
three times faster than those of the mouse (Han et al., 2013). Further, this study found 
that engraftment of human astrocytes into the mouse brain led to improved memory 
and learning when compared to non-engrafted mice. Thus it is important to bear in 
mind that human astrocytes may play more complex roles in disease processes than 
those of rodents. 
1.5.2 Astrocytes in ALS 
There is much evidence showing astrocytes to be affected by, and effectors of, the ALS 
disease process. Much of this information has come from the use of mutant SOD1 
(mSOD1) mouse models. The mutant SOD1-containing inclusions seen within motor 
neurons in the SOD1G85R mouse are also present in astrocytes of the SOD1G85R mouse 
(Bruijn et al., 1997) and human cases (Forsberg et al., 2011). Neuron-specific 
expression of mSOD1 did not lead to motor neuron degeneration (Pramatarova et al., 
2001). Similarly, expression of SODG37R in motor neurons and oligodendrocytes did not 
lead to disease onset in chimaeric mice (Yamanaka et al., 2008a). In addition, motor 
neurons of SOD1G93A mice do not up-regulate gene expression associated with cell 
death (Perrin et al., 2005) and if anything up-regulate genes involved in re-entry to the 
cell-cycle (Ferraiuolo et al., 2007), whereas motor neurons of human sALS cord do up-
regulate cell-death genes (Jiang et al., 2005), leading to confusion as to whether death 
signals may come from other cell types. The generation of chimaeric mice featuring 
mSOD1 expression in select groups of cells has shown wild-type glia to improve 
viability of mSOD1 motor neurons (compared to mSOD1 glia) (Clement et al., 2003). 
Astrocyte-specific expression of mSOD1 does not cause motor neuron death (Gong et 
al., 2000). However, transplantation of SOD1G93A glial restricted precursors into healthy 
rat spinal cord induced death of nearby motor neurons (Papadeas et al., 2011). An 
astrocytic role in disease has been further clarified using Cre-lox knockdown of mSOD1 
specifically in astrocytes in the SOD1G37R mouse model, which showed no effect upon 
disease onset, but a significant increase in survival time (Yamanaka et al., 2008b). In 
support of this, the knockdown of mutant SOD1 predominantly in astrocytes and 
motor neurons using adeno-associated virus 9 significantly increased lifespan in 
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SOD1G93A and SOD1G37R mice (Foust et al., 2013). In contrast to the study by Yamanaka 
et al (2008b) showing no astrocyte effect upon disease onset, knockdown of the 
SOD1G85R mutation in astrocytes of the SOD1G85R mouse did lead to a delay in both the 
onset and progression of disease (Wang et al., 2011). SOD1G37R has full dismutase 
activity, whereas SOD1G85R has no activity, and thus a different disease mechanism may 
be operating in this model. This further highlights the heterogeneity in SOD1-ALS 
mentioned previously (Section 1.3.1.1).  
Data from in vitro experiments reinforce in vivo findings and highlight astrocytes as key 
players in the disease progression. Expression of mSOD1 in vitro in mouse primary 
motor neurons alone did not lead to significant differences in survival between non-
transgenic and transgenic cells (Nagai et al., 2007). However, conditioned medium 
from astrocytes expressing mSOD1 was significantly more toxic to motor neurons than 
that from non-transgenic astrocytes, and was also significantly more toxic than that 
from transgenic microglia (Nagai et al., 2007). Additionally, treatment of motor 
neuronal precursors with conditioned medium from mSOD1-astrocytes had a 
significantly negative effect upon precursor proliferation and differentiation compared 
to wild-type, suggesting that disease-causing mutations cause detrimental effects at 
very early stages of life (Christou et al., 2013). 
In addition to these conditioned medium experiments, astrocytes derived from murine 
SOD1G93A embryonic stem cells (ESCs) are significantly more toxic to murine and 
human ESC derived motor neurons than astrocytes derived from wild-type SOD1 ESCs 
and the toxic effect is compounded when both cell types express SOD1G93A (Di Giorgio 
et al., 2007, Di Giorgio et al., 2008). Astrocyte toxicity seems to be motor neuron 
specific, as human ESC-derived inter-neurons are not affected in co-culture with 
SOD1G93A glia. Also, fibroblasts harbouring the SOD1G93A mutation do not cause ESC-
derived-motor neuron death (Di Giorgio et al., 2008). In the rat SOD1G93A model, a 
highly proliferative and highly toxic aberrant astrocytic-phenotype is observed, which 
has lead to the description of AbA (for aberrant astrocyte) cells in this model (Diaz-
Amarilla et al., 2011). In humans, Haidet-Phillips et al (2011) successfully differentiated 
neural progenitor cells from sALS and fALS patients into astrocytes, and showed these 
cells to be toxic to motor neurons in vitro. With reference to their role as metabolic 
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partners of motor neurons, astrocytes from pre-symptomatic SOD1G93A mice show 
reduced lactate provision for motor neurons and increased secretion of pro-NGF 
(nerve growth factor), the latter of which coincided with an increase in the pro-NGF 
receptor p75 on motor neurons and increased apoptosis. Replenishment of lactate and 
blockade of the p75 receptor led to complete rescue of motor neurons co-cultured 
with SOD1G93A astrocytes (Ferraiuolo et al., 2011a).  
It is important to recognise that most work on the non-cell autonomous effect of 
astrocytes has been performed in SOD1-ALS. More recent studies using mutant TDP-43 
models has cast doubt upon the role of non-cell autonomy in that particular subtype of 
ALS. Unlike SOD1-ALS models (Pramatarova et al., 2001), mutant TDP-43 expression in 
motor neurons alone is enough to lead to an ALS phenotype (Huang et al., 2012). 
Separate studies have found astrocytes to be toxic/non-toxic in TARDBP-related ALS. 
Haidet-Phillips et al (Haidet-Phillips et al., 2013) have found that glial restricted 
precursors (GRP) isolated from TDP-43A315T mice do not give rise to astrocytes that 
cause toxicity to motor neurons in vitro. When these TDP-43A315T GRPs were 
transplanted into the spinal cord of wild-type rats they did not cause motor neuron 
death, in contrast to GRPs derived from SOD1G93A mice (Papadeas et al., 2011).  
In support of the studies by Haidet-Phillips et al. (2013) and Papdeas et al. (2011) , iPS 
derived TDP-43 astrocytes were not toxic to iPS derived motor neurons (WT or TDP-43) 
(Serio et al., 2013). Additionally, SOD1G93A astrocytes are known to be very toxic, and 
express the mutant transgene at a level of around 11-fold more activity compared to 
the 3-fold increase in expression seen by Haidet-Phillips et al. (Haidet-Phillips et al., 
2013). Care must be taken in the analysis of GRP transplantation experiments before 
excluding mutant TDP-43 astrocytes as contributors to disease. The transplantation of 
GRPs will only lead to a small proportion of astrocytes in the spinal cord possessing the 
mutant gene, and previous studies have shown wild-type glia to be neuroprotective 
(Clement et al., 2003). In addition, the inability of astrocytes to cause disease on their 
own does not mean that they are not involved in the disease progression. Indeed 
Huang et al. (2012) showed that mutant TDP-43 expression in motor neurons alone 
produced an ALS phenotype, with profound astrocytic and microglial activation. 
Furthermore, expression of mutant TDP-43 or FUS in motor neurons alone has been 
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found to induce the expression of lipocalin 2 in astrocytes, which acts as a toxic factor 
(Bi et al., 2013). Finally, Tong et al. (Tong et al., 2013) did see MN degeneration in 
models with TDP-43M337V expression solely in astrocytes, indicating that further work in 
this area is needed. Finally, fibroblasts from C9ORF72-ALS and sALS patients that are 
directly converted to astrocytes are toxic to co-cultured motor neurons in vitro (Meyer 
et al., 2013), indicating that astrocyte toxicity is common mechanism amongst ALS 
genetic sub-types. 
1.5.2.1 Astrocytes are key players in excitotoxicity and oxidative stress in ALS 
The contribution of oxidative stress and glutamate excitotoxicity and the 
interconnectivity between these processes is a key feature of astrocytes in ALS. Under 
normal homeostatic conditions, glutamate is co-transported from the synaptic cleft 
into astrocytes with Na+ and H+ (in exchange for K+) through the glutamate 
transporters EAAT1 and EAAT2 (Bak et al., 2006). Astrocytic glutamate uptake is an 
energy intensive process often occurring far away from the cell body; the glutamate 
transporter GLT-1 has recently been demonstrated to co-localise with mitochondria 
and glycolytic enzymes in astrocyte processes (Genda et al., 2011), a process which 
requires co-culture with neurons in vitro (Ugbode et al., 2014). Astrocytes are able to 
influence glutamatergic activity by the release of ATP which acts to inhibit 
neurotransmission (Zhang et al., 2003). In ALS, mSOD1 associates with the 
mitochondrial membrane causing disruption of mitochondrial energy metabolism and 
increased ROS  in SOD1G93A astrocytes (Mattiazzi et al., 2002, Cassina et al., 2008), 
which would therefore lead to lower ATP production and exacerbation of excitotoxic 
damage. 
To compound the vulnerability of motor neurons to glutamate through their lack of 
the GluR2 subunit, the expression of the glutamate transporter EAAT2 is reduced in 
astrocytes during ALS (Howland et al., 2002). Thus a key glutamate removal 
mechanism is lost. In rat models, astrocytes modulate neuronal GluR2 subunit 
expression via a secreted protein factor, whilst in the same study rats transgenic for 
SOD1G93A were shown to have reduced GluR2 expression (Van Damme et al., 2007). 
The authors conclude that astrocytes protect against excitotoxicity both by glutamate 
uptake and modulation of GluR2 protein levels and that this protection is lost during 
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ALS. Crossing of SOD1G93A mice with mice over-expressing EAAT2 (a.k.a. GLT1) 
improved the motor outcomes but did not significantly delay disease onset or 
progression in these mice, suggesting that excitotoxicity is not the main mechanism in 
disease progression (Guo et al., 2003). In contrast, the astrocyte glutamate transporter 
GLT1 was increased in expression upon β-lactam treatment in SOD1G93A mice and this 
correlated with significant increases in motor neuron survival and overall survival time 
(Rothstein et al., 2005). This difference may be due to timing, where treatment in the 
study by Rothstein et al. (Rothstein et al., 2005) was started at disease onset rather 
than over-expression operating from birth. In support of the importance of glial 
modulation of excitotoxicity, GRPs injected into the spinal cord of SOD1G93A rats 
differentiated into astrocytes with retention of GLT-1 at end stage disease which led to 
decreased motor neuron loss (Lepore et al., 2008), emphasising the importance of 
astrocyte glutamate uptake for neuronal health. In addition, Riluzole, which is thought 
to mediate some of its protective effects through protection against excitotoxic 
damage, increases the expression of GLT-1 upon astrocytes in vitro (Carbone et al., 
2012). 
Excitotoxicity, oxidative stress and mitochondrial damage are intimately linked in 
SOD1-ALS. ROS, produced through processes such as mitochondrial oxidative 
phosphorylation, inflammation or through mSOD1 itself, leads to decreased expression 
of astrocytic glutamate transporters and a build up of glutamate in the synaptic cleft 
(Bush, 2002, Valentine and Hart, 2003). The toxicity of astrocytes towards motor 
neurons may be mediated through ROS; reduced oxygen consumption in astrocytic 
mitochondria, as shown in SOD1G93A rat astrocytes (Cassina et al., 2008), leads to 
enhanced ROS production. Murine SOD1G93A astrocytes have also been seen to cause 
defects in mitochondria of wild-type motor neurons when co-cultured (Bilsland et al., 
2008). In keeping with their role in the inflammatory response (Section 1.5.2.2), 
astrocytes have been found to increase expression of iNOS and neuronal NOS (nNOS) 
during neurodegeneration (Almer et al., 1999, Sasaki et al., 2000, Anneser et al., 2001), 
resulting in increased amounts of nitric oxide stress to neurons. 
Astrocytes are able to withstand higher amounts of oxidative stress than neurons. The 
nuclear factor erythroid 2-related factor 2 (NRF2) transcription factor has a major role 
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in the protective response to oxidative stress; astrocytes have much higher levels of 
Nrf2 induction than neurons upon oxidative insult in a mouse model (Kraft et al., 
2004). In a SOD1G93A related cellular model of ALS, the down-regulation of Nrf2 and 
glucose-6-phosphate dehydrogenase expression in the NSC34 neural cell line lead to 
weakened defences against oxidative stress (Kirby et al., 2005). Further, NRF2 
expression in motor neurons is reduced in post-mortem tissue of ALS patients 
compared to controls (Sarlette et al., 2008). Astrocytes are an attractive target to 
compensate for this neuronal NRF2 reduction; activation of NRF2 with fibroblast 
growth factor-1 (FGF-1), thought to be released upon motor neuron damage, leads to 
increased production of haem oxygenase-1 (HO1) in astrocytes and increased motor 
neuron survival in co-culture (Vargas et al., 2005). Astrocytes also produce more 
antioxidant glutathione upon activation of the NRF2 pathway which protects neurons 
from glutamate-induced toxicity (Shih et al., 2003). Neurons are incapable of 
glutathione uptake, therefore glutathione is metabolised to cysteine in the 
extracellular space (ECS) and taken up by neurons for neuronal glutathione synthesis 
(Dringen, 2000). Recently, NRF2 has been shown to regulate the expression of the 
EAAT3 transporter on neurons, responsible for increased cysteine uptake and 
subsequent glutathione synthesis upon stimulation by ROS (Escartin et al., 2011). Thus, 
NRF2 activation during oxidative stress leads to increased astrocytic glutathione 
secretion, increased cysteine levels in the ECS, and corresponding increased levels of 
neuronal EAAT3 to take up cysteine for neuronal glutathione synthesis and protection. 
This protective mechanism is lost during ALS progression. 
1.5.2.2 Astrocyte-mediated inflammation in CNS injury and ALS 
In contrast to acute or sub-acute CNS injury, ALS involves a much slower activation of 
astrocytes and the role of inflammation is less well established. Nevertheless, 
inflammation is a key feature of ALS progression, involving glial and immune cell 
proliferation, release of ROS and pro-inflammatory cytokines and induction of cell 
death. Injury to the CNS induces reactive astrogliosis, an increase in astrocyte 
proliferation and migration around the site of injury, which in acute injury cases may 
form a glial scar (Sofroniew, 2009). Astrogliosis may be preceded by de-differentiation 
to an earlier developmental stage, as seen in stab injury to the neocortex (Buffo et al., 
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2008). The increased astrocytic presence serves to form a tight separation between 
the damaged and healthy tissue, but the consequence of this is scar tissue which is 
inhibitory to axonal regrowth (see Fawcett and Asher (1999)). However, knock down of 
reactive astrogliosis leads to increased leakiness of the BBB, greater migration of 
systemic inflammatory cells and more neuronal death (Faulkner et al., 2004). This 
demonstrates a positive role of inflammation and highlights the complexities that will 
be faced in controlling the inflammatory response. 
Astrogliosis, precedes behavioural defects in mice transgenic for mutant TDP-43 
(Swarup et al., 2011). Recent experiments using mice transgenic for both TDP-43 and 
GFAP-luciferase (to allow in vivo imaging of astrogliosis) showed higher astrocytic 
expression of pro-inflammatory cytokines (transgenic vs. control) when stimulated 
with bacterial LPS in vitro, and found evidence for interaction between TDP-43 and p65 
resulting in amplified inflammatory responses (Swarup et al., 2011). Furthermore, the 
use of a super-inhibitor of the NF-κB complex led to decreased astrogliosis and motor 
neuron death in mutant TDP-43 transgenic mice (Swarup et al., 2011). IFNγ production 
by astrocytes increases with disease stage in SOD1G93A mice and induces motor neuron 
cell death (Aebischer et al., 2011), and increased TGFβ signalling is concurrent with 
astrogliosis, however TGFβ may act as a protective mechanism (Phatnani et al., 2013).  
A master regulator of inflammatory gene expression, NF-κB, plays a key role in the up-
regulation of 35-60% of tested pro-inflammatory genes in fALS and sALS-astrocytes 
compared to non-diseased controls (Haidet-Phillips et al., 2011). In contrast to these 
findings, astrocyte-specific knockdown of NF-κB has been shown not to affect disease 
initiation and progression in a SOD1G93A mouse model of ALS (Crosio et al., 2011, 
Frakes et al., 2014). However, ALS is a non-cell autonomous process, therefore NF-κB 
activation in other cells may supply the required pro-inflammatory factors, and the 
aforementioned study by Haidet-Phillips et al. (2011) found only 35-60% of pro-
inflammatory genes to be influenced by NF-κB, which implies a level of redundancy is 
present in the inflammatory response.  
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1.5.2.3 Toxicity or loss of support? 
A key question regarding astrocytes in ALS is whether they are toxic to motor neurons 
or whether motor neurons die due to a loss of astrocyte support. Given the evidence 
described in the previous sections, it seems that a combination of both factors is most 
likely. In terms of toxicity, astrocytes secrete lipocalin 2 (Bi et al., 2013), increased 
amounts of nitric oxide (Anneser et al., 2001) and pro-inflammatory cytokines (Haidet-
Phillips et al., 2011). At the same time, there is down-regulation of astrocytic 
glutamate transporters leading to excitotoxicity (Howland et al., 2002), and a lower 
amount of lactate provision by astrocytes to neurons for energy production (Ferraiuolo 
et al., 2011a). Given that the latter study saw this lactate deficit at the pre-
symptomatic stage, perhaps loss of support is an early feature which follows through 
to a toxic phenotype as the disease progresses. Indeed, if supportive factors such as 
IGF1 or GNDF are delivered pre-symptomatically to SOD1G93A mice there is a significant 
delay in disease onset (Kaspar et al., 2003). 
1.5.3 Microglia 
The macrophages of the CNS are called microglia, which differ from archetypal 
macrophages in appearance and behaviour; being extremely sessile and possessing a 
ramified morphology at rest (Stollg and Jander, 1999). Nevertheless microglia are 
highly immune competent and possess multiple immune receptors such as toll-like 
receptors (TLR) 1-9 and receptors for pathogen associated molecular patterns (PAMPs) 
(Xavier et al., 2014). They produce multiple different cytokines and up-regulate MHC II 
expression in response to TLR ligation (Olson and Miller, 2004), and secrete increased 
amounts of superoxide upon activation (Colton and Gilbert, 1987). Lastly, microglia are 
capable phagocytes involved in the clearance of cell debris and dying cells (Raff et al., 
1979). Microglia are in a constant state of surveillance with each cell moving and 
covering a certain area and as such, are dominant at sites of acute CNS injury (Kigerl et 
al., 2009).  
As with macrophages of the peripheral immune system, microglia exist on a spectrum 
of activation. Classical activation of macrophages occurs in the presence of pro-
inflammatory factors such as bacterial lipopolysaccharide (LPS) or interferon-γ (IFNγ) 
secreted in a typical Th1-type immune response (Schroder et al., 2004). This pro-
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inflammatory activation state is characterised by antigen presentation, high expression 
of the transcription factor IRF5, increased nitric oxide production, and a cytokine 
expression profile consisting of high amounts of Interleukin (IL)-12 and IL-23 and low 
amounts of IL-10 (Mantovani et al., 2004, Krausgruber et al., 2011). In contrast to this 
pro-inflammatory state, macrophages also exist in an alternatively activated 
phenotype, induced by Th2-type cytokines such as IL-4 (Stein et al., 1992). 
Alternatively activated macrophages are characterised as immunosuppressive and 
involved in tissue repair and secrete high amounts of IL-10 and IL-1 receptor antagonist 
(IL1RA) (Mosser, 2003). These two ends of the macrophage activation spectrum have 
been designated M1 for classically activated macrophages and M2 for alternatively 
activated macrophages (Mosser, 2003). Initial differentiation into M1 or M2 cells can 
be stimulated by granulocyte-macrophage colony stimulating factor (GM-CSF) or 
macrophage colony stimulating factor (M-CSF) respectively (Gordon and Martinez, 
2010). IFNγ then primes classically activated (M1) macrophages (Mosser, 2003) whilst 
interleukin 4 (IL4) and interleukin 13 (IL13) prime the alternatively activated phenotype 
(Stein et al., 1992). This binary categorisation of macrophages is overly simplistic, for 
instance another population of macrophages is seen to develop in response to IgG-
opsonised cells and classical activation signals that induces a Th2-type humoral 
immune response (Anderson and Mosser, 2002). M2 macrophages can therefore be 
subdivided into: M2a, which develop in response to IL-4 and IL-13; M2b, an IL-10 high, 
IL-12 low expressing cell-type that develops in response to FCγ receptor ligation and 
activation of toll-like receptors or Interleukin-1 receptors (Sutterwala et al., 1997, 
Sutterwala et al., 1998); and M2c cells that develop in response to IL-10 (Mantovani et 
al., 2004). Central to the two ends of the activation spectrum are IRF5, a transcription 
factor which polarises towards the M1 phenotype (Krausgruber et al., 2011), and 
Krüppel like factor 4 (KLF4) which in combination with STAT6 regulates polarisation 
toward an M2 phenotype and is important in the repression of pro-inflammatory 
genes (Liao et al., 2011). The inflammatory gene suppression by KLF4 is postulated to 
occur through competition for p300 and PCAF, which are co-activators of NFĸB (Liao et 
al., 2011).  
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1.5.4 Microglia in ALS 
Similar to astrocytes, microglial proliferation (microgliosis) is a hallmark of ALS from 
the symptomatic stage onwards (Alexianu et al., 2001). mRNA transcripts for markers 
of microglia are significantly increased over controls and there is increased levels of 
the chemoattractant MCP-1 in ALS spinal cord (Henkel et al., 2004, Henkel et al., 2006). 
Microgliosis per se may not lead to motor neuron death. As previously mentioned in 
section 1.4.6, depletion of proliferating microglia did not affect motor neuron 
degeneration even though it did affect number of activated cells in SOD1G93A mice 
(Gowing et al., 2008). 
Microglia transition between activation states during ALS. Levels of pro-inflammatory 
cytokines such as TNFα were increased in the SOD1G93A spinal cord with disease 
progression and treatment of a microglial cell line with these cytokines in vitro led to 
increased levels of nitrite production (Hensley et al., 2003). Treatment of microglial 
cells with mutant SOD1 (mSOD1) leads to M1 polarisation, through interaction with 
toll-like receptors 2 and 4 and CD14, and subsequent toxicity towards motor neurons 
when placed in co-culture (Zhao et al., 2010). Interestingly mSOD1 treatment of motor 
neurons in the absence of microglia does not lead to cell death, suggesting that the 
mutant protein is not toxic to motor neurons in isolation. The PU.1 knockout mouse, 
which lacks B and T cells and cells of the myeloid lineage such as macrophages and 
microglia, has shown that mSOD1 prompts neurons to signal to microglia and induce a 
toxic phenotype. When PU.1-/- and SOD1G93A mice were crossed to produce 
SOD1G93A/PU.1-/- mice and were then given bone marrow transplants, wild type bone 
marrow led to significantly increased survival time over SOD1G93A bone marrow (Beers 
et al., 2006). In this study, injection of SOD1G93A bone marrow into the singly transgenic 
PU.1-/- strain did not lead to motor neuron death, therefore it was only when SOD1G93A 
was present in all cells that SOD1G93A microglia became toxic, suggesting a neuronal 
signal is the cause of microglial activation in this disease (Beers et al., 2006).  
In keeping with a toxic role of mSOD1-expressing microglia in disease, knockout of 
mSOD1 specifically in microglia significantly extends survival of SOD1G37R mice but does 
not affect onset (Boillee et al., 2006). This is concordant with the aforementioned 
study which performed the same knockout in astrocytes (Yamanaka et al., 2008b). 
  32 
With further similarity to the studies performed upon astrocytes, knockdown of 
SOD1G85R in microglia alone did significantly affect both onset and survival, again 
showing the importance of disease mutation (Wang et al., 2009). Meissner (2010) 
show that mutant SOD1 treatment of microglia leads to caspase 1 and IL1β activation. 
The knockout of caspase 1 or IL1β leads to increased survival time in SOD1G93A mice. 
Non-transgenic microglia are neuroprotective when transplanted into SOD1G93A 
animals lacking any endogenous microglia (Beers et al., 2006). Finally, the 
proinflammatory transcription factor NF-ĸB increases with disease progression in the 
SOD1G93A mouse and knock-down of NF-ĸB in microglia but not astrocytes ameliorates 
inflammatory damage and extends survival in SOD1G93A mice (Frakes et al., 2014). 
In contrast to M1 polarisation, M2 microglia are thought to be neuroprotective. M2 
microglia promote differentiation of oligodendrocyte precursor cells and subsequent 
remyelination following damage to the corpus callosum (Miron et al., 2013). Miron et 
al (2013) also found M2 microglia to decrease with age in mice, a factor that might 
explain the positive correlation between age and neurodegenerative diseases. In the 
SOD1G93A model of ALS, M2 microglia are most abundant at disease onset whereas at 
end-stage disease markers of the M1 phenotype dominate (Liao et al., 2012). An 
increased amount of M2 microglia in cervical vs. Lumbar spine may contribute to the 
decreased pathology seen in cervical spine in early disease (Beers et al., 2011). 
Microglia can also be supplemented by macrophages derived from the bone marrow in 
the periphery; Lewis et al (2009) found that CX3-CR1 macrophages labelled with GFP 
were present in the CNS of the mSOD1 mouse model of ALS. Similarly, Butovsky et al. 
(2012) found that peripheral monocytes had a pro-inflammatory phenotype prior to 
disease onset and that these cells infiltrated the spinal cord as the disease progressed. 
In contrast to the above studies, a recent study by Chiu et al (2013) in which flow 
cytometry was used to characterise cell populations present in the spinal cord of the 
SOD1G93A mouse at different time-points suggests that microglia in the CNS are not 
supplemented by peripheral macrophages. In addition, a dual RNA-sequencing and 
microarray approach was used to show that microglia in the CNS of the SOD1G93A 
mouse have a distinct activation profile from the classic M1 and M2 datasets. This 
profile is characterised by increased expression of neurotrophic genes such as Igf1 but 
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also of neurotoxic genes such as Nox2. However, the comparisons made by Chiu et al 
(2013) were drawn between ALS microglia and LPS-treated RAW 264.7 macrophages 
(the M1 dataset) and IL-4 stimulated human bone marrow derived macrophages (the 
M2 dataset). Such singular stimuli would produce large-scale and highly polarised gene 
expression changes which would not reflect the multitude of factors acting upon a 
microglial cell during ALS progression. Thus, there may still be a subtle skewing of ALS-
microglia toward the M1 or M2 end of the spectrum during disease progression. 
Nikodemova (2013) show decreased expression of both M1 and M2 markers with 
disease progression, perhaps showing a decreased reactivity of the cells for either 
phenotype. 
The separation into “bad” M1 cells and “good” M2 cells is not so clear cut and is 
dependent upon the disease concerned. In experimental autoimmune encephalitis 
(EAE), a model of the neuroinflammatory disease multiple sclerosis, injection with IL-4 
conditioned bone-marrow-derived macrophages (BMDM) (Vaknin et al., 2011) or IL-10 
and IL-13 activated peripheral blood monocytes (Mikita et al., 2011) ameliorated 
symptoms whereas injection of the SOD1G93A mouse with IL-4-conditioned BMDMs 
from an early disease stage led to an acceleration of the disease which was not seen 
with IFNγ-conditioned BMDMs (Vaknin et al., 2011).  
1.5.4.1 Astrocytes and microglia are partners in inflammation 
Given the similarity of astrocytes and microglia in their response and toxicity during 
ALS progression, it is not surprising that they act in a synergistic way during 
inflammatory events. In the previously mentioned study by Yamanaka et al. (2008b) 
astrocyte-specific knockdown mSOD1 in a mouse model reduced microgliosis and 
microglial production of nitric oxide but did not affect astrogliosis (Yamanaka et al., 
2008a), suggesting that microglial activation by astrocytes is due to dysregulated 
communication between astrocytes and microglia rather than just increased astrocyte 
proliferation. In the non-diseased state, astrocytes synthesise the inhibitory 
neurotransmitter γ-aminobutyric acid (GABA), which reduces microglial activation 
during inflammatory cues (Lee et al., 2011). 
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Microglia are also able to signal to astrocytes; treatment of SOD1G93A mice with 
granulocyte colony stimulating factor (GCSF) decreased both micro- and astrogliosis 
despite astrocytes being deficient in the GCSF receptor (Pollari et al., 2011). Microglial 
TNFα release was decreased in this study, suggesting TNFα as a microglial signal for 
astrocyte activation. Indeed, TNFα can hyper-stimulate SOD1G93A astrocytes leading to 
increased production of pro-apoptotic factors such as caspase-8 and pro-inflammatory 
prostaglandin E2 (Hensley et al., 2006).  
In line with this large amount of glial crosstalk, astrocytes express a multitude of 
receptors for different cytokines. Increased expression of the IFNγ receptor has been 
suggested for multiple neurodegenerative diseases and conditioned media from IFNγ 
treated astrocytes is toxic to neuronal cell lines (Hashioka et al., 2009). Increased 
astrocytic expression of Toll-like receptor 4 (TLR4) and the receptor for advanced 
glycation products (RAGE) in human sALS post-mortem tissue supports the 
inflammatory role that these cells play in human disease (Casula et al., 2011). These 
findings contradict earlier results from Lenhardt et al. (2002, 2008), which showed TLR-
4 to be expressed exclusively upon microglia and not astrocytes, and which 
interestingly found TLR-4 to be bound by a heat shock protein (HSP60) (Lehnardt et al., 
2008), which have also been found to induce inflammatory factor production by 
astrocytes in Alzheimer’s Disease (Bruinsma et al., 2011). These inconsistent findings 
for glial TLR-4 expression may be due to the use of different tissue types; non-diseased 
rat cells were used in vitro by Lehnardt et al. whilst human post-mortem sALS tissue 
was used by Casula et al. This suggests that during the disease process astrocytes, 
perhaps through de-differentiation, can express markers more typical of microglia such 
as TLR-4 leading to amplification of a local neurogenic inflammatory state.  There is 
also evidence that microglia start to express markers more typical of astrocytes during 
disease progression in the SOD1G93A rat (Trias et al., 2013), though this may be a 
feature of the highly aggressive disease course in this model. 
Despite the focus upon the harmful inflammatory reaction during neurodegeneration, 
glial inflammation has a positive effect at least in the initial stages of disease. Phase III 
trials of minocycline, an inhibitor of proinflammatory enzymes and microglial 
activation which has previously proven beneficial in the MPTP mouse model of 
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Parkinson’s Disease (Du et al., 2001, Investigators, 2006), led to worse scores on the 
ALS functional rating scale than placebo (Gordon et al., 2007). Similarly, SOD1G93A rats 
receiving transplants of glial restricted precursors plus minocycline treatment showed 
reduced microgliosis but an initial deterioration in motor function (Papadeas et al., 
2011). Welser-Alves et al. (2011) have recently found microglial stimulation with 
lipopolysaccharide (LPS) to induce tissue inhibitor of metalloproteinase-1 (TIMP-1) 
expression in astrocytes through an IL-1β dependent manner, and microglia are also 
important in clearance of cellular debris for subsequent regeneration (Neumann et al., 
2009). 
1.5.5 Oligodendrocytes  
In addition to astrocytes and microglia, oligodendrocytes are the third glial cell-type 
that plays a role in ALS. Oligodendrocytes are important in the CNS as they produce 
the myelin which ensheathes the axonal compartment of neurons and allows fast 
saltatory conduction of nerve signals. Due to their close contact with long axons, these 
cells are also vital for metabolic support of the axon (Philips and Rothstein, 2014). NG2 
cells, also known as oligodendrocyte precursor cells (OPCs), are abundant cells in the 
CNS that were originally thought to give rise to neurons, astrocytes and 
oligodendrocytes (Nishiyama et al., 2009). It has been suggested that NG2 cells 
specifically give rise to oligodendrocytes in the CNS (Kang et al., 2010). However, NG2 
cells in cerebellar slices express GFAP, suggesting that they are also capable of 
differentiating into astrocytes in vivo (Leoni et al., 2009). NG2 cells may play a role at 
the synapse as they have been seen to receive synaptic inputs (Bergles et al., 2000), 
and are now considered a cell-type in their own right (Trotter et al., 2010). 
1.5.5.1 Oligodendrocytes in ALS 
In comparison to astrocytes and microglia there is relatively little data on the role of 
oligodendrocytes and their precursors in ALS. The main role of these cells, myelin 
production, appears compromised during disease progression. Myelin sheathes of 
axons show progressive disorganisation and loss from the symptomatic stage onwards 
in the SOD1G93A rat (Niebroj-Dobosz et al., 2007). In ALS patients, there is significantly 
less myelin in the motor cortex and ventral horn of the spinal cord at end-stage (Kang 
et al., 2013). In addition to myelin loss, TDP-43, the major constituent of protein 
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aggregates in ALS, localises with cells of oligodendrocyte morphology in cases of FTD 
(Neumann et al., 2007) and ALS (Philips et al., 2013), which may impair 
oligodendrocyte function. 
During disease progression in the SOD1G93A mouse the proliferation of OPCs 
significantly increases with most new oligodendrocytes produced in the ventral horn 
grey matter, the site of motor neuron degeneration (Magnus et al., 2008, Philips et al., 
2013, Kang et al., 2013). Despite this increased production of OPCs, the number of 
oligodendrocytes in the spinal cord of these mice at end-stage is not increased, 
suggesting that oligodendrocyte death is also a feature of the disease process. As with 
astrocytes and microglia, mutant SOD1 has been selectively excised from 
oligodendrocytes in the SOD1G37R mouse. Excision of SOD1G37R  led to a significant delay 
in the onset of disease and a significantly increased lifespan, however disease 
progression appears to be unaffected (Kang et al., 2013). 
Recently, it has been suggested that oligodendrocytes affect neuron survival in ALS 
through perturbed lactate provision (Lee et al., 2012). MCT1 (a.k.a. SLC16A1), a lactate 
transporter highly expressed by oligodendrocytes is lost from the motor cortex of 
human ALS tissue and progressively from the ventral horn of symptomatic SOD1G93A 
mice (Philips et al., 2013, Lee et al., 2012). Furthermore, MCT1 expression is increased 
upon knockout of SOD1G37R solely in oligodendrocytes (Kang et al., 2013).  
1.5.6 The involvement of other cell types in ALS 
Although motor neurons and the three main forms of glia described above are key 
players in ALS pathogenesis, other cell types in the CNS and peripheral nervous and 
immune systems are also affected and involved. Due to ALS featuring a dying back 
phenomenon of motor neurons from the neuromuscular junction to the cell body, 
skeletal muscle cells could be a site of neurotoxicity. However, deletion of mSOD1 
from skeletal muscle tissue of SOD1G37R mice does not affect the disease onset or 
progression and increasing the muscle mass also does not improve motor symptoms 
(Miller et al., 2006). Similarly, endothelia of the blood brain barrier (BBB) also have a 
very close association with astrocytes and neurons in the CNS, and the BBB is seen to 
breakdown during disease progression in the SOD1G93A mouse (Zhong et al., 2008, 
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Miyazaki et al., 2011) and ALS patients (Leonardi et al., 1984, Winkler et al., 2013). As 
with muscle cells, selective depletion of SOD1G37R within endothelia did not affect 
disease onset or survival in SOD1G37R mice (Zhong et al., 2009). In addition to 
endothelial cells, another important cell at the BBB, pericytes, are significantly reduced 
in ALS subjects versus controls, so perhaps this also leads to BBB disruption (Winkler et 
al., 2013). Lastly, another study featuring knockdown of mSOD1 within Schwann cells, 
the myelinating cells of the peripheral nervous system (PNS), actually led to a more 
aggressive disease course with accelerated disease progression (Lobsiger et al., 2009). 
Therefore a blanket approach targeting all cell types may not prove effective in ALS. 
In addition to cells located within the central and peripheral nervous systems, cells of 
the peripheral immune system are also involved in ALS pathogenesis. T-helper cells 
and T-cytotoxic cells are present in the ventral horns of patients with ALS (Engelhardt 
et al., 1993). Evidence suggests that T-cells are important modulators of astrocyte and 
microglial behaviour. Crossing of SOD1G93A mice with mice deficient in T helper cells 
leads to a faster disease progression (Beers et al., 2008). Surprisingly, astro- and 
microgliosis is decreased in these animals whilst transcript levels of the inflammatory 
cytokines TNFα and NOX2 are increased. This phenotype was rescued by a bone 
marrow transplant from wild-type mice which restored functional T-cells. Support for 
this neuroprotective role of T-cells comes from Chiu et al (2008) who found that CD4+ 
and CD8+ T-cells infiltrated the spinal cord during disease progression and promoted a 
neuroprotective phenotype in microglia. When crossed with a T-cell deficient mouse 
strain, SOD1G93A mice showed decreased amounts of microgliosis but microglia had 
also lost their neuroprotective phenotype (Chiu et al., 2008). The type of T-cell is 
important for disease progression. As with M1 and M2 microglia, T-helper cells can be 
divided into pro-inflammatory Th1 cells and anti-inflammatory Th2 cells. In the 
SOD1G93A mouse motor symptoms first occur in the hindlimbs rather than the 
forelimbs, due to more intense motor neuron death in the lumbar versus cervical cord. 
There is greater expression of neurotrophic factors such as BDNF and GDNF and anti-
inflammatory cytokines in the cervical cord of these mice coupled to a greater 
expression of Th2 genes compared to the lumbar cord where Th1 genes dominate 
(Beers et al., 2011). Another class of T-cell, T-regulatory cells (T-regs), suppress the 
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expression of microglial NOX2 and ROS to a greater extent than cytotoxic T-effector 
(Teff) cells, through the secretion of anti-inflammatory cytokines IL-4, IL10 and TGFβ 
(Zhao et al., 2012). T-regs are reduced in the peripheral blood of patients with rapidly 
progressing ALS compared to slow progressing and non-ALS controls (Henkel et al., 
2013). Treatment of peripheral T-cells may hold promise for disease progression. 
Activation of Natural Killer T-cells with a ligand that promotes an anti-inflammatory 
phenotype led to an extension in survival of SOD1G93A mice and an increase of T-cells 
within the spinal cord, again providing evidence of the beneficial effects of T-cells 
(Finkelstein et al., 2011). 
1.6  Gene expression profiling identifies dysregulated pathways in ALS 
As discussed, much is already known regarding the pathogenic mechanisms operating 
in ALS and the effect that astrocytic manipulation can have. From these broader 
disease concepts gene expression profiling using microarray technology has been used 
to delineate specific pathways that may serve as therapeutic targets. 
1.6.1 Microarray technology 
Microarray is a powerful tool for analysing the expression of thousands of genes at the 
same time. In essence, many thousands of probes are fixed to a solid surface and bind 
to complementary cDNA or cRNA targets within a sample. Fluorescent labelling of the 
target allows quantification and thus estimation of gene expression (Allison et al., 
2006). The use of photolithography for production of microarray chips was pioneered 
in 1991 (Fodor et al., 1991), and proof that gene expression measurements could be 
multiplexed came using a slightly different method involving the attachment of 48 
cDNA probes to a glass slide to identify differential gene expression in Arabidopsis 
thaliana (Schena et al., 1995). Today, microarray technology allows comparisons based 
upon factors such as disease status, treatment status, transgene expression and time 
series data (Gresham et al., 2008). 
Two main types of microarray platform exist: cDNA microarrays and oligonucleotide 
microarrays such as those produced by Affymetrix, the latter of which are now the 
major microarray platform. In cDNA microarrays, cDNA probes are attached to the 
support surface and are then used to probe a sample containing cDNA species, 
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produced by reverse transcription of sample mRNA. In oligonucleotide arrays, probes 
are designed from genomic sequences and used to interrogate a sample of 
complementary RNA (cRNA). On Affymetrix oligonucleotide microarrays, there is a 25-
nucleotide probe which perfectly matches the target mRNA species which sits next to a 
probe which is identical apart from the 13th nucleotide. This second probe acts as a 
mismatch probe to control for non-specific binding. Sample mRNA is first reverse 
transcribed to cDNA using primers containing a T7 promoter sequence. T7 polymerase 
then binds to these sites and reverse transcribes the cDNA into cRNA whilst also 
incorporating a biotin label. This biotinylated cRNA is then fragmented so as to allow 
more efficient binding to probes and is then hybridised to the probes on the array. The 
arrays are washed to remove unbound cRNA, and a streptavidin-phycoerythrin stain is 
then used to visualise the bound biotinylated cRNA on the arrays and allow 
quantification of gene expression (Figure 1.3). 
In general, cDNA microarrays are conducted using a two-colour method and 
oligonucleotide microarrays by a one-colour method. In the two colour method the 
two samples to be compared are reverse-transcribed in the presence of different dyes, 
which are incorporated into the cDNA product. Equal amounts of both samples are 
then hybridised onto the same microarray and the fluorescence read. If a gene has a 
higher expression in one condition over another then its corresponding dye will 
dominate at that probe position, however if a gene is equally expressed in both 
conditions then the dyes will merge to give a different colour (e.g. red and green to 
give yellow). In the single colour method samples from each condition are kept 
separate and are hybridised onto different arrays. The expression level on each chip is 
then calculated using internal standards and these levels compared between 
conditions. Both methods have shown consistency in the results they produce 
(Patterson et al., 2006).  
1.6.2 Chip manufacture 
For oligonucleotide arrays such as those produced by Affymetrix, microarray chips are 
synthesised using a process called photolithography. In this process a solid support 
such as a glass slide or a nylon membrane is coated with photolabile protection groups 
(Fodor et al., 1991). Light is then shone through a mask such that only specific areas of 
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the support lose protection. Nucleotides are added to the support and only adhere 
where this protection has been removed. These nucleotides also contain photolabile 
protection groups meaning that subsequent nucleotide addition can only occur if the 
protection group is removed by light. The successive use of different masks results in 
the targeting of desired nucleotides to desired locations on the array (Fodor et al., 
1991). This method allows the synthesis of thousands of 25-nucleotide long probes, 
each specific to a region of a target mRNA.  
1.6.3 Competing technologies 
Microarrays have developed beyond simply being able to measure gene expression 
and are now able to measure the abundance of different splice-forms of a gene by 
probing different exons within an mRNA (Affymetrix, 2005). Such exon arrays have 
been found to produce results in keeping with conventional IVT arrays in analysis of 
stimulated T cells, with the added benefit of information regarding alternative 
transcript abundance (Whistler et al., 2010).  
Another development in the field of large-scale gene expression profiling is next 
generation sequencing (NGS). Using this technique, the whole transcriptome of a cell 
can be sequenced giving information on expression level, transcript variants, single 
nucleotide polymorphisms etc. The process works by fragmenting the starting sample 
into small fragments of 90 base pairs (in the Illumina system) which then bind to a flow 
cell. The fragments are sequenced one base at a time using a PCR method and 
fluorescent nucleotides and are then joined back into continuous sequences using 
computer software (Mardis, 2008). The technique is expensive relative to microarray 
technologies and also requires a lot of computing power, such that data analysis can 
take days at a time. 
1.6.4  Application to ALS 
Microarray analysis in ALS first focused upon whole tissue homogenates from the 
motor cortex and spinal cord. In homogenates from patient spinal cord the analysis of 
~6800 genes identified increased expression of pro-inflammatory transcripts and 
dysregulated expression of mitochondrial transcripts and transcripts involved in 
excitotoxicity (Dangond et al., 2004). In another study of whole spinal cord from ALS 
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patients, increased lysosomal enzyme and cholesterol transport transcript expression 
was seen (Offen et al., 2009), with common gene expression between ALS patients and 
SOD1G93A mice. Microarray analysis of whole tissue from the motor cortex of ALS 
patients shows an increased expression of immune transcripts and impairment of ion 
homeostasis and glycolysis (Lederer et al., 2007).  
These initial experiments, though providing valuable information, did not identify cell 
specific gene expression and therefore the contribution of different cell-types to 
disease. To tackle this problem, microarray analysis was performed upon the NSC34 
neuronal cell line transfected with human SOD1G93A (Kirby et al., 2005). SOD1G93A 
dysregulated the antioxidant response of NSC34 cells, with Nrf2, the master regulator 
of anti-oxidant gene expression, down-regulated by 3.14 fold in comparison to cells 
transfected by vector only (Kirby et al., 2005). Other studies have focused upon 
isolation of primary cell-types from the mSOD1 mouse model. Vargas et al. (2008b) 
cultured astrocytes from neonatal SOD1G93A rats and performed gene expression 
profiling, showing a phenotype with decreased trophic support. However the time 
spent in culture may mean that gene expression profiling of in vitro astrocytes does 
not accurately reflect the in vivo situation (Blackburn, 2010). 
Another method of analysing the gene expression of a specific cell type is to identify 
and remove it from tissue post mortem. Several microarray studies in ALS have utilised 
the laser capture microdissection (LCM) technique. LCM is a technique in which a laser 
is fired through a thermo-reactive film onto a tissue section. Consequently, the film 
adheres to the tissue in the targeted region, which can then be removed. The 
combination of this technique with immunohistochemistry allows the identification 
and capture of specific cell types, and is as close as possible at capturing the gene 
expression profile of a cell in vivo. This technique has been successfully used to capture 
motor neurons from: sALS spinal cord for use on conventional microarrays (Jiang et al., 
2005); sALS spinal cord for use on exon-level arrays which identified aberrant splicing 
in sALS versus control motor neurons (Rabin et al., 2010); and SOD1-ALS human spinal 
cord motor neurons (Kirby et al., 2011). In this latter study, the PI3K/PTEN pathway 
was identified as altered in a direction favouring cell survival in those motor neurons 
which had survived the disease course. PTEN knockdown led to increased survival in 
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NSC34 and primary motor neurons expressing SOD1G93A in in vitro validation studies 
(Kirby et al., 2011). 
LCM has allowed longitudinal studies to be performed using the mSOD1 mouse model, 
allowing gene expression to be characterised at different stages of the disease. Laser 
capture microdissected motor neurons from the SOD1G93A mouse model at pre-
symptomatic (~60 day), symptomatic (~90 day) and late-stage (~120 day) has been 
performed (Ferraiuolo et al., 2007). In this analysis: pre-symptomatic motor neurons 
showed an up-regulation of genes involved in transcription and translation, 
carbohydrate metabolism and mitochondrial respiratory chain components; 
symptomatic motor neurons showed a dysregulated expression of transcription, 
signalling and cell cycle activity genes; and late-stage motor neurons showed 
dysregulated expression of immune response, axonal transport genes, a repression of 
transcription, and up-regulation of genes encoding proteins involved in the cell cycle 
(Ferraiuolo et al., 2007). This correlates with the laser captured motor neuron 
microarray data from human SOD1-linked ALS cases in which transcriptional repression 
was identified (Kirby et al., 2011). 
In addition to motor neurons, LCM-microarray studies are now being performed upon 
astrocytes and have revealed a key role for astrocytes in metabolic homeostasis in 
early disease. A reduction in lactate provision is seen in pre-symptomatic SOD1G93A 
astrocytes (Ferraiuolo et al., 2011a), which when re-supplied exogenously leads to 
motor neuron rescue. This provides an example of the power of microarray to identify 
therapeutic targets. In a different approach, de Oliveira et al. (2013) performed 
microarray of whole tissue from two pre-symptomatic time points and then confirmed 
whether genes were differentially expressed in astrocytes using subsequent LCM and 
qPCR. 
Again, it is important to remember the heterogeneity of ALS; mutations in several 
other genes cause ALS through apparently different pathological mechanisms to SOD1 
and this is evident in gene expression data. For example, expression analysis of human 
motor neurons from patients with a mutation in CHMP2B (charged multivesicular 
protein 2B) showed perturbations in MAPK and calcium signalling and also in 
  43 
autophagic activity (Cox et al., 2010), whilst mice with a deletion in the hypoxia 
response element in the promoter of VEGF, which causes an ALS-like disorder, display 
differential expression of genes involved in cholesterol metabolism as well as nervous 
system development (Brockington et al., 2010).  
Further investigation of microarray data using functional in vitro and in vivo studies is 
now common. The field of gene therapy offers an opportunity to correct the 
dysregulated gene expression seen in microarray studies. Gene therapy has already 
proved effective in treatment of the SOD1G93A mouse. For example, viral delivery of 
IGF-1 has been shown to be protective in the SOD1G93A mouse (Kaspar et al., 2003) and 
delivery of short hairpin RNA to knock down SOD1 expression has been performed by 
Foust et al. (2013). Certain viral sub-types, such as adeno-associated virus 9 (AAV9), 
preferentially target astrocytes and neurons (Foust et al., 2009), making the 
modulation of neuronal and astrocyte gene expression a reality. 
1.7 Summary of the current situation 
Astrocytes play a fundamental part in almost every aspect of neuronal health. The 
oxidative stress, excitotoxic and inflammatory reactions that occur during ALS are 
mediated by complex interactions between astrocytes, microglia and neurons and 
there is promise that modification of these cells’ behaviour may modulate the disease 
course. 
As previously mentioned, riluzole, a drug which counteracts glutamate excitotoxicity, is 
the only approved drug for ALS and extends life by approximately three months on 
average (Miller et al., 2007). This demonstrates the significance of excitotoxicity, a 
process which astrocytes are a key part of, in disease progression. A major problem in 
finding effective therapeutic strategies for the treatment of ALS is the multifaceted and 
non-cell autonomous disease process (Figure 1.2). In addition to inflammation, 
metabolic support, oxidative stress and excitotoxicity, disruptions in processes such as 
ion regulation and neurogenesis also occur. All of these processes are heavily 
interconnected such that the targeting of one element may not ameliorate disease 
progression. Knockdown of mSOD1 in multiple different cell types of mSOD1 
transgenic mice shows a differential contribution of each cell type to the onset and the 
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duration of disease progression, thus understanding the contributions of each affected 
cell type is also important for therapeutic intervention.  
The definitive mechanism that starts the ALS disease process remains elusive. This 
highlights a major obstacle in the study of ALS in that the long time-course of disease 
means that many homeostatic functions are dysregulated by the time symptoms 
appear. In ALS, genetic mutations in fALS patients allow causal links to be established, 
however for the remaining ~90% of sALS patients pinpointing the cause of disease 
remains difficult. Due to the complexity of the disease process a top-down approach is 
needed so that interactions between different disease mechanisms can be identified. 
This approach can then be used to study the specific changes that occur in astrocytes 
during ALS and how these affect their interaction with motor neurons. Work with 
animal models is vital, allowing different time-points of disease and specific cell types 
to be investigated. The development of a SOD1G93A mouse model which has a highly 
consistent disease course (Mead et al., 2011) has allowed for the separation of the 
disease course into pre-symptomatic (60 day), symptomatic (90 day) and late-stage 
(120 day) disease. This robust disease model gives strength to microarray studies of 
the various time-points, and has already led to the previously mentioned important 
findings at the pre-symptomatic time point (Ferraiuolo et al., 2011a). 
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1.8 Hypothesis and aims 
Astrocytes have been laser-capture microdissected and RNA extracted from 
symptomatic and late-stage time points of the SOD1G93A mouse and non-transgenic 
controls. Microarray has been performed, however these data are still to be analysed. 
This analysis will investigate astrocyte behaviour throughout the disease time-course 
and also compare toxicity and loss of support as potential astrocyte-mediated disease 
mechanisms in ALS. Importantly as stated earlier, although the SOD1G93A mouse-model 
recapitulates the human pathology, differences are still observed between murine and 
human SOD1-ALS. In addition, human astrocytes have greater complexity than mouse 
astrocytes. Thus, it is important to conduct similar studies of human astrocytes. 
Therefore, human SOD1-ALS patient and healthy control astrocytes will be laser 
capture microdissected post-mortem and microarray analysis performed. This will 
create the first microarray analysis of human astrocytes in SOD1-ALS. 
Two hypotheses will be tested by this project. 
1.8.1 Microarray of astrocytes from the SOD1G93A mouse model 
The hypothesis tested in this part of the project will be: 
Astrocytes in symptomatic and late-stage SOD1G93A transgenic mice possess 
dysregulated gene expression that reveals the contribution of astrocytes to motor 
neuron death throughout the disease course.  
The initial aims of this project are as follows: 
1. To conduct an analysis of microarray data from symptomatic and late-stage 
SOD1G93A astrocytes isolated from murine spinal cord by LCM. 
2. To conduct validation studies to investigate pathways discovered through 
microarray analysis. 
3. To evaluate how the symptomatic and late-stage microarray data fits in with 
data obtained from pre-symptomatic SOD1G93A astrocytes so as to build a 
picture of the role of astrocytes over the course of the disease. 
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1.8.2 Microarray of astrocytes from SOD1-ALS human subjects 
The hypothesis of this part of the project is: 
Astrocytes in SOD1-ALS human subjects possess dysregulated gene expression that 
reveals the contribution of astrocytes to motor neuron death. 
The aims of this part of the project are as follows: 
1. To isolate astrocytes from human spinal cord of SOD1-ALS subjects and controls 
by LCM for use in microarray analysis. 
2. To conduct an analysis of microarray data from isolated astrocytes. 
3. To conduct validation studies to investigate pathways discovered through 
microarray analysis. 
4. To evaluate how the data from human SOD1-ALS cases compares to that seen 
in microarray analysis of SOD1G93A astrocytes. 
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2 Materials and methods 
2.1 Materials 
The SOD1G93A mouse model, staining, laser capture microdissection (LCM) and 
microarray analysis were performed as in Ferraiuolo et al. (2011a) and are summarised 
below. 
2.1.1 SOD1G93A transgenic mouse model 
Mice used were male high copy number B6SJL-Tg (SOD1G93A) 1 Gur/J, which had been 
backcrossed onto C57Bl/6 J Ola/Hsd (Harlan) for over 20 generations, and their non-
transgenic littermates. All procedures were performed according to UK Home Office 
regulations. Symptomatic and late-stage mice were euthanised by Dr Laura Ferraiuolo 
by intraperitoneal injection of Pentobarbital (supplied by University veterinary 
services) and transcardially perfused with PBS containing 30% sucrose. The CNS was 
removed and snap-frozen in liquid nitrogen, and then stored at -80˚C. Subsequent 
staining and LCM of symptomatic and late-stage astrocytes performed by Mr Paulius 
Viskaitis and Dr Dilraj Sokhi respectively. 
For primary motor neuron culture, embryos of C57Bl/6 J Ola/Hsd (Harlan) mice were 
used at gestational day 13.  
2.1.2 Cases for human microarray study 
Cases for the microarray analysis of human SOD1-astrocytes and controls were 
obtained from the Sheffield MND Brain Tissue Bank and according to local research 
ethics committee (LREC) regulations and were stored as frozen blocks at -80˚C (Table 
2.1). 
2.1.3 Chemicals and reagents 
General reagents were sourced from either Fisher Scientific or Sigma unless otherwise 
stated. Plastics for tissue culture were obtained from Sigma unless otherwise stated.
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Table 2.1 Details of the human cases and controls from which astrocytes were obtained. Mutations are described based upon the recommendations of the 
Human Genome Variation Society (www.hgvs.org). sALS = sporadic-ALS. 
ID Disease 
status 
Mutation Disease 
duration 
(months) 
Date of death Post mortem 
interval 
Age (death) Gender Reason for death 
Tissue for human array studies       
2JK4 Control    24  80 Female Pulmonary 
embolism 
2JK3 Control    25 71 Male Burst aortic 
aneurysm 
2JK7 Control    24 54 Female Ovarian cancer 
135.34 Control    24 89 Female Unknown 
2JK10 Control    12 82 Male Pulmonary 
fibrosis 
20/07 Control    32 77 Male Lobar pneumonia 
34/92 SOD1-ALS p.E101G 41   23 40 Female ALS 
37/04 SOD1-ALS p.I114T 13  27 60 Female ALS 
49/94 SOD1-ALS p.I114T 14  50 66 Female ALS 
Cells for tissue culture studies       
155 Control        
AG Control        
170 Control        
210 SOD1-ALS p.D77Y       
295 SOD1-ALS p.D91A       
009 sALS Unknown       
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2.2 Methods 
2.2.1 Gene expression profiling of murine SOD1G93A astrocytes 
2.2.1.1 Rapid staining procedure of murine astrocytes 
Rapid staining of astrocytes for LCM was performed as in Ferraiuolo et al (2011a). This 
protocol allows rapid isolation of astrocytes so as to preserve RNA quality. Sections 
(10µm) of frozen mouse lumbar spinal cord or human cervical spinal cord were placed 
on microscope slides and fixed in 4˚C acetone for 3 mins. Sections were then incubated 
in goat serum blocking solution for 3 mins at room temperature. For the mouse study, 
the primary antibody used was rabbit polyclonal anti-ALDH1L1 (Abcam, #ab 79727) at 
1:50 dilution whereas for the human study anti-GFAP (DAKO # Z0334) at 1:150 was 
used. Primary antibody was added to the slides and left for 3 mins at room 
temperature. Slides were washed 3 times in Tris-buffered saline (TBS) for 10 secs and 
incubated with secondary antibody (1:200 in TBS) for 3 mins. Slides were washed 3 
times in TBS for 10 secs then incubated in ABC solution for 3 mins at room 
temperature. Goat serum, secondary antibody and ABC solution were from the 
Vectastain rabbit IgG kit (Vector Labs # PK-6101). Slides were washed 3 times in TBS for 
3 mins and incubated in diaminobenzidene for 3 mins in the dark. The reaction was 
stopped in water for 15 secs and dehydrated in a graded alcohol series: 70%, 95% and 
100% for 15 secs followed by xylene for 5-10 mins. Slides were then allowed to dry at 
room temperature for 30 mins.  
2.2.1.2 Laser capture microdissection of murine astrocytes 
In the mouse study, laser capture of ~1500 astrocytes from the ventral horn of the 
lumbar spinal cord was performed using the Arcturus Pixcell II microdissection 
instrument (Life Technologies, Carlsbad, CA) with Arcturus Capsure Macro LCM Caps 
(Life Technologies #LCM0211) (Figure 2.1). LCM of symptomatic and late-stage 
astrocytes was performed by Mr Paulius Viskaitis and Dr Dilraj Sokhi respectively. For 
qPCR validation one of the non-transgenic littermates had astrocytes laser captured 
using the Arcturus Veritas microdissection instrument (Life Technologies). RNA was 
extracted from captured cells using the Arcturus Picopure RNA Isolation kit (Life 
Technologies #12204-01) and tested for RNA quantity using the Agilent Nanodrop 
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spectrophotometer ND-1000 (Agilent Technologies, Santa Clara, CA)  and for quality 
using the RNA 6000 PicoChip kit (Agilent # 5067-1513).  
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Figure 2.1 The process of capturing cells using LCM through to gene expression profiling by 
microarray analysis using the Affymetrix platform. Cells are labelled with specific antibody and 
captured using LCM equipment (top). The RNA is extracted, reverse transcribed and then in 
vitro transcription performed with biotin-labelling of the resultant cRNA. cRNA is then 
fragmented and hybridised to the GeneChip, which contains perfectly matching probes and 
mismatch probes containing a non-matching base at the 13th nucleotide position, which 
control for non-specific binding. Following wash and stain steps, presence of mRNA species is 
visualised using a scanner, whereby increased signal is reflective of increased expression of the 
target transcript. 
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2.2.1.3 Microarray analysis 
RNA was linearly amplified using the Genechip two-cycle cDNA synthesis kit 
(Affymetrix #900432). cRNA was generated using the GeneChip Expression 3’ 
Amplification Reagents for IVT labelling (Affymetrix). 15µg of cRNA for each of 3 x 
SOD1G93A and 3 x NTg mice was fragmented and hybridised onto Mouse Genome 430 
2.0 Genechips (Affymetrix #900495).  
2.2.1.4 Data processing and analysis  
Quality control checks were performed using the Affymetrix Expression Console 
software and the packages “simpleaffy” (Miller), “affyqcreport” (Parman et al.) and 
“affyPLM” (Bolstad) within Bioconductor (Gentleman et al., 2004) and R (R-Core-Team, 
2014) following the script in Appendix 1. Initial GeneChip analysis for determination of 
differentially expressed transcripts was performed using Genespring GX (Agilent) and 
the Probe Logarithmic Intensity Error (PLIER) algorithm, as in the analysis of 60 day 
astrocytes by Ferraiuolo et al. (2011a). Transcripts with fold change ≥ 2 and p ≤ 0.05 
were defined as differentially expressed as in Ferraiuolo et al. (2011a). Due to an n 
number of 3 in the mouse study, multiple testing correction was not used on 
microarray data. Probesets were filtered from the dataset using MAS5 present call in 
Bioconductor, whereby a probeset was excluded if it was called absent in all samples 
(see Filter section of Appendix 1).  
2.2.1.5 Gene Ontology categorisation 
For Gene Ontology categorisation, the Database for Annotation, Visualisation and 
Integrated Discovery (DAVID) v6.7 was used (http://david.abcc.ncifcrf.gov/) in 
combination with NetAffx Analysis Centre (www.affymetrix .com) and Genecards V3 
(www.genecards.org). All DAVID analyses were run using the functional annotation 
clustering tool with the Gene Ontology terms for biological process, cellular 
compartment and molecular function selected, and using the highest stringency 
settings. Enrichment of pathways in the Kyoto Encyclopedia of Genes and Genomes 
(KEGG) was also performed using DAVID. These databases were chosen for 
investigation in DAVID due to the clarity of the annotations provided. 
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2.2.2 Quantitative PCR (qPCR) validation 
2.2.2.1 cDNA synthesis 
The Quantitect Reverse Transcription Kit (Qiagen # 205311) was used for all cDNA 
synthesis. Primers were optimised using either Universal cDNA which had been 
synthesised from Universal Mouse Reference RNA (Agilent  #740100), or cDNA 
obtained from cultured cells, at a concentration of 12.5ng/µl. Amplified RNA from 
SOD1G93A and NTg astrocytes (from which aliquots had also been taken for the arrays) 
was synthesised to cDNA for qPCR validation of microarray results.  
2.2.2.2 Primer design and optimisation 
Genes were chosen for validation from categories that were enriched in both the 
symptomatic and the late-stage time-points. Primers were designed for genes of 
interest using the Primer Blast tool from NCBI 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). Accession numbers for each gene 
were entered and primers designed within or near to the region of the corresponding 
probe on the Affymetrix Mouse Genome 430 2.0 GeneChip. Primer pairs were chosen 
that did not bind to non-specific targets and that detected all transcripts of a gene (if 
multiple transcripts were present). Primers were designed to produce amplicons of 50-
150bp in length and to overlap an exon boundary. If an exon boundary could not be 
overlapped controls were used which had received no reverse transcriptase enzyme 
during cDNA synthesis, thus checking for the presence of genomic DNA. Primers were 
ordered from Sigma Aldrich at a synthesis scale of 0.025µmol and desalt purification 
and were kept at a stock concentration of 100µM at -20°C according to manufacturers 
instructions. A range of primer concentrations were tested (Table 2.2) and the 
optimum primer concentration was chosen as the concentration that produced the 
best replicates and the cleanest dissociation curve. Agarose gel electrophoresis was 
performed to confirm that products were the correct size. Primer sensitivity was then 
tested using a serial 1:2 dilution of cDNA from 12.5ng/µL to 0.2ng/µL with subsequent 
generation of a standard curve. Primers were taken forward to qPCR validation if they 
had an r2 value of 0.98 or above and were between 90 and 110% efficiency. For primer 
optimisation and validation, reactions were performed in 20µL reaction volumes 
containing 10µL Brilliant III Ultra Fast SYBR®Green qPCR mastermix (Agilent # 600882), 
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1µL cDNA (12.5ng/µL), forward and reverse primers (concentrations indicated in Table 
2.2) and the reaction volume completed with nuclease free water. qPCR was run at 
95˚C for 10 mins followed by 40 cycles of 95˚C for 30 secs and 60˚C for 1 min, this was 
then followed by 95˚C for 1 min, 55˚C for 30 secs and 95˚C for 30 secs. 
2.2.2.3 qPCR of samples 
qPCR was performed on a Stratagene MX3000p qPCR instrument (Stratagene, CA) with 
analysis performed using the MXPro software v4.10 build 389 by Stratagene. To 
calculate relative concentration differences between SOD1G93A astrocytes and NTg 
controls the 2(-Delta Delta Ct) method was used (Livak and Schmittgen, 2001). Gapdh 
was chosen as the housekeeping gene due to a consistent expression level across all 
GeneChips. Genes were tested for statistical significance using a one-tailed 
independent samples t-test in Graphpad Prism v 6.05 (Graphpad Software Inc.). 
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Table 2.2 Primer concentrations used in primer optimisation for qPCR. Primers were first 
tested at concentrations in the range 150/150nM to 600/600nM. However if spurious products 
were observed (indicative of non-specific product amplification) then concentrations in the 
range 50/50nM to 150/150nM were tested. 
Forward primer 
concentration (nM) 
Reverse primer 
concentration (nM) 
50 50 
100 50 
50 100 
100 100 
150 100 
100 150 
150 150 
150 300 
300 150 
300 300 
600 300 
300 600 
600 600 
 
Table 2.3 Primers and primer concentrations used in qPCR validation of mouse microarray data 
and subsequent microglial phenotype studies. 
Gene category Gene name Gene 
symbol 
Primers (5’ – 3’) Conc. 
Used 
(nM) 
Lysosome Cathepsin D Ctsd FW:TGCTGCCCTCTGCCTGTCTGA 150 
   RV:AGGGCGGCAGGACAAGACAA 150 
 Cathepsin S Ctss FW:CGACGCCAGCCATTCCTCCTT 150 
   RV:AGAGTCCCATAGCCAACCACAAGA 150 
 Hexosaminidase A Hexa FW:TCGCTGAGAGACTGTGGAGCAGTA 150 
  RV:GGCCTGGATTCCTCTCCTCACCA 150 
 Lysosomal-associated 
protein 
transmembrane 5 
Laptm5 FW:AGCACCTGGAGGCTGGGAAGTC 
RV:TTGCCATCAGAGCAGTGGCTCAT 
150 
150 
    
Complement 
components 
C1qb C1qb FW:CACCAACGCGAACGAGAACT 150 
  RV:GGCCAGGCACCTTGCA 150 
Immune 
response 
C-X-C motif 
chemokine 10 
Cxcl10 FW: TAGCTCAGGCTCGTCAGTTCTA 300 
 RV: TGGGAAGATGGTGGTTAAGTTC 150 
 Chemokine (C-C 
motif) ligand 6 
Ccl6 FW: GCAGGCATTGTCACCCACTT 50 
  RV: AGGCGGAGTCCACATGAATAC 100 
Extracellular 
Matrix 
Matrix 
metalloproteinase 9 
Mmp9 FW: TGGGCCCCAGGAGTCTGGATAAG 
RV: CGAATCTCCAGACACGCCCCTTG 
150 
150 
   
 Tissue Inhibitor of 
Metalloproteinase 1 
Timp1 FW: CTGTGGGAAATGCCGCAGAT 150 
  RV: GTTCTGGGACTTGTGGGCATA 300 
 Lipoprotein Lipase Lpl FW: CGGCATCCCCATTATTGCTA 300 
   RV: CTTTCCAGTGTTTACAAGCATTC 300 
 Chondrolectin Chodl FW: ACACGTGCCTTACAATTATTCTT 150 
   RV: ACCTGTGATTTGTACTGCAGATG 150 
Other Insulin-like growth 
factor binding protein 
5 
Igfbp5 FW:CCCCGCCTCTCTTCCCTGTTAG 50 
  RV:GGCCAGAGTCTGTGAAGTGGTGA 50 
 Activating 
transcription factor 3 
Atf3 FW:TTCTGAGAGTCTGGGGATCTGCCAT 100 
  RV:TCCCCTGGTGCCAGCCAGTTC 100 
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Gene category Gene name Gene 
symbol 
Primers (5’ – 3’) Conc. 
Used 
(nM) 
M1 microglial 
marker 
Nitric Oxide synthase 
2 
Nos2 FW:TGGAGACTGTCCCAGCAATG 300 
 RV: GCGCAGAACTGAGGGTACAT 150 
 Prostaglandin-
endoperoxide 
synthase 2 
Cox2 
(Ptgs2) 
FW: CCCATGGGTGTGAAGGGAAATA 
RV: AAGTGCTGGGCAAAGAATGC 
300 
150 
    
M2 microglial 
marker 
Arginase 1 Arg1 FW:CTCCAAGCCAAAGTCCTTAGAG 300 
  RV:AGGAGCTGTCATTAGGGACATC 300 
 Chitinase, acidic Ym1 FW:TCACTTACACACATGAGCAAGAC 300 
   RV: CGGTTCTGAGGAGTAGAGACCA 300 
House keeping Glyceraldehyde-3-
phosphate 
dehydrogenase 
Gapdh FW: GCTACACTGAGGACCAGGTTGTCT 300 
  RV: AGCCCCGGCATCGAA 300 
 
2.2.3 Functional studies of murine astrocytes 
2.2.3.1 Isolation of astrocytes from neonatal animals 
SOD1G93A and NTg littermate neonatal mouse pups up to a maximum of 2 days old 
were euthanised by cervical dislocation. The head was removed and kept on ice and 
tail clips taken for genotyping (Section 2.2.3.2) Under sterile conditions, the skull was 
cut dorso-ventrally along the midline and peeled back, and the brain removed in one 
piece. The brain was placed in Hanks Balanced Salt Solution (HBSS) without Calcium or 
Magnesium (HBSS-/-) and the hindbrain, diencephalon, and meninges removed to 
leave the cortical hemispheres. The cortical hemispheres were transferred into 
minimal amounts of HBSS -/- and finely chopped with a scalpel. The resulting tissue 
was then taken up in a P1000 pipette with a pre-cut tip (tips were cut with sterile 
scissors to give a larger aperture) and placed in a falcon tube with 6mL of HBSS-/- 
(Lonza #BE10-547F) on ice to settle. Once settled the HBSS-/- was replaced with 6mL of 
HBSS containing Calcium and Magnesium (HBSS+/+) and 100µL 2.5% Trypsin with 
Versene (Lonza, #BE17-160E), 30µL 10mg/mL Collagenase (Sigma, #C6885) and 30µL 
10mg/mL DNAse (Sigma #D5025-15KU) added. Each falcon was placed at 37˚C for 15 
minutes, with gentle mixing performed every five minutes, and the tissue was then 
triturated 10 times using a 10mL stripette (where one trituration equals a movement 
up and down the stripette). This step was repeated and 6mL of Dulbecco’s Modified 
Eagles Medium (Lonza, #BE12-741F) containing 10% Foetal Bovine Serum (Biosera, 
#S1900-500) and 1% Penicillin/Streptomycin (Lonza, #DE17603E) added to neutralise 
  58 
the trypsin (this medium formulation is hereafter called “DMEM complete”). Falcons 
were then spun at 400g for 4mins to pellet the cells. Pellets were re-suspended in 4mL 
DMEM complete and plated in T25 flasks (Greiner one bio #609175). 
2.2.3.2 Genotyping of neonatal animals 
Tail clips from neonatal animals were taken and placed in 0.5mL eppendorf tubes. 
30µL of QuickExtract DNA Extraction Solution (Epicentre # QE09050) was added to 
each tube, making sure that the clip was submerged. Tubes were vortexed and briefly 
centrifuged to make sure contents were at the bottom, and were then placed onto a 
heat-block at 65˚C for 30 minutes, with brief vortexing and centrifugation halfway 
through the incubation period. When the 30 minutes had elapsed, tubes were 
incubated at 98˚C for 2 minutes, giving DNA extract ready for use in PCR. For each 
animal, 1µL of DNA extract was then added to a 0.2mL eppendorf tube containing 
4.5µL nuclease free water, 2µL FIREPol 5x PCR Mix RTL 7.5 (Solis Biodyne # 04-12-
00115). Primers were added at a concentration of 400nM for human SOD1 (FW: 5’ 
CATCAGCCCTAATCCATCTGA 3’, RV: 5’ CGCGACTAACA ATCAAAGTGA 3’) and IL2 as a 
control (FW: 5’ CTAGGCCACAGAATTGAAAGATCT 3’, RV: 5’ GTAGGTGGAAATTCTA 
GCATCATC 3’). Samples were then run on a thermal cycler with the following 
conditions: 94˚C for 5 mins followed by 30 cycles of: 94˚C for 1 min; 60˚C for 45 secs; 
72˚C for 30 secs, and a final extension at 72˚C for 10 mins. Products were then run on a 
2% agarose gel (1g agarose in 50mL TAE buffer) containing 1µL ethidium bromide with 
DNA Hyperladder IV (Bioline # BIO-33029) for 25 minutes at 60V. When visualised 
under UV light, non-transgenic mice present a single band at ~320 base pairs (bp) 
whereas transgenic mice present two bands, one at ~320bp and one at ~250bp. 
2.2.3.3 Sub-culture of mouse SOD1G93A astrocytes 
All cell culture was performed under sterile conditions in a Labgard ES Class II 
Biological Safety Cabinet. Once the primary cell layer was 100% confluent, Parafilm® 
(Pechiney # PM996) was wrapped around the top of the flasks and they were placed 
onto a shaker overnight at 225 r. p. m. at 37˚C to remove overlying microglia. Overlying 
microglia could be harvested at this stage for use in experiments (Section 2.2.3.10). 
Cells were then washed with DMEM/Ham’s F12. This was then replaced with HBSS-/- 
containing 0.25% trypsin (without Versene Lonza # BE17-160E) and 1mM EDTA added 
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in a 1:2 ratio with DMEM/Ham’s F12. Flasks were incubated at 37˚C for 45-60 minutes 
until the astrocytic monolayer detached as a sheet or as small pieces of a sheet. The 
flasks were then placed vertical, allowing astrocytic sheets to sink to the bottom where 
they were collected using a P1000 pipette. The astrocytic sheets were placed into 
15mL falcon tubes with 6mL HBSS-/- containing 0.25% trypsin and incubated at 37˚C 
for 10 minutes, followed by trituration ~20 times to resuspend astrocytes as single 
cells. trypsin was neutralised with 6mL DMEM complete and falcons centrifuged for 4 
minutes at 400g. Supernatant was removed and pellets resuspended in 12mL DMEM 
complete. This was then plated in T75 culture flasks. All subsequent passages were 
performed once flasks had reached 90% confluence. Cultures were trypsinised in HBSS-
/- containing 0.25% trypsin and incubated at 37˚C for 15 minutes. Once cells were in 
suspension, DMEM complete was added in equal volume to HBSS-/- to neutralise 
trypsin, and the resulting solution was removed to a 15mL falcon tube. This was then 
spun at 400g for 4 minutes, the supernatant removed, and the pellet resuspended in 
DMEM complete. The resulting cell suspension was split between 2 or 3 x T75 culture 
flasks, and the volume of the flasks made up to 12mL using DMEM complete. Cells 
were kept at 37˚C with 5% CO2. 
2.2.3.4 Isolation and culture of primary embryonic motor neurons for separated co-
culture 
Motor neurons and astrocytes were cultured in a separated co-culture as in Ferraiuolo 
et al. (Ferraiuolo et al., 2007). In a tissue culture hood, paraffin wax was heated to 
~100°C and three spots pipetted into the bottom of a well of a 24 well tissue culture 
plate for each replicate. Wax was allowed to set and wells were then washed twice 
with sterile distilled water. Poly-D-ornithine (1:1000) was pipetted in to cover the 
surface of the well and the plate was incubated overnight at 4°C. The following 
morning, poly-D-ornithine was removed and the plate washed twice with water, then 
allowed to dry completely. Once dry, laminin (1:200, Gibco #23017-015) was spotted in 
to the coverslips in 50µL volumes and plates were incubated at 37°C for a minimum of 
2 hours. 
Pregnant C57BL/6 mice were euthanised at gestational day 13 and the embryonic sac 
dissected out and placed into a petri dish on ice. In a tissue culture hood, embryos 
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were removed from the embryonic sac and placed into ice cold PBS in a petri dish. 
Using a dissecting microscope the head and lower limb buds were removed using 
sterile dissection instruments. The embryo was placed belly down and the skin cut 
along the back to reveal the spinal cord. The cord was removed from the body and 
meninges removed. It was then cut into 4 pieces and placed into a 15mL falcon tube 
containing 1 mL of ice cold PBS. This process was repeated until all embryos had been 
processed. Spinal cords were pooled in the last step into the 1mL of PBS. Cords were 
trypsinised by adding 10µL of 2.5% trypsin without versene followed by a 10 minute 
incubation at 37°C in which tissue was agitated at the halfway point. Trypsin was 
neutralised with 1mL containing 80% L15 media (Fisher # 10339113), 10% BSA (4%; 
Sigma # A3311-10G) and 10% DNAse (1mg/mL; Fisher # 11478533). The tube was 
agitated to disaggregate tissue fragments and then triturated twice with a P1000 
pipette. The tissue fragments were allowed to settle and the supernatant was 
removed to a new tube. To the remaining fragments 1mL of a mix containing 88% L15, 
10% BSA(4%) and 2% DNAse was added and the tissue triturated six times with a 
P1000 pipette. The fragments were allowed to settle and the supernatant removed. 
This step was repeated until the majority of tissue had been broken down. Using a 
sterile glass Pasteur pipette a 1.5mL cushion of BSA(4%) was added to the bottom of 
the tube, taking care to avoid mixing of the BSA and media, and preps were 
centrifuged for 5 minutes at 370g at room temperature. The supernatant was then 
removed and the pellet resuspended in 1mL of L15 by trituration six times with a 
P1000 pipette.  Optiprep solution (3.7%) was prepared for density centrifugation of 
cells as follows: 0.8g D-glucose, 2mL Tricine (10mM), 1.23mL of Optiprep solution 
(Axis-Shield #1114542) and 16.77mL of sterile H2O, which was then filter-sterilised. 
Using a sterile glass Pasteur pipette 1.5mL of the 3.7% optiprep solution was layered 
underneath the cell suspension taking care not to mix the two. The cell suspension was 
then spun for 15 minutes at 755g at room temperature. After this step, motor neurons 
were located at the interface of the cell suspension and the 3.7% optiprep solution, 
whilst glial cells were contained in a glial pellet at the bottom of the tube. Neuronal 
cells were removed from the interface in a volume of 1mL and added to a new falcon 
tube containing 9mL L15 medium. A 1.5mL cushion of 4% BSA was added to the 
bottom of this tube as before and cells were spun for 5 minutes at 370g at room 
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temperature. Following this step the majority of supernatant was removed and the cell 
pellet resuspended in 200µL of complete motor neuron medium (Neurobasal medium 
(Fisher# 10770954) containing: 1X B27 (Fisher# 10620975), 2% horse serum (Life 
#16050-122), L-glutamine (0.5mM), 1% penicillin/streptomycin (Lonza #DE17-603E), L-
glutamic acid (25µM), 5ng/mL CNTF (R&D systems #557-NT-010), 1ng/mL GDNF (R&D 
systems #512-GF-010), 1ng/mL BDNF (Fisher #10605414). L-glutamic acid was removed 
from medium after first 3-5 days. Excess laminin was removed from the 24 well plate 
and motor neurons added at a density of 5 x 104 cells per well. Medium was added to a 
final volume of 0.5mL. Motor neuron presence was confirmed by staining with 
antibodies against Islet 1 at 1:1000 (Abcam #ab109517), SMI32 at 1:1000 (Covance 
#Smi-32r) and Map2 at 1:2000 (Sigma #M4403). 
2.2.3.5 Antibodies used for characterisation of murine cultures 
Cell cultures were characterised using a combination of flow cytometry and 
immunocytochemistry (ICC) (Table 2.4).  
2.2.3.6 Analysis of purity of cell cultures by flow cytometry of and ICC 
Astrocytes were characterised using anti-mouse GLAST-APC conjugated antibody and 
isotype control. Microglia were characterised using anti-mouse CD11b-FITC and 
isotype control. Flow cytometry was performed on a FACSCalibur (BD) flow cytometer 
using PI (stock at 500µg/mL added as 2µL immediately prior to FACS analysis) to 
remove dead cells from the analysis. Due to dim staining of the CD11b antibody upon 
the microglial cultures, this antibody was tested in ICC to define culture purity, with a 
rabbit polyclonal anti-GFAP antibody used to identify contaminating astrocytes. Three 
separate preparations of microglia were performed (Section 2.2.3.3) and plated onto 
Poly-D-ornithine coated ø0.13mm coverslips. Coverslips were stained as in section 
2.2.3.7. and fields of view were captured in a horizontal transect through the middle of 
the coverslip (12-13 images) as in section 2.2.3.9. The number of CD11b+ cells in each 
field were counted by 3 independent scorers and the average of all three scorers 
calculated and expressed as percentage of all cells. 
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Table 2.4 Antibodies used in flow cytometry of astrocyte and microglial cultures. 
Cellular 
target 
Antigen Conjugate Isotype Host 
species 
Raised 
against 
Dilution Supplier and 
code 
 
Primary antibodies 
Astrocyte GLAST APC IgG2a Mouse Human, 
mouse, 
rat 
1:11 Miltenyi 
Biotech 
# 130-098-
803 
Microglia Cd11b FITC IgG2b Rat Mouse 1:100 Ebioscience # 
11-0112-81 
 
Isotype controls 
  APC IgG2a Mouse  1:11 Miltenyi 
Biotech # 
130-098-850 
  FITC IgG2b Rat  1:100 Ebioscience # 
11-4031-81 
 
2.2.3.7 Preparation of coverslips for staining of astrocytes and microglia 
Under sterile conditions, 1.1mm coverslips (Scientific Laboratory Supplies # MIC3366) 
were sterilised in 70% ethanol and then submerged in 1:1000 (in water) poly-dL-
ornithine for at least 30 minutes at room temperature. Coverslips were then placed 
into wells of a 24-well plate (Greiner bio one # 662160) and allowed to dry. Cultured 
cells were trypsinised and counted, and a minimum of 5000 cells aliquoted onto each 
coverslip in 50µL aliquots. The coverslips were incubated for 30 minutes to allow 
attachment of cells and then the media topped up to 1mL. Once cells had grown to at 
least 40% confluence, coverslips were fixed in 4% formaldehyde solution (4% w/v 
paraformaldehyde in PBS) for 20 minutes at room temperature. Coverslips were 
washed three times with PBS and used immediately for immunocytochemistry.  
2.2.3.8 Procedure for staining of murine astrocytes and microglia 
Cd11b staining of microglia was performed using the same antibody as used for flow 
cytometry (Table 2.4). Coverslips were washed 3 times with PBS and then blocked in 
5% goat serum for 1 hour at room temperature. Primary antibodies were diluted as 
indicated in Table 2.4 in blocking solution. Coverslips were transferred to parafilm and 
80µl of primary antibody added to each coverslip and incubated overnight at 4˚C. 
Following incubation, coverslips were transferred back to a 24 well-plate and washed 
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with PBS then mounted on glass microsope slides using Vectashield Hard-Set Mounting 
Medium with DAPI (Vector Laboratories #H-1500).  
In order to identify astrocytic contamination in microglial cultures, GFAP staining of 
microglia was performed as above with the following additional steps. Following 
fixation and washing with PBS, cells were permeabilised in 0.1% TritonX-100 (VWR # 
28817.295) for 3 minutes. Cells were then washed and received primary antibody and 
overnight incubation at 4˚C. Following incubation, coverslips were transferred back to 
a 24 well-plate and washed with PBS then transferred back to parafilm. 80µL of HRP-
conjugated anti-rabbit secondary antibody diluted in blocking solution was added to 
coverslips and left for 1 hour at room temperature. Coverslips were then transferred 
back to the 24 well-plate and washed with PBS 3 times and mounted as with CD11b 
stained microglia. 
Table 2.5 Antibodies used in Immunocytochemistry of astrocyte and microglial cultures.  
Cellular 
target 
Antigen Conjugate Isotype Host 
species 
Raised 
against 
Dilution Supplier and 
code 
 
Primary antibodies 
Astrocyte GFAP N/A IgG Rabbit Cow 1:1000 DAKO #Z0334 
Microglia Cd11b FITC IgG2b Rat Mouse 1:100 Ebioscience # 
11-0112-81 
 
Secondary antibodies 
 Rabbit FC 
region 
HRP  Goat Rabbit 1:1000 Dako #P0448 
 
2.2.3.9 Imaging of murine astrocytes and microglia 
For imaging of Cd11b stained microglial cells, microscopy was performed on a Zeiss 
Axioplan 2 microscope using the 20X objective. Images were captured using a 
Hamamatsu C4880-80 muti-format CCD Camera and the Openlab software version 
5.0.2. (Improvision Ltd., Coventry, UK) using the settings in Table 2.6. 
Table 2.6 Camera settings used for imaging of Alexa Fluor 488 and Hoescht 33342 
fluorescence. 
Stain Exposure Gain  Offset 
GFAP (Alexa fluor 
488) 
200 ms 0 0 
Hoescht 33342 30 ms 0 0 
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2.2.3.10 Treatment of microglia with astrocyte-conditioned medium 
As in Wyss-Coray et al. (2003), serum free media (DMEM/F12 1:1) containing 1x N2 
supplement (hereafter “serum-free medium”) was used for inflammation studies 
involving astrocyte monocultures. This both reduced the inherent variability associated 
with the use of FBS, and also negated the potential inflammatory effects that FBS can 
induce. For co-culture experiments serum was removed from motor neuron medium 
and 1x N2 supplement added. 
Serum free medium was added to T75 flasks of SOD1G93A and NTg astroctes at 90% 
confluence in a volume of 12mL and left for 3 days before being collected. Medium 
was spun at 400g for 4 minutes to remove cell debris and was then stored at -20°C.  
For co-culture medium, astrocytes were plated onto poly-D-ornithine coated coverslips 
at a density of 5 x 105 and allowed to reach confluence in DMEM complete (see section 
2.2.3.1). The day after primary motor neurons were plated, confluent astrocyte 
coverslips were inverted and placed face down on to the wax blobs in the motor 
neuron plates (see Section 2.2.3.4) such that the two cell types faced each other but 
were not touching. Co-cultures were left for 3 days before collection of media. Media 
was spun to remove debris and stored at -20°C. 
Microglia were collected floating in the medium following the overnight shake of 
astrocyte cultures (Section 2.2.3.3) and were plated at a density of 7.5 x 105 per well in 
a 6 well plate that had been pre-coated with poly-D-ornithine. Cultures were 
maintained in 1:1 complete astrocyte medium:NTg-conditioned astrocyte medium 
(hereafter “microglial medium”). To assess whether microglial phenotype was altered 
by medium from SOD1G93A vs NTg astrocytes, microglial medium was replaced with a 
1:1 mix of fresh serum-free medium with conditioned medium obtained from the 
above-mentioned monocultures and co-cultures of SOD1G93A and NTg astrocytes. 
Cultures were left for 3 days, at which point all medium was collected and stored at -
20°C and cells collected in Trizol for subsequent analysis. 
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2.2.3.11 RNA extraction from cultured cells 
RNA was extracted from cultured cells using Trizol reagent (Life # 15596-026). Trizol 
was added to cells in the tissue culture dish at a volume of 1mL per 10cm2 culture area. 
Samples were collected in 1.5mL eppendorf tubes and stored at -20°C or taken 
forward for extraction. Samples were incubated for 5 minutes at room temperature, 
then 0.2mL chloroform was added per 1mL of Trizol used in initial collection. The 
samples were shaken vigorously for 15 seconds and then incubated for 3 minutes at 
room temperature. Samples were then centrifuged for 10 minutes at 12000g at 4°C. 
The aqueous phase was removed and transferred to a new 1.5mL eppendorf tube. 
Glyco-blue (Life # AM9516) was added to the aqueous phase at a quantity of 7.5µg to 
allow easier identification of the RNA pellet in subsequent steps. To this, 500µL of 
100% isopropanol was added per 1mL of Trizol used in the initial collection. Samples 
were incubated for 10 minutes at room temperature before centrifugation for 10 
minutes at 12000g at 4°C. The supernatant was then removed leaving the RNA pellet. 
The pellet was then washed with 75% ethanol by adding 1mL of ethanol per 1mL of 
initial Trizol reagent, vortexing the sample and centrifugation for 5 minutes at 7500g at 
4°C. This step was repeated to achieve a thorough wash. Ethanol was then removed as 
much as possible and samples were left for 15 minutes at room temperature to air dry 
the pellet. RNA was resuspended in RNAse-free H2O (Fisher # HYC-001-218C). RNA 
quantity was assessed on an Agilent Nanodrop spectrophotometer ND-1000 (Agilent 
Technologies, Santa Clara, CA).  
2.2.3.12 Assay of β-hexosaminidase enzyme activity in murine spinal cord 
Male SOD1G93A and NTg mice were euthanised via intraperitoneal injection of 
pentobarbital at symptomatic and late-stage time-points (n=3 for each group at each 
time-point). As a further control, three male mice over-expressing human wild-type 
SOD1 and corresponding to a late-stage time-point were euthanised. Mice were 
perfused with sterile PBS and the spinal cord and brain were dissected and snap frozen 
in liquid nitrogen. Before freezing, spinal cords were cut just above the lumbar 
enlargement to give “upper cord” and “lower cord” portions. Sections of tissue (~5mg) 
were dissected on dry ice from the thoracic section of the upper cord and the lumbar 
section of the lower cord homogenised using a glass tissue homogeniser (Jencons, 
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England) in 95µL of distilled H2O. Protein concentration of homogenates was 
measured using BCA assay (Sigma #B9643) and samples diluted to 1mg/mL using 
distilled H2O. 5µL of diluted homogenate was added to 500µL McIlvaine citrate–
phosphate pH 4.5 buffer and 100µL aliquots taken. All tubes and substrate solution (4-
Methylumbelliferyl N-acetyl-β-D-glucosaminide, Sigma #M2133) were warmed for 2 
minutes at 37°C, before substrate was added at timed intervals in 100µL volumes to all 
tubes. All tubes were then incubated at 37°C for 10 minutes and stopping solution 
(0.25M glycine buffer pH10.4) added at timed intervals. During this assay, the 
substrate is hydrolysed by β-hexosaminidase to 4-methylumbelliferone. Adding the 
alkaline stopping buffer causes the 4-methylumelliferone to fluoresce at a different 
wavelength to unhydrolysed substrate. Sample fluorescence was read using a FLUOstar 
Omega platereader (BMG Labtech) with excitation settings of 365nm and emission of 
450nm.  
2.2.3.13 Phagocytosis assay  
Labelled cell debris was created using NSC34 cells and Vybrant Dil cell-labelling 
solution (Life #V-22885). Vybrant Dil (Vybrant) weakly fluoresces until bound to a cell 
membrane, where it becomes strongly fluorescent with the peak in the emission 
spectrum at 565nm. NSC34 cells were maintained in DMEM containing 10%FBS and 1% 
Penicillin/Streptomycin (complete medium) at 37°C and 5%CO2. Vybrant was 
resuspended in complete medium to a final dilution of 1:200 and placed upon cells for 
20 minutes at 37°C. Vybrant-containing complete medium was removed and fresh 
complete medium (free of Vybrant) was put on the cells for 10 minutes at 37°C. 
Control NSC34 flasks received the same treatment in the absence of Vybrant. Cells 
were incubated in serum free DMEM for 48 hours to induce cell death via oxidative 
stress. Medium was then collected containing the floating cells and cells were counted 
using a haemocytometer. Aliquots were then made and frozen at -80°C.  
SOD1G93A and NTg astrocytes were plated into a 384-well optical plate (Greiner Bio One 
#781091) at a density of 3 x 103 cells per well. After 24 hours medium was changed to 
serum-free medium (DMEM/F12 1xN2). At 48 hours medium was replaced with serum-
free medium containing Vybrant-labelled cellular debris at a density of 125 cells µL-1. 
Cultures were then left for a further 48 hours to allow phagocytosis to take place. 
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Cultures were washed three times with PBS and fixed with 4% PFA for 15 minutes at 
room temperature and stained for GFAP as in section 2.2.3.5 and using the GFAP 
antibody in Table 2.7. Plates were analysed using the InCell analyser (GE Healthcare, 
Little Chalfont, UK) and InCell Developer Toolbox v. 1.9. 
Table 2.7 Antibodies used in staining of phagocytosis assay.  
Cellular 
target 
Antigen Conjugate Isotype Host 
species 
Raised 
against 
Dilution Supplier 
and code 
 
Primary antibodies 
Astrocyte GFAP N/A IgG Rabbit Mouse 
Rat 
Cat 
Human 
1:1000 AbCam 
#ab7260 
 
Secondary antibodies 
 Rabbit FC 
region 
Alexa fluor 
488 
IgG Goat Rabbit 1:200 Life 
#A11008 
 
2.2.3.14  HMGCR and SREBP2 staining of murine spinal cord 
Spinal cord sections (10µm) of late-stage murine SOD1G93A and age-matched NTg spinal 
cord were stained for the presence of 3-hydroxy-3-methylglutaryl-CoA reductase 
(HMGCR), an important enzyme in the first steps of cholesterol synthesis, and sterol 
regulatory element binding protein 2 (SREBP2), a master regulator of cholesterol 
synthesis genes. Primary anti-body used was  rabbit α-SREBP2 (AbCam #Ab28482) at 
1:400 dilution and rabbit α-HMGCR (AbCam #Ab174830) at 1:100. Blocking solution, 
secondary antibody and ABC solution were all contained within the Vectastain rabbit 
IgG kit (Vector Labs # PK-6101). Tissue sections were fixed in acetone at 4°C for 10 
minutes, followed by blocking for 30 minutes at room temperature (all subsequent 
steps at room temperature). Primary antibody was added to tissue sections for 1 hour 
followed by a 5 minute wash in TBS. Secondary antibody was added for 30 minutes 
and sections again washed for 5 minutes in TBS. ABC solution was then added for 30 
minutes followed by a final 5 minute wash in TBS. Staining was visualised by adding 
diaminobenzidene for 3 minutes and then stopping the reaction in water. To visualise 
nuclei, slides were put in haemotoxylin for 20 seconds and placed in Scott’s tap water 
for a few seconds. Slides were then dehydrated in a graded alcohol series of 70%, 90% 
and 100% ethanol followed by 10 minutes in xylene. Coverslips were mounted onto 
  68 
slides using DPX mounting solution. SREBP2 staining was visualised on a Nikon Eclipse 
Ni microscope with a Nikon DS-Ri1 camera using brightfield settings of 9.5ms exposure 
for 20X magnified images and 44ms exposure for 40X magnified images. 
2.2.4 Gene expression profiling of human astrocytes 
2.2.4.1 Rapid staining procedure of human astrocytes 
Sections (10µm) of human cervical spinal cord were placed on microscope slides and 
fixed in 4˚C acetone for 3 mins. Sections were then incubated in goat serum blocking 
solution for 3 mins at room temperature. Primary antibody anti-GFAP (DAKO # Z0334) 
at 1:150 in blocking solution was added to the slides and left for 3 mins at room 
temperature. Slides were washed 3 times in Tris-buffered saline (TBS) for 10 secs and 
incubated with secondary antibody (1:200 in TBS) for 3 mins. Slides were washed 3 
times in TBS for 10 secs then incubated in ABC solution for 3 mins at room 
temperature. Goat serum, secondary antibody and ABC solution were from the 
Vectastain rabbit IgG kit (Vector Labs # PK-6101). Slides were washed 3 times in TBS for 
3 mins and incubated in diaminobenzidene for 3 mins in the dark. The reaction was 
stopped in water for 15 secs and dehydrated in a graded alcohol series: 70%, 95% and 
100% for 15 secs followed by xylene for 5-10 mins. Slides were then allowed to dry at 
room temperature for 30 mins.  
2.2.4.2 Laser capture microdissection of human astrocytes 
LCM was performed in the same manner as for the mouse study (Section 2.2.1.2). LCM 
of samples was performed with Dr Gabriela de Oliveira. The Veritas capture system 
was used to capture ~1500 astrocytes from the ventral horn of the cervical spinal cord 
per sample onto the Arcturus Capsure Macro LCM caps. RNA quantity and quality were 
then checked using the Nanodrop spectrophotometer ND-1000 and RNA 6000 
PicoChip Kit respectively.  
2.2.4.3 Microarray analysis 
RNA was linearly amplified using the Two Rounds Amplification Kit (Affymetrix). At this 
stage cRNA was used to generate cDNA, which was then tested by PCR for presence of 
GFAP, CD68, and OLIG2; markers of astrocytes, microglia and oligodendrocytes 
respectively. Only the samples that were enriched for the astrocyte marker GFAP were 
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taken forward to be put on the arrays. RNA was linearly amplified using the Genechip 
two-cycle cDNA synthesis kit (Affymetrix #900432). cRNA was generated using the 
GeneChip Expression 3’ Amplification Reagents for IVT labelling (Affymetrix). 15µg of 
cRNA for each of 3 x SOD1 patients and 4 x controls was fragmented and hybridised 
onto Human Genome U133 Plus 2.0 Genechips (Affymetrix # 900470).  
2.2.4.4 Human astrocyte data analysis and enrichment analysis 
As in the mouse study, Bioconductor  and R (2014) were used for quality control of the 
human arrays using the simpleaffy, affyQCReport  and affyPLM packages and the script 
in Appendix 1. Expression data was then filtered using the same script as in the mouse 
analysis and subsequent analysis of differential gene expression performed using the 
PUMA package (Pearson et al., 2009) (full script in Appendix 1). To exclude any genes 
differentially expressed due to gender differences between the SOD1 and control 
cases, a differential expression analysis was performed upon males versus females. 
Any genes shown as differentially expressed due to gender were removed from the 
final gene list. To exclude age as a confounding variable, genes of interest were 
subjected to correlation analysis of expression level with age and tested using the 
Pearson’s correlation test for significance. Enrichment analyses were performed using 
the DAVID database. 
2.2.4.5 qPCR validation of genes differentially expressed in human SOD1-ALS 
astrocytes. 
Primers were designed for genes of interest using the same methods as for the mouse 
arrays (Section 2.2.2.2). Primers for the housekeeping gene β-actin were designed 
within the “X00351_3_at” probeset target sequence based upon it having a low 
standard deviation and high expression level across the arrays. 
Primetime primers were ordered as pre-prepared assays for the assessment of tight 
junction gene expression in cultured HUVECs. A reaction volume of 10µL was used, 
consisting of: 5µL of Brilliant III Ultra-fast qPCR mix (Agilent #600880), 0.5µL of assay 
mix, 3.5µL of H2O and 1µL of cDNA template (12.5ng/µL). qPCR was run using the 
programme described in section 2.2.2.2. 
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Table 2.8 Primers and primer concentrations used in qPCR validation of human microarray data. Asterisks represent primer pairs obtained from the 
primerbank database: http://pga.mgh.harvard.edu/primerbank (Wang and Seed, 2003, Spandidos et al., 2008, Spandidos et al., 2010).Primetime primers 
were used for qPCR of tight junction genes in cultured endothelia. 
SYBR primers 
Gene category Gene name Gene 
symbol 
Primers (5’ – 3’) Conc. Used (nM) 
Inflammation Chitinase 3 like 1 CHI3L1 FW: GGCAACCAGTGGGTAGGATA 300 
   RV: CTTCAGGTACTGCACCTTGCT 300 
Tight Junction Claudin-5 * CLDN5 FW: CTCTGCTGGTTCGCCAACAT 150 
   RV: CAGCTCGTACTTCTGCGACA 150 
 Junctional Adhesion 
Molecule 2 
JAM2 FW: AAAGAAACCTCCTTCCAGAAGAGTA 150 
  RV: GTAACAACGGTGGCTTTGGT 150 
Gap junction Gap junction protein, 
Gamma 1, 45kDa 
GJC1 FW: TTGGGCGTCTCACCCTTTTC 150 
  RV: GCACAAAGGGTGCAGTGTTC 150 
Transcription factor Endothelial PAS domain 
protein 1 
EPAS1 FW: GGGACGACACCTCTGGTTTT 150 
 RV: GTTGGCCCAATGTGCTTTGT 150 
Signalling Transforming growth factor 
beta 2 
TGFB2 FW: GGAAGGGGTGAAGTGCTAGT 150 
  RV: ACCATGCCAACGATCAAATTGT 150 
 Transforming growth factor, 
beta receptor 1 
TGFBR1 FW: ATGTTGCTCAGTTACTCAAATGGT 300 
  RV: AGCCTAAAGAATCCTGCACAAA 300 
Nucleocytoplasmic transport Karyopherin alpha 6 KPNA6 FW: GAGGAACCCCTGAGCAGAT 300 
 RV: AGCAAGTCACATAGGGGTTTG 300 
House keeping β-actin ACTB FW: TCCCCCAACTTGAGATGTATGA   300 
  RV: AACTGGTCTCAAGTCAGTGTACAGG 300 
Primetime primers 
Gene category Gene name Gene 
symbol 
IDT assay code 
Transcription factor Endothelial PAS domain 
protein 1 
EPAS1 Hs.PT.58.39757158.g 
    
Tight Junction Junctional Adhesion 
Molecule 2 
JAM2 Hs.PT.58.26304499 
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 Tight junction protein 2 
(zona occludens 2) 
TJP2 Hs.PT.58.2167474 
 Occludin OCLN Hs.PT.58.15235048 
House keeping β-actin ACTB Hs.PT.56a.19461448.g 
  72 
2.2.5 Functional studies of human astrocytes 
2.2.5.1 Cell culture for human functional studies 
iAstrocytes were produced from human fibroblasts of ALS patients and controls by Dr 
Kathrin Meyer as previously described (Meyer et al., 2013). iAstrocyte culture medium 
consisted of DMEM+GlutaMax (Gibco #10566-016) supplemented with 1% anti/anti 
(Gibco #15240-062), 1mL N2 (Gibco #17502-048)  and 10% FBS.  Human umbilical vein 
endothelial cells (HUVECs) were obtained as a gift from Professor Paul Evans at the 
University of Sheffield, U.K. and were also bought from a commercial supplier (Promo-
cell #C-12250). HUVECs were cultured in Endothelial Culture medium (Sciencell #1001). 
GFP-expressing mouse motor neurons were obtained from cultures of embryoid 
bodies as in Wichterle et al. (2002) and Haidet-Phillips et al. (2011) by Dr Laura 
Ferraiuolo. Embryonic stem cells (ESC) were obtained from a mouse expressing 
enhanced green fluorescent protein (eGFP, hereafter “GFP”) under the control of the 
motor neuronal HB9 promoter. These were grown on mouse embryonic fibroblasts 
(MEFs). Twice a week the mouse ESCs were lifted and dissociated using trypsin to form 
embryoid bodies (EBs), from which differentiation was induced by addition of 2µM 
retinoic acid (Sigma #R2625) and 2µM purmorphamine (Calbiochem #540220). After 5 
days the EBs were dissociated and sorted by flow cytometry for GFP using a 
FACSVantage/DiVa flow cytometer (BD). Plates were prepared for motor neurons by 
coating with poly-D-ornithine (1:1000) for 24 hours at room temperature followed by 
laminin (1:200, Gibco #23017-015) coating for 24 hours at 37˚C. Motor neuron medium 
consisted of DMEM/F12 (Gibco #11320-074) supplemented with 5% horse serum, 1% 
N2 supplement, 1% B27 supplement (Fisher #10620975), 10ng/mL BDNF (Invitrogen 
#10908010), 10ng/mL GDNF (Invitrogen #PHC7041) and 10 ng/mL CNTF (Invitrogen 
#PHC7015).  Co-cultures of astrocytes and endothelia were set up on Corning 
Transwell inserts (Corning #3470) in a 24 well plate. All inserts were coated on both 
sides with fibronectin (Millipore #FC010) diluted 1:200 in D-PBS by placing 100µL and 
600µL in the top and bottom chambers respectively. 
2.2.5.2 Co-culture of HUVECs, iAstrocytes and GFP-motor neurons 
On day 1 astrocytes were seeded onto the underside of inverted inserts at a density of 
2x104 cells per insert in 70µL of iAstrocyte medium and placed into a 150cm2 petri dish 
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(Figure 2.1). Petri dishes were then placed into an incubator for 90 minutes to allow 
cells to adhere. After 90 minutes excess medium was removed and the transwells were 
placed in the correct orientation in a 24 well plate containing 600µL of fresh iAstrocyte 
medium per well. 100µL of iAstrocyte medium was then added to the top chamber and 
the cells were incubated overnight. Also on day 1, GFP-expressing motor neurons were 
sorted by flow cytometry and plated at a density of 3 x 104 intermediate-gate cells per 
well of a 24 well plate in motor neuron medium. After 24 hours incubation (day 2), 
media was removed from the transwells containing astrocytes and they were 
relocated into the same wells as the motor neurons. The upper and lower chambers of 
the new co-culture were given a full media change into 100µL and 600µL of motor 
neuron media respectively and placed at 37˚C for 48 hours (until day 4). On day 4 
media was changed to both wells and 4 x 104 HUVECs seeded into the top chamber of 
the transwells. The resultant cultures will hereafter be termed BBB, for blood brain 
barrier. Co-cultures were then left for a further 3 days until day 7. On day 7, 100µL of 
motor neuron media was added to the top chamber and 400µL added to the bottom 
chamber such that total media for each chamber was 200µL (top) and 1000µL 
(bottom). This step was added as the higher volume allowed easier and more 
reproducible measurements using the transendothelial electrical resistance (TEER) 
equipment. Plates were then put at 37˚C for a further 2 hours to allow wells to 
equilibrate before measurements.   
2.2.5.3 Preparation of selection plates used in cloning 
LB-agar for selection plates was made using 32g LB-Agar powder in 1L of distilled 
water. After an autoclave cycle LB agar was allowed to cool and antibiotic added to a 
final concentration of 1X. Agar was then poured into 100mm2 petri dishes and allowed 
to set. Terrific broth (TB) for growth of bacteria in suspension was made using 47g of 
TB (Invitrogen #22711-022) in 1L of distilled water with antibiotic added to a final 
concentration of 1X. 
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D      HUVEC 
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Figure 2.1 a) Schematic of astrocyte-endothelia-motor neuron co-culture (BBB) setup. 
Astrocytes (2 x 104) were seeded onto inverted transwells for 90 minutes followed by culture 
for 24 hours in iAstrocyte medium. Also on day 1, GFP-motor neurons (3 x 104) were seeded 
into 24-well plates. Astrocytes and motor neurons were combined on day 2 and cultured in 
motor neuron medium for 2 days. On day 4, HUVECs (4 x 104) were added to the top chamber 
of transwells. Cultures were left for 3 days until day 7 before measurements of barrier integrity 
were performed. b) Diagram of plate setup for co-culture experiments. Three replicates were 
performed for all three cell types (BSCB) for both control and ALS, two replicates were 
performed for control cultures containing iAstrocytes and motor neurons but no HUVECs and 
three replicates were performed for control cultures containing HUVECs only. 
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2.2.5.4 EPAS1 cloning 
The anti-oxidant transcription factor endothelial PAS-domain containing protein 1 
(EPAS1- also known as HIF2α) was purchased from Addgene (#18950). PCR was 
performed upon the plasmid isolated from the resultant cultures using the primers in 
Table 2.9.  
Table 2.9 Primer sequences used in EPAS1 cloning and sequencing. Recognition motifs for 
restriction enzymes are highlighted in red. 
Primer Restriction site Sequence (5’-3’) 
Cloning 
FW (5’-3’) Xba1 AAAAAATCTAGAATGACAGCTGACAAGGAGAAG 
RV (5’-3’) Xba1 AAAAAATCTAGATCAGGTGGCCTGGTCCAG 
Sequencing 
LCNX Fw N/A AGCTCGTTTAGTGAACCGTCAGATC  
EPAS1 Seq A Rv N/A CAATCTCACTCAGGACGTAGTTG 
EPAS1 Seq B Fw N/A GAGGAGCTGCTTGGCCGCTCAG 
EPAS1 Seq B Rv N/A ATGGTGGATCTGGGGGCCACTG 
EPAS1 Seq C Fw N/A CACAGTCCCTTCCTCCTGGACAAG 
pBOB Rv N/A GGCATTAAAGCAGCGTATCC  
 
The PCR product was ligated into the pCRTM-Blunt II-TOPO® (TOPO) vector using the 
Zero Blunt Topo PCR cloning kit (Invitrogen #450245). The plasmid was then 
transformed into One Shot TOP10 E. coli (Invitrogen #K2800-20) and plated onto 
kanamycin selection plates for 16 hours at 37˚C. Resistant colonies were picked and 
placed into 2mL kanamycin-TB and shaken at 225 rpm for 12 hours at 37˚C. Cultures 
containing the correctly orientated insert were chosen for scaling up by placing 50µL of 
culture into 50mL of fresh kanamycin-TB and placing on a shaker at 225 rpm for 12 
hours at 37˚C. Cultures were harvested and plasmid DNA removed using the Genelute 
HP plasmid midi-prep kit (Sigma #NA0200-1KT). The EPAS1 insert was removed using 
Xba1 and run on a 1% agarose gel containing 0.01% ethidium bromide. The band of 
correct size was cut from the gel and the DNA extracted using the Qiaquick Gel 
extraction kit (Qiagen #28706). Vector pCSC-SW-PW (pBOB) (Addgene #12335) DNA 
was also cut using Xba1 and dephosphorylation and ligation with insert performed 
using the Rapid DNA dephos and ligation kit (Roche #04898117001). The ligation was 
then transformed into One Shot Stbl3 E. Coli (Invitrogen #C7373-03) and grown for 16 
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hours at 37˚C on carbenicillin selection plates. Colonies were picked and expanded in 
carbenicillin-TB until a final culture of 1L was obtained and plasmid DNA extracted and 
purified using density gradient centrifugation in caesium trifluoroacetate with 
ethidium bromide followed by phenol-chloroform extraction. EPAS1 was sequenced 
externally using the primers in Table 2.9.  
 
Feature Start  End 
CMV promoter 2525 3029 
EPAS1 3112 5724 
WPRE 5893 6468 
ITR 832/6886 1012/7066 
pBR322 origin 9315 9934 
Ampicillin resistance 10089 10949 
 
Figure 2.2 A) Plasmid map of pBOB plasmid containing the EPAS1 transgene and B) feature 
table containing locations of main features. 
b) 
a) 
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2.2.5.5 Lentivirus production 
Lentivirus containing the plasmid with the gene of interest was produced in HEK293 
cells which had been maintained in Iscove’s Modified Dulbecco’s Medium (IMDM; 
Gibco #12440053) medium (10%FBS, 1% L-glutamine, and 1% penicillin/streptomycin) 
in 2-chamber cellstack culture vessels (Corning #3269). On the day of transfection, 
media was changed 2 hours prior to addition of plasmids. Plasmids were added to 
160mL of 2% IMDM at in the following amounts: MDL-helper containing gag and pol: 
116.64µg; REV-helper containing rev: 45.28µg; CMV-VSV-G containing envelope gene: 
60µg and plasmid containing transgene: 180µg. After 24 hours media was removed 
and 160mL of fresh low-serum (2% FBS) IMDM added. Media was then fully replaced 
at 48, 72 and 96 hours after transfection and old medium kept for virus collection. 
Collected medium was filtered using a 250mL vacuum filter bottle (Corning #430768) 
and placed into Beckman ultracentrifuge tubes (Beckman #326823) in 34mL aliquots 
and spun at 22500 rpm for 2 hours at 4˚C in a Sorval #630 rotor. Supernatant was 
decanted and virus eluted with 50µL of TNE buffer overnight at 4˚C.  
2.2.5.6 Viral titration 
Viral RNA was isolated using the Nucleospin RNA virus kit (Machery Nagel #PT4028-1) 
and subsequently titred using the Lenti-X qRT-PCR titration kit (Clontech #PT4006-2). 
2.2.5.7 Transduction of iAstrocytes and HUVECs with EPAS1 
Co-cultures were repeated with iAstrocytes, HUVECs, or both cell types transduced 
with EPAS1 at 4.7x109 copies per mL respectively corresponding to a multiplicity of 
infection (MOI) of 20. Virus was added in a 50µL aliquot to 7mL of medium 2 days 
before cells were due to be added to co-cultures. Media was changed 24 hours later. 
The plate setup for these experiments is shown in Figure 2.3.  
Additionally, HUVECs were transduced with EPAS1 (20MOI) in a 6 well culture dish and 
RNA collected after 48 hours using the Trizol method as in section 2.2.3.11. RNA was 
synthesised to cDNA using the Quantitect Reverse Transcription kit (Qiagen) for use in 
qPCR experiments.  
  78 
A) 
 1 2 3 4 5 6 
A Control 
BSCB -/+ 
Control 
BSCB +/- 
Control 
BSCB +/+ 
ALS 
BSCB -/+ 
ALS 
BSCB +/- 
ALS 
BSCB +/+ 
B Control 
BSCB -/+ 
Control 
BSCB +/- 
Control 
BSCB +/+ 
ALS 
BSCB -/+ 
ALS 
BSCB +/- 
ALS 
BSCB +/+ 
C Control 
BSCB -/+ 
Control 
BSCB +/- 
Control 
BSCB +/+ 
ALS 
BSCB -/+ 
ALS 
BSCB +/- 
ALS 
BSCB +/+ 
D  
 
     
 
B) 
 1 2 3 4 5 6 
A  
 
     
B  Control no 
HUVEC (+) 
ALS no 
HUVEC (+) 
HUVEC 
only (+) 
  
C  Control no 
HUVEC (+) 
ALS no 
HUVEC (+) 
HUVEC 
only (+) 
  
D    HUVEC 
only (+) 
  
 
Figure 2.3 Setup of plates for co-cultures where iAstrocytes, HUVECs, or both cell types had 
been transduced. (A) All variations of transduced BBB and B) transduced controls). -/- 
represents iAstrocytes/HUVECs.  
 
2.2.5.8 Transendothelial Electrical Resistance (TEER) measurements 
To measure the ease with which ions were able to pass through the BBB models, 
transendothelial electrical resistance (TEER) was performed using EVOM resistance 
measurement equipment with STX2 electrode (World Precision Instruments). An 
electrode is placed in each chamber of the transwell and the voltage required to reach 
10µA of current measured. The EVOM uses Ohms law to produce a readout in Ohms. A 
fibronectin-coated transwell containing no cells was used as a blank control and values 
were subtracted from values for test transwells. The resultant value was divided by 
0.33cm2 (the area of the transwell) to give a final value of ohms per cm2. An increased 
amount of tight junctional coupling leads to lower ion flux across the membrane and 
therefore higher resistance readings.  
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2.2.5.9 Dextran flux assay 
Permeability of the BBB models to solutes was measured using FITC-conjugated 4 kDA 
Dextrans (Sigma Aldrich #46944). Following TEER measurement, media was removed 
from both chambers of test wells and replaced with 600µL of fresh media in the 
bottom chamber and 100µL of media containing 1mg/mL FITC-Dextran in the top 
chamber. Plates were incubated for 2 hours at 37˚C and 50µL aliquots of media 
removed from the bottom chamber into a 96 well ELISA plate. Fluorescence was read 
on an ELISA plate reader at 485nm excitation. 
2.2.5.10 Immunocytochemistry of cells used in human functional studies 
For staining of tight junction formation, HUVECs were seeded onto fibronectin coated 
coverslips (1:200) at a density of 40 000 cells per slip. Once confluent, medium was 
removed and cells were immediately fixed using a 1:1 ratio of fresh ECM: 4%PFA for 15 
minutes at room temperature. Coverslips were washed three times with TBS and 
blocked for 1 hour at room temperature in TBS containing 10%FBS and 0.01% Triton 
X100. Primary antibody was put on at the dilutions indicated in Table 2.10 in blocking 
solution and coverslips stored at 4˚C overnight. Primary antibody was washed off three 
times with TBS followed by a 1 hour incubation at room temperature with secondary 
antibody. All secondary antibodies were used at a dilution of 1:200. Secondary 
antibody was removed and TBS containing DAPI (1:1000, Invitrogen) was put on the 
coverslips for five minutes at room temperature. TBS-DAPI was removed and 
coverslips were washed twice more with TBS and mounted using PVA –Dabco on glass 
non-coated slides. Microscopy was performed on an Olympus BX61 microscope using 
Slidebook software (v 5.5.4, Intelligent Imaging Innovations). 
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Table 2.10 Primary antibody dilutions used in immunocytochemistry of human iAstrocytes and 
HUVECs. 
Cellular 
target 
Antigen Conjugate Isotype Host 
species 
Raised 
against 
Dilution Supplier 
and code 
 
Primary antibodies 
Astrocyte α-CD44 N/A IgG2b Mouse Human 1:1000 BD #550392 
Astrocyte α-S100β N/A IgG Rabbit Cow 1:500 Swant #37a 
HUVEC α-CD31 N/A IgG1 Mouse Human 
Mouse 
1:500 AbCam 
#ab24590 
HUVEC α-Cldn5 N/A IgG Rabbit Human 1:250 AbCam 
ab#131259 
HUVEC α-ZO1 N/A IgG Rabbit Mouse 
Chicken 
Dog 
Human 
1:100 Abcam 
#ab59720 
HUVEC α-Occludin N/A IgG Rabbit Dog 
Rat 
Human 
1:100 Invitrogen 
#71-1500 
 
Secondary antibodies 
 Rabbit FC 
region 
Alexa 
fluor 488 
IgG Goat Rabbit 1:200 Life 
#A11008 
 Mouse FC 
region 
Alexa 
fluor 488 
IgG Goat Mouse 1:200 Life 
#A11001 
 Mouse FC 
region 
Cy3 IgG Goat Mouse 1:200 Life 
#A10521 
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3 Results: Gene expression profiling of SOD1G93A astrocytes from symptomatic and 
late-stage disease 
3.1 Introduction 
Microarray analysis was performed upon SOD1G93A and NTg control astrocytes isolated 
by LCM from the ventral horn of the lumbar spinal cord in symptomatic (90 day old) 
and late-stage (120 day old) mice. Astrocytes from SOD1WT overexpressing mice were 
not analysed due to the low number of differences seen between SOD1WT and NTg 
controls from previous studies of LCM motor neurons (Ferraiuolo et al., 2007) and 
from the functional studies performed in the analysis of presymptomatic SOD1G93A 
astrocytes (Ferraiuolo et al., 2011a). The hypothesis to be tested was that SOD1G93A 
transgenic mice possess dysregulated gene expression that reveals the contribution of 
astrocytes to motor neuron death throughout the disease course. This was followed by 
enrichment analysis to identify targets for investigation by functional validation 
studies. 
3.2 Quality control of astrocyte GeneChips 
Quality control (QC) analysis of the astrocyte microarray data showed the GeneChip 
results from the symptomatic stage to be similar in percentage present call (mean = 
50.42, range = 36.27-57.81) and scaling to the chips from the late-stage time-point 
(Figure 3.1). Affymetrix recommend that scale factors should be within 3-fold of each 
other for successful comparisons (Wilson et al.), and  only one GeneChip (2835) fell 
outside these criteria when all GeneChips were analysed together (see blue strip in 
Figure 3.1). Within the symptomatic and late-stage groups, all GeneChips were within a 
3-fold scaling factor of each other. Actin and Gapdh 3’-5’ ratios were comparable for all 
GeneChips (Actin mean = 5.08, range = 3.89-5.89, Gapdh mean = 4.42 range = 3.51-
5.16) and all six GeneChips within each time point showed similar mean RNA 
degradation patterns (Figure 3.2). 
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Figure 3.1 Quality control of symptomatic and late-stage microarray chips for SOD1G93A and 
NTg control astrocytes.  Pre-normalisation performed in Bioconductor using the simpleaffy 
package. Chips are listed on the left, percentage present call is in red, average background is in 
blue to the right of chip ID. The scale factor graph to the right of each chip represents the 
signal intensity for each chip. The blue strip represents the range where the individual average 
chip intensities are within three-fold of the overall chip intensity. The symptomatic and late-
stage time-points are similar both in terms of percentage present call and also in scale factor. 
On the far right of the figure are triangles and circles indicating the ratio of 5’ actin to 3’ actin 
and 5’gapdh to 3’gapdh respectively. This is a measure of RNA degradation; when the symbol 
is coloured red it indicates a greater than 3-fold ratio between the 3’ and 5’ ends of the 
transcript. 
Scale factor Chip ID 
  84 
 
 
Figure 3.2 RNA degradation plot showing the mean intensity of probes, from the 5’ to the 3’ 
ends of their respective target sequence, for each of the a) symptomatic GeneChips and b) 
late-stage GeneChips. All arrays are similar to each other in RNA degradation profile.  
 
3.3 Symptomatic GeneChip quality control analysis 
Normalised unscaled standard error (NUSE) and relative log expression (RLE) plots are 
both measures of assessing array quality included within the simpleaffy package 
(Miller) in Bioconductor. NUSE plots allow comparisons of the standard error for 
probesets on each array (Figure 3.3). Each probeset on the array is normalised by 
a) 
b) 
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setting its median standard error across the GeneChips as 1 (Eijssen et al., 2013, Hruz 
et al., 2008, Genevestigator.com). Consequently a poor quality GeneChip will have a 
larger standard error than 1 for the majority of its probesets and will show as higher on 
the graph. A NUSE score of 1.1 is considered a sign of a poor quality array. The 
GeneChips used for analysis of symptomatic SOD1G93A and NTg astrocytes are all below 
the 1.1 level. The higher position and larger spread of values for 5025 (SOD1G93A) and 
5007 (NTg) are indicative of slightly lower quality data for these arrays (Figure 3.3). 
However, these two GeneChips are split between the two conditions and all other 
GeneChips are of good quality, therefore all GeneChips were carried forward to 
downstream analysis. 
 
Figure 3.3 Normalised unscaled standard error (NUSE) plot for GeneChips from symptomatic 
SOD1G93A astrocytes and NTg controls. Probesets have been normalised across arrays such that 
for each probeset the median expression across arrays is equal to one. Therefore lower quality 
GeneChips have a standard error greater than one and show as higher on the plot. An average 
level of 1.1 (dotted line) indicates a low quality array. Although 5025 and 5007 are of a lower 
quality than the other arrays in the experiment, they are below the 1.1 level and are split 
between the conditions.  
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The relative log expression (RLE) plot is another method of visualising array quality. RLE 
values are derived by dividing the probeset expression level by the median expression 
level for that probeset across the arrays in the experiment. Thus, RLE shows how much 
a particular GeneChip deviates from the group of GeneChips as a whole. Poorer quality 
GeneChips will show a larger spread of values. As with the NUSE plot, 5025 (SOD1G93A) 
and 5007 (NTg) are a poorer quality than the rest of the GeneChips used in the 
experiment but are still centred close to 0 and are only slightly larger in terms of data-
spread (Figure 3.4). 
 
Figure 3.4 Relative log expression (RLE) for the GeneChips used in analysis of symptomatic 
SOD1G93A astrocytes. The RLE is derived by dividing probeset expression level by the median 
expression level for that probeset on all GeneChips. The more variable a GeneChip is from the 
median, the larger its spread of values on the RLE plot. There is a bigger spread of values for 
the 5025 and 5007 GeneChips, implying that these arrays are of a lower quality than those in 
the rest of the experiment.  
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Following the results of the NUSE and RLE plots, the signal intensities across the arrays 
were analysed. This step can help to identify outlying arrays which have average 
intensity different to the group as a whole. As can be seen in Figure 3.5a, 5025 and 
5007 have a greater amount of probesets with a lower signal intensity in comparison 
to the other four GeneChips. This indicates that the quality control issues are due to 
inefficient hybridisation of target cRNA to probes. GeneChips were normalised using 
the PLIER algorithm, in keeping with a previous analysis of pre-symptomatic astrocytes 
performed by Ferraiuolo et al. (2011a). The PLIER algorithm uses data from the 
mismatch probe (MM) to calculate background signal and subtracts this from the 
perfect match (PM) probe giving a signal intensity value. This value is then normalised 
across arrays using quantile normalisation. Following normalisation GeneChips 5025 
and 5007 showed similar profiles to the rest of the GeneChips in the experiment 
(Figure 3.5b).  
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Figure 3.5 Density plot of log intensity values for symptomatic SOD1G93A astrocytes and NTg 
controls prior to (a) and following (b) normalisation. a) Even before the normalisation step all 
six arrays show a similar distribution in intensity values indicating a similar level of 
hybridisation. b) After the normalisation step all six arrays are very similar in their distribution 
of intensity values indicating that normalisation was effective.  
a) 
b) 
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3.4 Late-stage GeneChip analysis 
GeneChips for late-stage SOD1G93A and NTg astrocytes were analysed using the same 
quality control measures as for the symptomatic GeneChips. As shown in Figure 3.1, 
Figure 3.2b and Figure 3.6. to Figure 3.8 the late stage analysis suggests an outlying 
GeneChip: 2835 (SOD1G93A). This GeneChip has a lower percentage present call versus 
the average of all GeneChips (Figure 3.1Figure 3.1) and shows a lower quality when 
looking at the NUSE (Figure 3.6) and RLE (Figure 3.7) plots where it contains a larger 
spread of values. However 2835 is within the three-fold scale factor required by 
Affymetrix to analyse GeneChips as a group, Actin and Gapdh 3’-5’ ratios are similar for 
all GeneChips (Figure 3.1), the entire group of arrays show a similar RNA degradation 
profile (Figure 3.2), and the NUSE plot is centred below 1.1 (Figure 3.6). Pre 
normalisation there is a slightly higher density of intensities at the lower end of the 
scale compared to the other late-stage GeneChips (Figure 3.9).  However, following 
normalisation the similarity between intensities of the late-stage GeneChips is 
improved. Therefore it was decided to keep 2835 within the experiment and proceed 
with further analysis. 
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Figure 3.6 NUSE plot for late stage SOD1G93A and NTg astrocytes. As described in (Figure 3.3), 
probesets have been normalised across arrays such that for each probeset the median 
expression across arrays is equal to one. Lower quality GeneChips have a standard error 
greater than one and show as higher on the plot. An average level of 1.1 (dotted line) indicates 
a low quality array. Array 2835 is clearly an outlier in this analysis and of a lower quality than 
the other late-stage GeneChips. 
 
Figure 3.7 RLE plot for late stage SOD1G93A and NTg astrocytes. Array 2835 is lower quality than 
the rest of the arrays as many more of its probesets deviate from the median values obtained 
from the whole group. 
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Figure 3.8 Density plot of log intensity for late-stage SOD1G93A and NTg astrocytes a) before 
and b) after normalisation. a) All GeneChips show a similar shaped curve with no outliers in 
terms of log intensity. Even the outlier 2835, identified through the NUSE and RLE plots, was in 
line with other GeneChips. b) The similarity between GeneChips was further improved 
following normalisation. 
a) 
b) 
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3.5 Enrichment of glial cellular markers 
Markers of different cell types present within isolated astrocytes from the murine 
spinal cord were looked at in terms of PLIER-normalised expression value to determine 
the degree of enrichment for astrocytes on the arrays (Figure 3.9). Astrocyte markers 
Gfap, S100b, and Aqp4 were enriched within both datasets, particularly in comparison 
to markers of microglia, endothelia and pericytes. Gfap, a marker of astrocyte 
activation, was increased in expression in SOD1G93A versus NTg, as was Aqp4. In 
contrast S100b appeared decreased in SOD1G93A versus NTg. The oligodendrocyte 
markers Mbp and Mobp were also enriched within the dataset for both the 
symptomatic and late-stage GeneChips. A table of individual expression values for all 
transcripts is provided in Appendix 2. 
To assess whether cellular markers of other cell types (such as Mbp) might be 
expressed by astrocytes, and therefore represent astrocyte signal on the arrays, 
GeneChips from cultured SOD1G93A and NTg astrocytes previously analysed at The 
University of Sheffield were processed using PLIER and the expression levels of 
different cellular markers assessed (Figure 3.10). These cultures represent a ≥95% pure 
population of astrocytes, and astrocytic markers such as Aqp4, Gfap and Aldh1l1 are 
enriched within the dataset in comparison to markers of other cell types. In contrast to 
LCM-captured material, transcripts representing oligodendrocytes are low upon these 
arrays. In summary, the LCM-captured material represents an enriched population of 
astrocytes and oligodendrocytes. For simplicity, material will hereafter be referred to 
as astrocytic in origin and functional experiments will be used to confirm astrocytic 
contribution. 
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Figure 3.9 PLIER expression values for different cellular markers upon the symptomatic and 
late-stage GeneChips. In circumstances where multiple probesets are present for a marker, the 
highest expression levels have been used. On both arrays there is enrichment of astrocyte 
markers and also of oligodendrocyte markers, whilst markers of neurons, microglia, endothelia 
and pericytes are comparatively low. Error bars = standard deviation. 
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Figure 3.10 PLIER expression values for different cellular markers upon the GeneChips 
generated from cultured SOD1G93A astrocytes and NTg controls. GeneChips show a high 
expression level for astrocyte markers such as Gfap, Aqp4 and Aldh1l1 whereas markers of 
other cell types are comparatively low. Error bars = standard deviation. 
 
3.6 Differential expression analysis results 
A list of genes with FC≥2 and p<0.05 for both symptomatic and late-stage categorised 
by gene function is shown in Appendix 3. The fold change cutoff of 2 or greater and p-
value threshold of 0.05 were chosen for consistency with the presymptomatic dataset 
from Ferraiuolo et al. (2011a) and to give a smaller gene list that was easier to analyse. 
At the symptomatic time point 321 probesets were differentially expressed with fold 
change ≥ 2 and p<0.05 in SOD1G93A astrocytes compared to NTg controls, with 139 
probesets showing decreased expression and 182 probesets increased expression. Due 
to the presence of multiple probesets for certain transcripts, this corresponded to 117 
transcripts decreased in expression and 159 transcripts increased in expression. At 
late-stage 2066 probesets were differentially expressed with fold change ≥2 and 
p≤0.05, with 1595 probesets showing decreased expression and 471 probesets with 
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increased expression. This corresponded to 1330 transcripts decreased and 355 
transcripts increased in expression. 
3.7 Analysis of differentially expressed genes in symptomatic and late-stage 
SOD1G93A astrocytes 
The gene lists obtained for the symptomatic and late-stage astrocytes were submitted 
to the Database for Annotation, Visualisation and Integrated Discovery (DAVID) online 
analysis software to identify enriched gene categories within the dataset. The 
functional annotation clustering tool allows annotations from multiple databases to be 
aggregated and combined for each probeset. The degree of enrichment of an 
annotation term in the gene list compared to what would be expected at random can 
be calculated.  
3.7.1 Enrichment analysis of differentially expressed genes from symptomatic 
SOD1G93A astrocytes 
Differentially expressed transcripts from SOD1G93A astrocytes extracted at the 
symptomatic disease stage were subjected to functional annotation clustering using 
DAVID. The most enriched categories within the dataset were those involved in 
channel activity and ion homeostasis (ranked 1 and 10), those involved in possible 
immune function (ranked 2, 3, 4, 6, 7, 8 and 9) and the lysosome (ranked 5) (Table 3.1).  
Functional annotation clustering of the full gene list does not show which categories 
are increased or decreased in expression in SOD1G93A vs. NTg astrocytes. Therefore, to 
assess enrichment within up-regulated and down-regulated transcripts separately, the 
gene list was split based upon direction of regulation and reanalysed in DAVID (Table 
3.2 and Table 3.3). The most enriched categories within the up-regulated genes were 
those involved in phagocytosis (ranked 1, 3 and 5), the lysosome (ranked 2) and other 
categories involving the immune response (ranked 4, 6, 7 and 8). In terms of down-
regulated transcripts, most of the gene categories were involved in ion homeostasis 
(ranked 1-5, 7 and 9). The top five clusters for the up-regulated transcripts contained 
annotation terms that passed a false discovery rate (FDR) of ≤ 0.05, whereas for the 
down-regulated transcripts the top 4 clusters contained annotation terms that passed 
below an FDR cut-off of 0.05 (for full details of clustering analysis see Appendices 4-6). 
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Table 3.1 All differentially expressed transcripts in symptomatic SOD1G93A astrocytes with p≤0.05 and FC≥2 were put through the DAVID functional 
annotation clustering tool on highest stringency settings using the databases for Gene Ontology (GO) Biological Process, Cellular Component and Molecular 
Function. The top 10 enriched categories ranked by DAVID enrichment score are summarised. Count = number of genes in list belonging to category, % = 
percentage of gene list made up by these genes, PValue is derived by comparison to the amount of enrichment that would be expected in a gene list based 
on the whole genome. The DAVID enrichment score is calculated based upon the significance of individual annotation enrichments within each cluster, the 
higher the significance of cluster terms the higher the enrichment score. 
 Summarised Cluster Term # genes % of 
gene list 
Most significant cluster term p (most sig 
term) 
DAVID Enrichment score 
1 Ion homeostasis 16 5.84 GO:0006873~cellular ion homeostasis 6.38E-05 3.70 
2 Immune response/antigen presentation 4 1.46 GO:0019864~IgG binding 4.71E-05 2.97 
3 Regulation of immune effector process 7 2.55 GO:0002706~regulation of 
lymphocyte mediated immunity 
 
6.10E-04 2.92 
4 Complement pathway 5 1.82 GO:0006958~complement activation, 
classical pathway 
8.98E-04 2.83 
5 Lysosome 11 4.01 GO:0005764~lysosome 0.001754 2.62 
6 Regulation of response to external stimulus 4 1.46 GO:0002863~positive regulation of 
inflammatory response to antigenic 
stimulus 
3.24E-04 2.51 
7 Positive regulation of immune effector 
process 
5 1.82 GO:0002708~positive regulation of 
lymphocyte mediated immunity 
0.003036 2.44 
8 Positive regulation of acute inflammatory 
response 
3 1.09 GO:0001803~regulation of type III 
hypersensitivity 
0.001 2.42 
9 Leukocyte proliferation 5 1.82 GO:0042098~T cell proliferation 0.001 2.38 
10 Channel activity 14 5.11 GO:0022838~substrate specific 
channel activity 
0.005 2.28 
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Table 3.2 Up-regulated transcripts (FC≥2, p≤0.05) in symptomatic SOD1G93A astrocytes were analysed by functional annotation clustering in DAVID and 
clusters are summarised as in Table 3.1. Categories relating to immune function are enriched within the dataset, including phagocytosis and the lysosome. 
 Summarised Cluster Term # genes % of 
gene list 
Most significant cluster term p (most sig 
term) 
DAVID Enrichment score 
1 Regulation of endocytosis/phagocytosis 7 4.46 GO:0050766~positive regulation of 
phagocytosis 
4.77E-08 5.94 
2 Lysosome 11 7.00 GO:0005764~lysosome 3.95E-06 5.22 
3 Phagocytosis/endocytosis 8 5.10 GO:0006909~phagocytosis 2.94E-07 4.01 
4 Regulation of immune effector process 6 3.82 GO:0002712~regulation of B cell 
mediated immunity 
7.21E-06 4 
5 Immune response/antigen presentation 4 2.55 GO:0019864~IgG binding 5.60E-06 3.32 
6 Cell proliferation 5 3.18 GO:0042098~T cell proliferation 1.18E-04 2.85 
7 Positive regulation of immune effector 
process 
4 2.55 GO:0002714~positive regulation of B 
cell mediated immunity 
2.57E-04 2.74 
8 Positive regulation of response to external 
stimulus 
3 1.91 GO:0001803~regulation of type III 
hypersensitivity 
2.50E-04 2.55 
9 Regulation of cytoskeleton organisation 5 3.18 GO:0032956~regulation of actin 
cytoskeleton organization 
0.002 
 
2.39 
10 Positive regulation of cell death 8 5.10 GO:0043065~positive regulation of 
apoptosis 
0.008 2.08 
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Table 3.3 Down-regulated transcripts (FC≥2, p≤0.05) in symptomatic SOD1G93A astrocytes were analysed by functional annotation clustering in DAVID and 
clusters are summarised as in Table 3.1. Most enriched categories relate to ion transport and channel activity. 
 Summarised Cluster Term # genes % of 
gene list 
Most significant cluster term p (most sig 
term) 
DAVID Enrichment score 
1 Voltage-gated channel activity 8 6.84 GO:0022843~voltage-gated cation 
channel activity 
1.63E-06 5.08 
2 Gated channel activity 9 7.69 GO:0005261~cation channel activity 1.47E-05 4.74 
3 Channel activity 10 8.55 GO:0005216~ion channel activity 2.78E-05 4.44 
4 Potassium ion transport 7 5.98 GO:0030955~potassium ion binding 2.06E-05 3.67 
5 Ion homeostasis 7 5.98 GO:0006873~cellular ion homeostasis 0.004 1.95 
6 Regulation of neurogenesis 4 3.42 GO:0045664~regulation of neuron 
differentiation 
0.02 1.43 
7 Cation homeostasis 4 3.42 GO:0006875~cellular metal ion 
homeostasis 
0.02 1.40 
8 Positive regulation of immune response 4 3.42 GO:0050778~positive regulation of 
immune response 
0.04 1.18 
9 Ion binding 23 19.66 GO:0046872~metal ion binding 0.11 0.92 
10 Muscle development 3 2.56 GO:0007519~skeletal muscle tissue 
development 
0.07 0.87 
 
 
  99 
3.7.2 Enrichment analysis of differentially expressed genes from late-stage 
SOD1G93A astrocytes 
Enrichment analyses for late-stage SOD1G93A astrocytes were performed as per the 
symptomatic gene list (section 3.6.1). As with the symptomatic analysis (Table 3.1), a 
similar pattern was observed where the highest ranked categories for all genes 
involved channel activity (Table 3.4). However there was a lower enrichment of 
transcripts involved in the immune response and a greater enrichment of transcripts 
involved in ATP biosynthesis (ranked 2, 4, 5, 6 and 7).  
When the gene list was divided into up and down-regulated genes a similar pattern to 
the symptomatic time-point was observed in the up-regulated transcripts, where 
lysosomal genes (Lysosome, rank 1) were the most enriched in the up-regulated gene 
list (Table 3.5) and phagocytosis transcripts were also enriched (rank 3). In the down-
regulated gene list, transcripts involved in ion homeostasis were the most enriched 
with ATP metabolism featuring in many of the other top-ranked categories (Table 3.6). 
Only the “lysosome” cluster contained annotations that passed a false discovery rate 
(FDR) of 0.05 for the up-regulated transcripts whereas the clusters “channel activity”, 
“nucleoside binding” and “cellular protein catabolic process” contained annotation 
terms that passed FDR ≤ 0.05 for the down-regulated transcripts (for full details of 
clustering analysis see Appendix 7-9). 
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Table 3.4 All differentially expressed transcripts in late-stage SOD1G93A astrocytes with p≤0.05 and FC≥2 were put through the DAVID functional annotation 
clustering tool on highest stringency settings. The top 10 enriched categories are summarised as in Table 3.1.  
 
 Summarised Cluster Term # genes % of 
gene list 
Most significant cluster term p (most sig 
term) 
DAVID Enrichment score 
1 Channel activity 62 3.71 GO:0022838~substrate specific 
channel activity 
6.56E-06 5.05 
2 Nucleotide biosynthesis 31 1.85 GO:0009165~nucleotide biosynthetic 
process 
0.002901 2.41 
3 Cellular protein catabolic process 71 4.25 GO:0019941~modification-dependent 
protein catabolic process 
0.003951 2.14 
4 ATPase activity coupled to transmembrane 
movement of substances 
18 1.08 GO:0043492~ATPase activity, coupled 
to movement of substances 
0.013 1.88 
5 ATP metabolic process 18 1.08 GO:0046034~ATP metabolic process 0.008 1.70 
6 Nucleoside triphosphate biosynthetic 
process 
17 1.02 GO:0006754~ATP biosynthetic process 0.008 1.66 
7 Nucleoside binding 173 10.35 GO:0030554~adenyl nucleotide 
binding 
0.04 1.35 
8 Cyclic nucleotide biosynthetic process 6 0.36 GO:0016849~phosphorus-oxygen 
lyase activity 
0.06 1.18 
9 Ion transmembrane transport 8 0.48 GO:0015985~energy coupled proton 
transport, down electrochemical 
gradient 
0.07 1.08 
10 Negative regulation of lipid/steroid 
biosynthesis 
3 0.18 GO:0010894~negative regulation of 
steroid biosynthetic process 
0.06 0.98 
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Table 3.5 Up-regulated transcripts (FC≥2, p≤0.05) in late-stage SOD1G93A astrocytes were analysed by functional annotation clustering in DAVID and clusters 
are summarised as in Table 3.1. As in the symptomatic analysis, the lysosomal and phagocytic pathways are enriched along with several other immune-
related pathways. 
 Summarised Cluster Term # genes % of 
gene list 
Most significant cluster term p (most sig 
term) 
DAVID Enrichment score 
1 Lysosome 16 4.64 GO:0005764~lysosome 1.71E-05 4.55 
2 Complement pathway 6 1.74 GO:0006958~complement activation, 
classical pathway 
2.52E-04 3.33 
3 Positive regulation of 
endocytosis/phagocytosis 
6 1.74 GO:0050766~positive regulation of 
phagocytosis 
7.64E-05 2.99 
4 Positive regulation of locomotion 6 1.74 GO:0030335~positive regulation of 
cell migration 
0.001759 2.57 
5 Regulation of immunoglobulin mediated 
immune response 
4 1.16 GO:0002891~positive regulation of 
immunoglobulin mediated immune 
response 
0.001 2.30 
6 Negative regulation of kinase activity 6 1.74 GO:0006469~negative regulation of 
protein kinase activity 
0.008129 2.07 
7 Protein maturation 7 2.03 GO:0051605~protein maturation by 
peptide bond cleavage 
0.003 2.02 
8 Positive regulation of acute inflammatory 
response 
3 0.87 GO:0002894~positive regulation of 
type II hypersensitivity 
0.006 2.01 
9 Regulation of phosphate metabolic process 15 4.35 GO:0042325~regulation of 
phosphorylation 
0.01 1.91 
10 Regulation of adaptive immune response 5 1.45 GO:0002821~positive regulation of 
adaptive immune response 
0.005 1.90 
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Table 3.6 Down-regulated transcripts (FC≥2, p≤0.05) in late-stage SOD1G93A astrocytes were analysed by functional annotation clustering in DAVID and 
clusters are summarised as in Table 3.1. As in the symptomatic analysis, several terms relating to channel activity are enriched within the gene list. 
 Summarised Cluster Term # genes % of 
gene list 
Most significant cluster term p (most sig 
term) 
DAVID Enrichment score 
1 Channel activity 58 4.36 GO:0005216~ion channel activity 2.23E-10 9.14 
2 Nucleoside binding 160 12.02 GO:0030554~adenyl nucleotide 
binding 
4.68E-09 8.09 
3 Cellular protein catabolic process 66 4.96 GO:0043632~modification-dependent 
macromolecule catabolic process 
6.27E-07 5.81 
4 Nucleobase, nucleoside, nucleotide and 
nucleic acid biosynthetic process 
28 2.10 GO:0009165~nucleotide biosynthetic 
process 
5.03E-05 4.15 
5 ATPase activity, coupled to 
transmembrane movement of substances 
17 1.28 GO:0016820~hydrolase activity, acting 
on acid anhydrides, catalyzing 
transmembrane movement of 
substances 
6.49E-04 3.19 
6 Purine nucleoside triphosphate metabolic 
process 
16 1.20 GO:0046034~ATP metabolic process 0.001 2.56 
7 Nucleoside triphosphate biosynthetic 
process 
15 1.13 GO:0006754~ATP biosynthetic process 0.001 2.46 
8 Anion binding 11 0.83 GO:0005254~chloride channel activity 0.009 1.88 
9 Intermediate filament-based process 5 0.38 GO:0060053~neurofilament 
cytoskeleton 
0.001 1.71 
10 Cyclic nucleotide biosynthetic process 6 0.45 GO:0009975~cyclase activity 0.02 1.66 
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3.7.3 Lysosomal gene up-regulation in symptomatic and late-stage astrocytes 
The lysosome is an organelle located within the cytoplasm responsible for the 
breakdown of waste products. Many enzymes are located within the lysosome for 
breakdown of carbohydrates, fats, protein and nucleic acids. There is a clear increase 
in expression of lysosomal genes in SOD1G93A astrocytes at both symptomatic & late-
stage time points (Table 3.7). The genes involved include several lysosomal digestive 
proteases: cathepsin D (Ctsd), cathepsin H (Ctsh), cathepsin S (Ctss), cathepsin Z (CtsZ); 
two glycosidases: hexosamindase A (Hexa) and hexosaminidase B (Hexb); and two 
minor lysosomal membrane proteins: solute carrier family 11 member 1 (Slc11a1) and 
lysosomal associated transmembrane protein 5 (Laptm5). 
Table 3.7 Lysosomal genes are enriched in differentially expressed genes of SOD1G93A 
astrocytes at the symptomatic and late-stage time-points. Where multiple probesets were 
differentially expressed the fold-change of the most significant probeset is given. Blank spaces 
indicate where genes are not significantly differently expressed (p≤0.05). 
Gene Full name Symptomatic 
FC 
Late-stage FC 
Cd68 cd68 +4.16 +3.74 
Ctsb cathepsin B  +2.34 
Ctsd cathepsin D +2.32 +3.28 
Ctsh cathepsin H +2.4 +2.77 
Ctss cathepsin S +2.53 +4.07 
Ctsz cathepsin Z +3.22 +4.67 
Hexa hexosaminidase A +2.26 +2.38 
Hexb hexosaminidase B +2.54 +2.96 
Laptm5 lysosomal-associated transmembrane protein 5 +2.81 +6.45 
Slc11a1 solute carrier family 11 (proton-coupled divalent 
metal ion transporters), member 1 
+2.87 +3.2 
 
3.7.4 Immune response and complement cascade up-regulation in astrocytes from 
the symptomatic and late disease stages 
Gene categories relating to the immune response are increased in expression at both 
the symptomatic and late-stage time-points in SOD1G93A astrocytes. In particular the 
complement pathway, an innate immune mechanism for the destruction of invading 
pathogens, is up-regulated at both stages (Table 3.8). The complement pathway 
consists of a cascade of protein activation, centred around C1q, the three components 
of which (C1qA, B & C) are up-regulated at symptomatic and further at late-stages in 
the microarray of astrocytes (Table 3.8). C1q binds to antigen-antibody and stimulates 
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the formation of the C3 convertase complex, which cleaves C3 to the pro-inflammatory 
anaphylatoxin C3a. C3a is a potent inducer of chemotaxis in phagocytes and acts upon 
complement component 3a receptor 1, which is up-regulated in symptomatic 
astrocytes (90d: +2.37). C3b, the other product of C3 hydrolysis, forms part of the C5 
convertase complex producing C5a, which also has chemotactic activity and triggers 
formation of the membrane attack complex (MAC) which permeabilises the pathogen 
cell wall (van Beek et al., 2003). Dysregulated complement components are present in 
both symptomatic and late stage SOD1G93A astrocyte gene lists, with C4b and C1q 
showing the highest significance (p ≤ 0.0001) of all dysregulated genes at late stage 
disease.  
Table 3.8 Genes involved in the complement cascade are enriched in differentially expressed 
genes of SOD1G93A astrocytes at the symptomatic and late-stage time-points. Where multiple 
probesets were differentially expressed the fold-change of the most significant probeset is 
given. Blank spaces indicate where genes are not significantly differently expressed (p≤0.05). 
Gene Full name Symptomatic 
FC 
Late-stage 
FC 
Itgb2 integrin beta 2 +2.85  
A2m alpha-2-macroglobulin +3.28 +11.38 
C1qa complement component 1 +3.97 +7.98 
C1qb complement component 1 +3.4 +8.89 
C1qc complement component 1 +3.91 +5.75 
C3 complement component 3  +9.44 
C3ar1 complement component 3a receptor 1 +2.37  
C4b complement component 4b +6.27 +28.67 
Cd55 cd55 -2.48  
 
In addition to the up-regulation of the complement system there is also up-regulation 
of chemotactic genes (Figure 3.9). Seven genes in the KEGG chemokine signalling 
pathway are differentially expressed in symptomatic SOD1G93A astrocytes. Only two of 
these genes, Ccl6 and Cxcl10 are differentially expressed at late-stage. Ccl3 has the 
second highest positive fold change (90d: +9.01) of all genes at the symptomatic time-
point. 
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Table 3.9 Genes in chemokine signalling pathways that are differentially regulated with FC≥2 in 
SOD1G93A astrocytes at the symptomatic and late-stage time-points. All chemokines show an 
up-regulation and only ccl6  and cxcl10 are differentially expressed at both time-points 
(p≤0.05). Where multiple probesets were differentially expressed the fold-change of the most 
significant probeset is given. Blank spaces indicate where genes are not significantly differently 
expressed (p≤0.05). 
Gene Full name Symptomatic FC Late-stage FC 
Adcy7 adenylate cylase 7 +3.02  
Ccl3 chemokine (C-C motif) ligand 3 +9.01  
Ccl4 chemokine (C-C motif) ligand 4 +2.12  
Ccl6 chemokine (C-C motif) ligand 6 +4.42 +2.85 
Ccl9 chemokine (C-C motif) ligand 9 +2.05  
Cxcl10 chemokine (C-X-C motif) ligand 10 +3.54 +10.37 
Dock2 dedicator of cyto-kinesis 2 +2.54  
 
The gene with the highest p-value between SOD1G93A and NTg astrocytes at the 
symptomatic time-point was activating transcription factor 3 (Atf3) (90d: +6.82; 120d: -
2.51). This transcription factor is part of a regulatory circuit involving the inflammatory 
transcription factor C/EBPδ (90 day: +2.97) and NFκB that is involved in innate immune 
response and modulation (Litvak et al., 2009). 
3.7.5 Disrupted ion transport in symptomatic and late-stage astrocytes 
There is a down-regulation of genes involved in ion homeostasis at both the 
symptomatic and late-stage time-points (Table 3.3Table 3.3 and Table 3.6). In 
particular genes involved in potassium transport are enriched within the two datasets 
(Table 3.13), indicating that there may be a loss of normal astrocyte buffering capacity. 
Astrocytes are important in the process of potassium buffering and loss of this function 
would impact upon processes such as action potential generation and voltage-gated 
channel activity (Kofuji and Newman, 2004). One of the main mechanisms of 
potassium uptake is via Na+/K+ ATPase pumps, of which three different forms (Atp1a1, 
Atp1a3 and Atp1b1) are down-regulated by late-stage disease. A down-regulation of 
several inwardly rectifying potassium channels, which allow greater ion influx than 
efflux, is also seen (Kcnj3, Kcnj14).  
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Table 3.10 Transcripts involved in potassium transport that are differentially expressed in 
SOD1G93A astrocytes at the symptomatic and late-stage of disease. All genes show a down-
regulation. Where multiple probesets were differentially expressed the fold-change of the 
most significant probeset is given. Blank spaces indicate where genes are not significantly 
different in expression (p≤0.05). 
Gene Full name Symptomatic FC Late-stage FC 
Atp1a1 
 
ATPase, Na+/K+ transporting, alpha 1 
polypeptide 
-3.19 
 
-2.33 
 
Atp1a3 
 
ATPase, Na+/K+ transporting, alpha 3 
polypeptide 
 
 -2.61 
 
Atp1b1 
 
ATPase, Na+/K+ transporting, beta 1 
polypeptide 
 
 -2.69 
 
Kcna1 
 
potassium voltage-gated channel, shaker-
related subfamily, member 1 
 
 -2.17 
 
Kcna6 
 
potassium voltage-gated channel, shaker-
related, subfamily, member 6 
-2.28 
 
 
Kcnab1 
 
potassium voltage-gated channel, shaker-
related subfamily, beta member 1 
-2.12 
 
-3.75 
 
Kcnb1 
 
potassium voltage gated channel, Shab-
related subfamily, member 1 
-2.08 
 
 
Kcng4 
 
potassium voltage-gated channel, 
subfamily G, member 4 
-2.37 
 
-2.53 
 
Kcnj14 
 
potassium inwardly-rectifying channel, 
subfamily J, member 14 
-3.66 
 
-3.96 
 
Kcnj3 
 
potassium inwardly-rectifying channel, 
subfamily J, member 3 
-2.09 
 
-4.06 
 
Kcnk1 
 
potassium channel, subfamily K, member 1 
 
 -2.58 
 
Kcnq5 
 
potassium voltage-gated channel, 
subfamily Q, member 5 
-2.04 
 
 
Kcnq5 potassium voltage-gated channel, 
subfamily Q, member 5 
-2.25 
 
-2.48 
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3.7.6 Altered cholesterol metabolism transcripts in late-stage SOD1G93A astrocytes 
In addition to DAVID enrichment analyses, during compilation of symptomatic and 
late-stage gene lists (Appendix 3) it was noticed that the late-stage gene list had many 
transcripts involved in cholesterol processing. Thirty-eight transcripts involved in the 
processing and transport of cholesterol were differentially expressed in the late-stage 
gene list, the majority of which (35 transcripts) were decreased in expression (Table 
3.11). Interrogation of the symptomatic gene list found four of these transcripts to be 
differentially expressed at the earlier stage, suggesting altered cholesterol metabolism 
to be a feature of late-stage disease. When these transcripts were mapped onto the 
pathway of cholesterol synthesis, decreased transcripts were seen to occur at the top 
and bottom of the pathway as well as in key transport steps (Figure 3.11). 
Table 3.11 Transcripts involved in cholesterol processing and metabolism that are differentially 
expressed in symptomatic and late-stage SOD1G93A astrocytes. Where multiple probesets were 
differentially expressed the fold-change of the most significant probeset is given. Blank spaces 
indicate where genes are not significantly different in expression (p≤0.05). 
Gene Full name Symptomatic FC Late-stage FC 
Abca5 ATP-binding cassette, sub-family A (ABC1), 
member 5  
 -3.21 
Abcb7 ATP-binding cassette, sub-family B 
(MDR/TAP), member 7  
 -2.44 
Abcc8 ATP-binding cassette, sub-family C 
(CFTR/MRP), member 8  
 -2.06 
Abcd2 ATP-binding cassette, sub-family D (ALD), 
member 2 
 -2.58 
Acat2 Acetyl-Coenzyme A acetyltransferase 2  -2.33 
Acsl4 acyl-CoA synthetase long-chain family 
member 4 
 -2.35 
Acsl6 acyl-CoA synthetase long-chain family 
member 6 
 -2.59 
Acss2 acyl-CoA synthetase short-chain family 
member 2 
 -2.23 
ApoE Apolipoprotein E +2.18 +5.23 
Capn7 calpain 7  -2.00 
Ch25h cholesterol 25-hydroxylase  -2.63 
Cyp51 cytochrome P450, family 51  -2.62 
Dbi diazepam binding inhibitor  +2.04 
Dhcr24 24-dehydrocholesterol reductase  -2.97 
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Gene Full name Symptomatic FC Late-stage FC 
Extl2 exostoses (multiple)-like 2  -3.38 
Fads6 fatty acid desaturase domain family, 
member 6 
 -2.14 
Far1 fatty acyl CoA reductase 1  -2.41 
Hmgcs1 3-hydroxy-3-methylglutaryl-Coenzyme A 
synthase 1 
 -3.11 
Hsd11b1 hydroxysteroid 11-beta dehydrogenase 1, -2.32 -5.05 
Hsd17b7 hydroxysteroid (17-beta) dehydrogenase 7
  
-2.05 -2.88 
Insig1 insulin induced gene 1  -2.14 
Insig2 insulin induced gene 2  -2.58 
Ldlr low density lipoprotein receptor  -3.39 
lpl lipoprotein lipase +5.99 -11.21 
Lrp11 Low density lipoprotein receptor-related 
protein 11 
 -3.96 
Lrp12 Low density lipoprotein-related protein 12  -2.28 
Lypd6b LY6/PLAUR domain containing 6B  -2.84 
Nsdhl NAD(P) dependent steroid dehydrogenase-
like 
 -2.96 
Nus1 nuclear undecaprenyl pyrophosphate 
synthase 1 homolog (S. cerevisiae) 
 -2.01 
Osbpl1a oxysterol binding protein-like 1A  -2.69 
Osbpl6 oxysterol binding protein-like 6  -3.19 
Osbpl8 oxysterol binding protein-like 8  -2.17 
Sc4mol sterol-C4-methyl oxidase-like  -2.97 
Sc5d sterol-C5-desaturase (fungal ERG3, delta-5-
desaturase) homolog (S. cerevisae) 
 -3.33 
Scd1 stearoyl-Coenzyme A desaturase 1  -2.43 
Sqle squalene epoxidase  -3.09 
Stard4 StAR-related lipid transfer (START) domain 
containing 4 
 -2.93 
Tspo translocator protein  +2.04 
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Figure 3.11 Transcripts differentially expressed in late-stage SOD1G93A astrocytes mapped onto 
some of the key steps in the synthesis of cholesterol. Downstream transport to plasma 
membrane/ER and mitochondria are also depicted. 
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3.8 Comparison of pre-symptomatic, symptomatic and late-stage gene expression 
profiling of SOD1G93A astrocytes 
SOD1G93A astrocytes from the pre-symptomatic stage have already undergone gene 
expression profiling by Ferraiuolo et al. (2011a) which enables a comparison of the 
gene lists generated at three time-points of the disease. The number of transcripts 
with differential expression passing p ≤ 0.05 and FC ≥ 2 in common between all three 
time-points was investigated using a Venn diagram (Figure 3.12). There is high 
variability in the number of transcripts differentially expressed at FC ≥ 2 between the 
three time-points, with the symptomatic stage showing a lower number of transcripts 
(294) compared to the pre-symptomatic (904) and late-stage (1986) GeneChips. The 
highest proportion of genes shared is between the symptomatic and late-stage time-
points. When these 180 genes are analysed for enrichment of gene categories, the 
immune response, lysosome and ion homeostasis are the most enriched categories 
(Table 3.12). 
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Stages % genes shared 
Pre-symptomatic + symptomatic 1.94% 
Pre-symptomatic + late-stage 4.01% 
Symptomatic + late-stage 10.29% 
All stages 0.63% 
 
Figure 3.12 Venn diagram of the differentially expressed genes passing statistical significance 
(p ≤ 0.05) and an FC ≥ 2 for all three time-points. The percentage overlap in differentially 
expressed transcripts is shown in the table below the Venn diagram. The symptomatic and 
late-stage GeneChips show the largest overlap in differentially expressed transcripts, with the 
pre-symptomatic and symptomatic gene-lists showing the lowest amount of overlap. 
1418 
772 87 
167 84 
6 
16 
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Table 3.12 Enriched gene categories within genes shared between the symptomatic and late-
stage gene lists. 
Rank Term Count % Enrichment score 
1 Positive regulation of immune response 12 6.70 5.71 
2 Lysosome 11 6.15 4.47 
3 Ion homeostasis 13 7.26 4.29 
4 Regulation of endocytosis 6 3.35 3.68 
5 Regulation of adaptive immune response 5 2.79 2.97 
6 Region of interest: Linker 2/Coil 2A/Coil 2B 3 1.68 2.57 
7 Alpha-2-macroglobulin 3 1.68 2.51 
8 Regulation of phosphorylation 10 5.59 2.40 
9 Complement pathway 4 2.23 2.39 
10 Positive regulation of cell death 9 5.03 2.32 
 
When the gene lists are separated into up-regulated and down-regulated genes and 
compared there is a clear difference in the degree of overlap between the three stages 
(Figure 3.13). There are many more up-regulated genes shared between the 
symptomatic and late-stages than any other combination of time-points (for full lists of 
shared genes see Appendix 10). The separation also shows that there is a large amount 
of transcriptional down-regulation at late-stage disease compared to the other time-
points which are more evenly split. The overlap between the pre-symptomatic + late-
stage and symptomatic + late-stage time-points is more evenly matched for down-
regulated transcripts, whereas the overlap between the pre-symptomatic and 
symptomatic time-points is again very small. Enrichment analysis was performed for 
the up and down-regulated transcripts shared between the symptomatic and late-
stage time-points (Table 3.13). Similar to the total gene list for each time-point (Table 
3.2 and Table 3.5), the lysosome was the most enriched category within the up-
regulated transcripts. Ion homeostasis was also enriched within the down-regulated 
transcripts, however the level of enrichment was much lower than the top three up-
regulated categories as seen by DAVID enrichment score. Finally, the up-regulated 
transcripts shared between all three time-points all belong to the immune and 
inflammatory response, whilst the eleven down-regulated transcripts contain a variety 
of annotation groups. 
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Stages % up-regulated genes 
shared 
% down-regulated genes 
shared 
Pre-symptomatic + symptomatic 0.8 2.6 
Pre-symptomatic + late-stage 0.8 3.6 
Symptomatic + late-stage 17 4.5 
All stages 0.31 0.56 
 
Figure 3.13 Venn diagram of the a) up-regulated and b) down-regulated genes that are 
differentially expressed in SOD1G93A astrocytes at pre-symptomatic, symptomatic and late-
stage disease. Numbers do not sum to those in Figure 3.12 as some transcripts change 
direction of differential expression through the disease course. 
a) b) 
2 
3 
101 4 
449 
332 
66 4 
11 
64 61 
372 
1414 
42 
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Table 3.13 Enriched gene categories within the transcripts shared between the symptomatic 
and late-stage gene lists. The top categories by enrichment score are the lysosome, immune 
response and phagocytosis categories. Potassium transport is also enriched within the down-
regulated transcripts. Count= number of genes, % = proportion of gene list. 
 Term Count % Enrichment score 
Up-regulated transcripts 
1 Lysosome 11 10.58 6.81 
2 Positive regulation of immune response 9 8.65 4.84 
3 Positive regulation of phagocytosis 5 4.81 4.01 
4 Phagocytosis 6 5.77 3.04 
5 Alpha-2-macroglobulin 3 2.88 2.95 
6 Mononuclear cell proliferation 4 3.85 2.73 
7 Regulation of organelle organisation 5 4.81 2.66 
8 Ion homeostasis 8 7.69 2.60 
9 Positive regulation of adaptive immune reponse 4 3.85 2.57 
10 Cation homeostasis 6 5.77 2.53 
Down-regulated transcripts 
1 Potassium transport 6 8.00 3.45 
2 Channel activity 5 6.67 2.03 
3 Synaptic transmission 5 6.67 1.91 
4 Muscle organ development 4 5.33 1.70 
5 Cholesterol/steroid biosynthesis 3 4.00 1.59 
6 Regulation of phosphorylation 5 6.67 1.52 
7 Regulation of protein modification  4 5.33 1.49 
8 Ion homeostasis 5 6.67 1.36 
9 Sex differentiation 3 4.00 1.14 
10 Cation homeostasis/cell adhesion 3 4.00 1.07 
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Table 3.14 Transcripts differentially expressed at pre-symptomatic, symptomatic and late-stage disease in SOD1G93A astrocytes. Very few transcripts are 
differentially expressed at all stages of the disease. 
Gene symbol Gene name Functional category Pre-symptomatic 
FC 
Symptomatic 
FC 
Late-stage FC 
Up-regulated transcripts     
Cxcl10 chemokine (C-X-C motif) ligand 10 Chemokine +2.94 +3.54 +10.37 
Csf2rb colony stimulating factor 2 receptor, beta, low-affinity 
(granulocyte-macrophage) 
Immune response +2.62 +2.54 +3.23 
Ncf4 neutrophil cytosolic factor 4 Inflammation +2.00 +2.04 +2.20 
Down-regulated transcripts     
Sv2b synaptic vesicle glycoprotein 2 b Neurotransmission -2.03 -2.31 -3.94 
Nefh neurofilament, heavy peptide Cytoskeleton -2.06 -2.01 -3.84 
Susd2 sushi domain containing 2 Immune response -2.19 -2.55 -3.31 
Hsd17b7 hydroxysteroid (17-beta) dehydrogenase 7 Cholesterol/steroid 
metabolism 
-2.41 -2.05 -2.88 
 
Dffa DNA fragmentation factor, alpha subunit Apoptosis -2.49 -2.49 -2.94 
Atp1a1 ATPase, Na+/K+ transporting, alpha 1 polypeptide Ion transport -2.61 -3.19 -2.88 
Polr3g polymerase (RNA) III (DNA directed) polypeptide G Immune response 
 
-2.63 -2.21 -2.14 
Rspo2 r-spondin 2 homolog (Xenopus laevis) 
 
Signalling -2.74 -9.64 -4.75 
Myh10 myosin, heavy polypeptide 10, non-muscle Axonogenesis -3.42 -2.01 -2.94 
Cd24a CD24a antigen Immune response -4.85 -3.84 -3.28 
Chodl chondrolectin 
 
Carbohydrate 
transport 
-6.97 -12.45 -7.46 
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3.9 qPCR validation of transcripts of interest 
To verify that genes called statistically significant after microarray analysis were 
regulated in the correct direction and to test for false positives, qPCR validation was 
performed upon RNA from the symptomatic time-point. Transcripts were chosen for 
qPCR validation from the up-regulated categories involving the lysosome, complement 
and immune pathways, for which astrocytes could feasibly be involved. Differentially 
expressed transcripts involved in the modification of the extracellular matrix (ECM) 
were also investigated due to their possible role in the immune response via 
infiltration of immune cells (Figure 3.14). Genes from the immune response category 
included: chemokine (C-C motif) ligand 6 (Ccl6; 90d: +4.42, 120d: +2.85), chemokine (C-
X-C motif) ligand 10 (Cxcl10; 90d: +3.54, 120d: +10.36), the first part of the 
complement cascade complement component 1 Q subcomponent B chain (C1qb; 90d: 
+3.4, 120d: +8.9) the stress response gene activating transcription factor 3 (Atf3; 90d: 
+6.82, 120d: +4.23) and the serpin peptidase inhibitor Serpina3n (90d: +3.9, 120d: 
+8.0). Lysosomal genes tested for validation were hexosaminidase A (Hexa; 90d: +2.26, 
120d: +2.38), cathepsin D (Ctsd; 90d: +2.32 120d: +3.28), cathepsin S (Ctss; 90d: +2.53, 
120d: +4.07) and lysosomal protein transmembrane 5 (Laptm5; 90d: +2.81, 120d: 
+6.45). In order for immune cells to infiltrate the CNS alterations need to be made to 
the structure of the ECM. The matrix metalloproteinase Mmp9 and its inhibitor Timp1 
were differentially expressed at both the symptomatic (Mmp9: -4.9; Timp1: +7.7) and 
late-stage (Mmp9: -4.2; Timp1: +6.35) time-points and were included for validation. 
Other genes tested for validation included chondrolectin (Chodl) which had the highest 
negative fold change on the symptomatic arrays, lipoprotein lipase (Lpl) and Igfbp5. Of 
the fourteen genes tested for qPCR validation, ten were confirmed significantly 
differentially expressed whilst the remaining four were regulated in the same direction 
but did not reach significance (Figure 3.14). 
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Figure 3.14 A summary of genes chosen for qPCR validation of symptomatic SOD1G93A and NTg astrocytes. Genes involved in the immune response: the 
chemokines Ccl6 and Cxcl10, the complement component C1qb, the stress response genes Atf3 and Serpina3n. Genes involved in the lysosome: Hexa, Ctsd, 
Ctss, Laptm5. Genes involved in extracellular processes: Igfbp5, Timp1, Mmp9, Chodl, Lpl.  Ten of the fourteen genes tested (71%) showed a significant 
difference by one-tailed t-test, whilst all genes showed a trend in the direction indicated on the microarrays. Values for SOD1G93A are normalised to their 
respective NTg control. n=3 for each group. Error bars = SEM. 
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3.10 Discussion 
Microarray analysis has been successfully performed upon symptomatic and late-stage 
astrocytes laser captured from the SOD1G93A mouse model for the first time. This novel 
study has allowed enriched pathways of differentially expressed genes to be identified 
and compared to earlier studies of pre-symptomatic astrocytes (Ferraiuolo et al., 
2011a). The resulting datasets provide information on the changing behaviour of 
astrocytes throughout motor neuron degeneration which is currently impossible to 
obtain from study of the human disease. 
3.10.1 Genes chosen for validation by qPCR 
As described in section 3.9, validation of the microarray analysis was carried out by 
performing qPCR of a select number of genes to replicate the microarray results. 
Targets were chosen that were present at both time-points to further avoid the chance 
of false positive results and also to enable future therapeutic strategies to target 
behaviour that is relevant throughout the disease course. The categories with the 
highest enrichment scores in Table 3.13, i.e. the lysosome, immune response and 
phagocytosis, were chosen for further investigation as they all might be involved in an 
immuno-active astrocyte phenotype. The decision was made to focus upon this aspect 
of the astrocyte phenotype rather than the defect in potassium transport and 
cholesterol processing due to the higher enrichment scores for the up-regulated 
categories in the DAVID analysis of shared genes (Table 3.13). 
Ten of the fourteen transcripts tested by qPCR replicated the significant difference 
seen between SOD1G93A and NTg in the microarray analysis. These transcripts included 
three of the four lysosomal targets tested, the complement component C1qb, the 
chemokine Ccl6 and the stress response factors Atf3 and Serpina3n, reinforcing the 
finding of a reactive astrocyte phenotype seen in the symptomatic and late-stage time-
points. Further targets of interest were: Chodl which is potentially involved in binding 
of sugar residues on pathogen cell membranes; Lpl which is involved in lipid 
metabolism but has also been seen to influence phenotype of the J774 macrophage 
cell line in vitro (Li and Renier, 2007) and is decreased in expression in NSC34 cells 
harbouring the SOD1G93A mutation (Kirby et al., 2005); and Igfbp5 which has previously 
been seen as up-regulated in ALS patient spinal cord and SOD1G93A mice and may 
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disrupt IGF signalling (Wilczak et al., 2003, Corti et al., 2007). Wilczak et al. suggest that 
Igfbp5 sequesters IGF from MN which kills them. It was interesting to see if astrocytes 
were down-regulating Igfbp5 in response to this, however the differential expression 
of Igfbp5 was not confirmed by qPCR. For the four genes (Cxcl10, Laptm5, Igfbp5 and 
Mmp9) which were not found to be significantly differentially expressed between 
SOD1G93A and NTg astrocytes by qPCR, these transcripts still show a trend in the same 
direction as shown by the microarray data analysis.  
3.10.2 Overlapping gene expression between time-points 
The Venn diagrams of all three time-points show the symptomatic and late-stage gene 
lists to be more similar to each other than either time-point is with the pre-
symptomatic gene list (Figure 3.12 and Figure 3.13), particularly in terms of up-
regulated genes. In comparison to the pre-symptomatic time-point, only 2 of the 14 
transcripts tested for qPCR validation are in common: Cxcl10 and Chodl. Cxcl10 is 
considered anti-inflammatory and has been shown to correlate with a slower disease 
progression (Tateishi et al., 2010) showing that astrocytes at early stage may still be 
non-reactive. The other shared transcript is chondrolectin, which encodes a protein 
required for endocytosis of glycoproteins and pathogens with carbohydrate-bearing 
surfaces and is down-regulated at all three time-points (Table 3.14). Chodl is also 
highly expressed in neurons and isoform-1 has been seen to be reduced in spinal 
muscular atrophy, another motor neuron disease (Sleigh et al., 2014).  
The pre-symptomatic time-point is highly associated with a loss of supportive function 
in SOD1G93A astrocytes, such as the provision of lactate to motor neurons (Ferraiuolo et 
al., 2011a). Other supportive functions are also lost in astrocytes as the disease 
progresses, such as the possible loss of potassium buffering capacity from down-
regulation of several potassium transporters (Table 3.10) through to the loss of 
cholesterol processing transcripts at late-stage (Table 3.11). However there is also a 
robust up-regulation of immune response behaviour at the symptomatic stage which 
also continues to late-stage disease (Table 3.7-Table 3.9). This suggests that a 
transition occurs between the pre-symptomatic and symptomatic time-points leading 
to a reactive astrocyte phenotype characterised by increased chemokine secretion, 
lysosomal up-regulation and up-regulation of stress response factors. This is reinforced 
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by a recent microarray study of SOD1G93A spinal cord at the pre-symptomatic ages of 
40 days and 80 days which showed an increased expression of antigen presentation 
transcripts at the later time point (de Oliveira et al., 2013). The smaller gene list seen 
at the symptomatic time-point may represent a midway point between the pre-
symptomatic astrocyte characterised by loss of supportive function through to the 
late-stage astrocyte where the disease burden has led to dysregulation of many genes. 
Culture of astrocytes from neonatal SOD1G93A mice showed that they are less able to 
respond to activating factors such as glutamate and LPS and consequently release 
lower amounts of trophic factors (Benkler et al., 2013), reinforcing the notion that 
younger astrocytes show a phenotype characterised by loss of normal supportive 
function. Additionally, reduction of mutant SOD1 in astrocytes does not disrupt disease 
initiation but does slow disease progression in the SOD1G37R mouse model (Yamanaka 
et al., 2008b). Perhaps in this study, reduction of SOD1G37R in astrocytes delayed the 
process by which astrocytes become reactive in disease, and may suggest that a 
reduction in this reactivity will ameliorate disease progression. These data are also in 
keeping with work that Appel and colleagues have performed with microglia in the 
SOD1G93A mouse, where microglia transition from a neuro-supportive to a neuro-toxic 
phenotype from early to late-stage disease (Liao et al., 2012).  
3.10.3 Comparison of astrocyte data with previous motor neuron analyses 
Having data for these three time-points of disease in the mouse model also allows 
comparison to an earlier microarray study conducted by Ferraiuolo et al. (2007) into 
motor neurons of the SOD1G93A mouse at pre-symptomatic, symptomatic and late-
stage disease. Similar to this analysis, differential expression was weighted towards up-
regulated transcripts at the pre-symptomatic and symptomatic time-points, whereas a 
large degree of transcriptional repression was seen at the late stage. Also in common, 
the symptomatic stage of disease contained the lowest number of differentially 
expressed genes suggesting that a transition occurs not only in astrocytes as the 
disease process takes hold. At pre-symptomatic stage in motor neurons there is an 
increase in transcripts involved in transcriptional and translational processes as well as 
lipid and carbohydrate metabolism and the electron transport chain. At symptomatic 
stage only 51 transcripts were differentially expressed, which also featured an 
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increased expression of genes involved in transcriptional regulation. However at late-
stage disease transcriptional repression was observed as well as a decrease in 
antioxidant pathways. Protein degradation pathways were increased, perhaps because 
of aggregated misfolded SOD1, and several cell cycle components were up-regulated 
suggestive that motor neurons are unsuccessfully trying to re-enter the cell cycle. Of 
note, components of the complement pathway are up-regulated, in common with late-
stage astrocytes, which may be linked to the astrocyte activation seen in the present 
microarray study. 
3.10.4 Enrichment of immune response genes at symptomatic and late-stage disease 
The enrichment of pathways involved in the immune response is in keeping with 
current literature. There is much evidence suggesting complement activation in ALS; 
complement component C3 is upregulated in SOD1G93A mouse spinal cord at 126 days 
and C1q and C3 are expressed in the neuromuscular junction at both 47 days and 126 
days (Heurich et al., 2011). In human ALS patients, increased levels of complement 
component C4d are seen in CSF (Tsuboi and Yamada, 1994) and increased complement 
component C3 is seen in serum (Goldknopf et al., 2006). In human sALS spinal cord 
there is increased staining for C1q and C3d in astrocytes and C1q, C3d and the 
membrane attack complex C5b-9 (MAC) in microglia (Sta et al., 2011). Sta et al. (2011) 
also showed an increased expression of C4 by qPCR, although their qPCR results found 
no significant difference between C1q expression in ALS vs. control, showing that 
expression at the RNA level and protein level do not always correlate. The use of whole 
spinal cord rather than specific cell types in qPCR may be the reason for these 
conflicting findings and shows an advantage of the LCM technique used in the current 
study. Previous microarray analysis of SOD1G93A murine motor neurons identified 
components of the complement cascade as up-regulated (Ferraiuolo et al., 2007), 
however this was only at the late-stage time point, with a trend for increased 
expression at the symptomatic time point. Thus, the current data point to an earlier 
astrocytic role in the recruitment of immune cells during the disease. Previous work 
has shown C5ar up-regulation in astrocytes in ALS and that inhibition of this receptor 
resulted in a prolonged life span in the mouse model (Woodruff et al., 2008). Our 
results add to evidence that complement dysregulation in astrocytes is important in 
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ALS, especially within the very early components of the pathway (C1qA, B and C are all 
up-regulated) which may mean that a therapeutic effect requires blocking the 
complement system in astrocytes at this stage of the cascade. Indeed, Stevens et al. 
(2007) found that C1q was important for pruning of synapses by astrocytes during 
development of the retina and that it became aberrantly re-expressed in retinal 
synapses in a mouse model of the neurodegenerative eye condition glaucoma. C1q 
was initially considered a tempting target for therapeutic intervention given that its 
up-regulation in astrocytes during disease could lead to unwanted synaptic 
elimination.  However, knockout of C1qa by Lobsiger et al. (2013) did not lead to a 
significant delay in disease onset or progression in the SOD1G37R mouse model. 
Additionally, Lobsiger et al. (2013) showed C3 deletion did not alter the disease course 
in the SOD1G93A model, providing further evidence that complement induction may not 
be a major contributor in the SOD1-ALS disease process. This may mean that the 
inflammatory response is not a key target for therapeutic intervention in astrocytes in 
ALS. For example it has recently been shown that selective knockdown of NFκB in 
astrocytes of the SOD1G93A mouse does not alter toxicity towards co-cultured motor 
neurons (Frakes et al., 2014). Alternatively, it may be that the numerous pathological 
mechanisms operating in the aggressive mouse model of disease mean that there is a 
redundancy in the pathophysiological processes. 
In addition to the up-regulated complement system, an up-regulation of chemokines is 
also seen at the two later time-points in disease, which could promote immune cell 
infiltration of the spinal cord, a matter of conflicting evidence. Using the marker Ly6C 
to distinguish monocytes derived from the spleen Butovsky et al. (2012) demonstrated 
monocyte recruitment to the spinal cord during disease progression in the SOD1G93A 
mouse. However parabiosis experiments using a mouse expressing GFP in all 
haematopoietic cells coupled to a SOD1G93A mouse showed minimal infiltration of GFP-
expressing cells to the CNS (Ajami et al., 2007) and a more recent experiment using 
FACS analysis of SOD1G93A mouse spinal cord failed to replicate the observation of 
increased Ly6C-expressing cells (Chiu et al., 2013) although there was a small increase 
in infiltrating lymphocytes. Given that such controversy exists, and that SOD1G93A 
astrocytes show differential expression of transcripts for a host of immuno-modulatory 
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factors, the simplest explanation would be that astrocytes are having a direct effect 
upon the recruitment and activation of microglia, the resident CNS immune cell. 
Microglia are seen to transition from a neuro-protective, or M1, phenotype to a neuro-
toxic (M2) phenotype during disease progression in the SOD1G93A mouse model (Liao et 
al., 2012). In addition, LPS-mediated M1 polarisation of microglia leads to increased 
production of nitrite and nitrate with a resulting significant negative correlation with 
motor neuron viability when in co-culture, an effect which is reversed by exogenous 
application of the M2-promoting cytokine IL4 (Zhao et al., 2006). Treatment of 
microglial cells with mutant SOD1 (mSOD1) led to M1 polarisation, through interaction 
with TLR 2 and 4 and CD14, and subsequent toxicity towards motor neurons when 
placed in co-culture (Zhao et al., 2010). It is important to appreciate that microglia in 
ALS are not polarised to either extreme and have a distinct disease phenotype (Chiu et 
al., 2013), however it still seems possible to measure which end of the spectrum these 
cells are leaning towards. 
3.10.5 Lysosomal up-regulation indicative of increased phagocytosis? 
At the symptomatic and late-stage time-points, transcripts for several lysosomal 
digestive enzymes are differentially expressed, including proteases, glycosidases and 
major and minor lysosomal membrane proteins. 
CtsD has previously been shown to be up-regulated in ALS spinal cord but reduced in 
motor neurons (Wootz et al., 2006). CTSD is down-regulated in human SOD1-related 
ALS motor neurons (Kirby et al., 2011) and in CHMP2B-related ALS motor neurons 
along with cathepsin B (CTSB) (Cox et al., 2010). By contrast, astrocytes show up-
regulation of CtsB in late-stage SOD1G93A mice (+2.23), and CtsH is up-regulated in 
astrocytes and microglia of the ventral horn in the mutant SOD1 mouse model as 
shown by immunohistochemistry (Fukada et al., 2007). This suggests that up-
regulation of the lysosomal system in ALS is astrocyte-specific.  
In contrast to a large increase in CtsD expression, an endogenous inhibitor of 
cathepsins, Cystatin C, is only slightly increased in SOD1G93A mouse spinal cord (Wootz 
et al., 2006) and mass spectrometry has been used to confirm a decreased level of 
Cystatin C in CSF of ALS patients compared to controls (Ranganathan et al., 2005, 
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Pasinetti et al., 2006). Hexosaminidase A (HexA) has previously been investigated as a 
cause of ALS or ALS-like disorders but a link was found to be unlikely (Drory et al., 
2003). However this study investigated HexA deficiency due to mutation rather than 
investigating up or down regulation e.g. through over-expression or knockdown.  
Increases in lysosomal-associated protein transmembrane 5 (LAPTM5) are seen in 
regressing neuroblastoma cells and overexpression of LAPTM5 leads to lysosomal-
membrane permeabilisation and non-caspase dependent cell death (Inoue et al., 
2009). Increased Laptm5 expression also leads to a significant increase in CTSD leakage 
in to the cytosol. Inoue et al (2009) found the increased accumulation of Laptm5 to be 
associated with decreased protein degradation efficiency, and perhaps the up-
regulation of Laptm5 seen in this study could bring about the same effects.  
Up-regulation of lysosomal proteins could be as a result of increased amounts of 
autophagy, perhaps to deal with SOD1G93A protein.  Wild-type and mutant SOD1 are 
degraded by autophagy in vitro (Kabuta et al., 2006). SOD1 and CTSD co-localisation in 
motor neurons of sALS patients has also been shown (Forsberg et al., 2010). However, 
in the symptomatic and late-stage data there is no up-regulation (p≤0.05, FC ≥2) for 
the classic autophagy related genes such as Beclin 1, Lc3-II, Vps34 or the Atg group of 
genes (Virgin and Levine, 2009). This means that if autophagy is increased, it is due to 
altered autophagic flux rather than induction. Alternatively, lysosomal up-regulation 
could be a result of increased phagocytosis of neuronal debris. Phagocytosis is 
enriched in astrocytes at symptomatic and late-stage in this study (Table 3.12) 
Astrocytes are enriched in genetic pathways that put them forward as professional 
phagocytes (Cahoy et al., 2008). Furthermore, astrocyte phagocytosis of cellular debris 
has been demonstrated in vitro (Chang et al., 2000) and appears to be protective to co-
cultured neurons (Loov et al., 2012).  
3.10.6 Quality of material used for microarray 
The data shown here portray astrocytes as undergoing a phenotypic change 
throughout the disease course. In order to perform an analysis using GeneChips from 
all three time-points and therefore have an overarching view of gene expression 
changes throughout the disease, it was necessary that array quality at each time-point 
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was similar. The LCM technique is vital for obtaining RNA from an enriched population 
of cells. However, a drawback of the technique is the degradation of RNA that occurs 
during the time taken to stain and laser-capture cells (Goldsworthy et al., 1999, 
Mikulowska-Mennis et al., 2002), hence the need for a rapid staining protocol that 
minimises the risk of RNA degradation (Mojsilovic-Petrovic et al., 2004). Even so, this 
leads to a lower quality of RNA on the arrays than could be achieved using cells 
obtained from in vitro cultures etc. Given this, it is important that samples put onto 
arrays are comparable in terms of RNA degradation such that valid comparisons can be 
made. All samples used for the arrays are outside the 3-fold boundary set by 
Affymetrix in terms of Gapdh and Actin 3’-5’ ratios (Figure 3.1). However, RNA 
degradation is expected to be higher in samples obtained through LCM and the RNA 
degradation plots in Figure 3.2 and Figure 3.7 show that all samples within each time-
point have a similar RNA degradation profile. To try to use the best quality RNA for 
microarray analysis, the RNA integrity number (RIN) of samples can be measured using 
the RNA 6000 PicoChip Kit. However, RIN values may not be an accurate predictor of 
RNA quality, as cDNA lengths do not seem to vary with differing RIN (Trabzuni et al., 
2011). The plot in Figure 3.1 shows that the samples from all the symptomatic and 
late-stage time-points are comparable in terms of quality metrics. The pre-
symptomatic Gene Chips previously analysed by Ferraiuolo et al. (2011a), whilst 
comparable within this time-point, were more than a scale-factor of three outside the 
GeneChips from the symptomatic and late-stage time-points meaning that an analysis 
where all GeneChips are analysed together could not be performed. However, the 
consistency of GeneChips within groups means that each time-point could be analysed 
separately and comparisons made subsequently. 
3.10.7 Astrocyte enrichment upon GeneChips 
The data in Figure 3.9 showing the abundance of different cellular markers on the 
arrays shows an enrichment for markers of astrocytes and oligodendrocytes. The levels 
of oligodendrocyte transcripts are higher than those found in expression data from 
cultured astrocytes (Figure 3.10). This is not unusual, markers of non-target cell types 
have previously been observed in material captured by LCM (Simpson et al., 2011). In 
addition previous analyses of laser captured motor neurons have shown differential 
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expression of myelin-related transcripts such as Mbp (Ferraiuolo et al., 2007). It is 
important to note however, that the relationship between transcript number and cell 
number is variable, therefore this is not the most robust measure of purity of LCM 
samples. For example the oligodendrocyte transcript Mbp is very highly expressed in 
oligodendrocytes due to their main role in production of the myelin sheath, meaning 
that a higher number of Mbp transcripts per cell will be seen versus a transcript such 
as Gfap. In support of this, recent RNA sequencing of purified mouse CNS-cell 
populations shows Mbp to be 55416-fold more highly expressed in oligodendrocytes 
than astrocytes, whereas Gfap does not feature in the top 500 transcripts which 
discriminate these two cell types (Zhang et al., 2014). Furthermore, the markers of 
each cell type must be looked at in the context of where the cells have been LCM 
captured; Gfap is not highly expressed in grey matter astrocytes (Cahoy et al., 2008) 
and so will not show as highly expressed on the arrays as would be expected in an 
astrocyte-enriched population from white matter. Lastly, the differing location of 
probesets within transcripts for different genes can mean that certain transcripts are 
more easily detected than others. If a probeset for Mbp is more 3’ than a probeset for 
Gfap it may lead to a higher level of detection in an RNA sample derived from 
degraded material. It is important to bear these caveats in mind when assessing 
enrichment based upon expression values from arrays. Nevertheless the data do show 
that astrocytes have been enriched within the samples and by focusing on genetic 
pathways that are more likely to occur in astrocytes than oligodendrocytes one can 
remove some of the bias that contaminating oligodendrocyte material might produce. 
3.10.8 Conclusions 
Based upon the enriched pathways described here, the major questions for functional 
studies of astrocytes are: 1) Are astrocytes involved in the immune modulation of 
microglia?; 2) Is there a difference between levels of phagocytosis in NTg vs SOD1G93A 
astrocytes? Functional studies should focus on providing data to answer these 
questions. 
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CHAPTER 4 
RESULTS 
Functional studies of SOD1G93A astrocytes 
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4 Results: Functional studies of SOD1G93A astrocytes 
4.1 Introduction 
To validate the results of gene expression profiling in symptomatic and late-stage 
SOD1G93A astrocytes in vitro experiments were designed. This involved the culture of 
murine neonatal astrocytes, microglia and embryonic motor neurons to investigate the 
previously identified categories of the lysosome, immune response and phagocytosis 
and immunohistochemistry to investigate altered cholesterol processing at late-stage 
disease. 
4.2 Purity of cultures used for mouse functional experiments 
Before conducting in vitro experiments, cultures were first tested for purity to ensure 
correct attribution of results to cell-type. Using flow cytometry, astrocyte cultures 
were found to be >95% (mean = 95.55% SD = 3.24 n=4) positive for the astrocyte 
marker GLAST (Figure 4.1a) and 0.51% positive for the microglial marker CD11b (SD = 
0.47 n = 4) with a 71.76 fold increase in GLAST-APC fluorescence over isotype control 
compared to a 1.14-fold increase in CD11b-FITC fluorescence over isotype control 
(Figure 4.1b). The shift in GLAST-APC fluorescence is clear when viewed against a 
histogram of the unstained control cells (Figure 4.1c). 
Microglial cultures were also established so as to investigate the astrocyte effect upon 
these cells. For microglial cultures, 52.53% (SD = 14.65 n = 4) of cells stained positively 
for Cd11b compared to 4.12% (SD = 1.01 n= 4) of cells which stained positively for 
GLAST (Figure 4.2). This corresponded to a 5.09-fold increase in CD11b fluorescence 
over isotype control compared to a 1.3-fold increase in median fluorescence for 
GLAST-APC over isotype control. Upon examination of median fluorescence histograms 
it was clear that there was a shift in fluorescence of the entire population of cells but 
that the level of fluorescence was insufficient to distinguish all cells from unstained 
controls. Therefore, microglial cultures were stained for CD11b (Figure 4.2d) and 
manually counted by three independent scorers. Microglial cultures comprised 93.81% 
CD11b+ cells (SD = 2.50 n = 3).  
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In order to establish a more realistic astrocyte phenotype, astrocytes were co-cultured 
with neuronal cultures enriched in motor neurons. This approach has previously 
revealed defects in lactate metabolism not seen when astrocytes were cultured as a 
mono-culture (Ferraiuolo et al., 2011a). Neuronal cultures used for astrocyte 
stimulation stained positively for the neuronal marker MAP2 and also contained cells 
expressing the motor neuronal marker Islet1 (Figure 4.3a). Islet1 is expressed only 
transiently in developing motor neurons (Kobayashi et al., 2011) therefore staining was 
also performed for the motor neuronal marker SMI32 which showed an increased 
amount of positive staining in comparison to Islet1 (Figure 4.3). 
 
 
 
Figure 4.1 Purity of astrocyte cultures as measured by flow cytometry. Astrocytes purified by 
mild trypsinisation were stained for the astrocytes marker GLAST and the microglial marker 
CD11b. a) Purity of astrocytes cultures is estimated to be 95.55% with 0.51% Cd11b positive 
cells. (n=4).b) GLAST-APC median fluorescence was 71.76-fold higher than respective isotype 
control whilst CD11b-FITC fluorescence was 1.14-fold higher than respective isotype control. 
c) Histograms of fluorescence for CD11b-FITC (left) and GLAST-APC (right) show a shift in 
fluorescence in the APC channel that is not observed in the FITC channel. Error bars = S.E.M.  
CD11b 
Unstained Unstained 
GLAST 
a) b) 
c) 
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Figure 4.2 Purity of microglial cultures measured by flow cytometry. a) Microglia purified by 
shaking were stained for the microglial marker CD11b with 52.53% detected as CD11b+ 
compared to 4.12% GLAST+ cells. b) Median fluorescence for CD11b-FITC was 5.09 fold higher 
than isotype control whilst GLAST-APC median fluorescence was increased by 1.3-fold. 
c) Median fluorescence histogram showing the shift in GLAST-APC (left) and CD11b-FITC (right) 
fluorescence versus unstained cells. d) CD11b immunocytochemistry showing CD11b+ 
microglia. Scoring by three independent scorers showed a microglial cultures to be comprised 
of 93.81% CD11b+ cells. n=4 for all flow cytometry, image taken at x20 magnification Scale bar 
= 50µm. Error bars = S.E.M. 
 
a) b) 
c) d) 
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Figure 4.3 Staining of neuronal cultures. a) Neuronal cultures contained cells that stained 
positively for the pan-neuronal marker MAP2 (red) and the motor neuronal marker Islet1 
(green). b) More cells stained positively for the motor neuronal marker SMI32 (red) compared 
to Islet 1 (green) indicating that these cells may be in different stages of development. Images 
taken at x63 magnification. Nuclei stained blue with Hoescht stain. Scale bar = 25µm. 
 
4.3 qPCR for array genes on cultured astrocytes 
To test whether transcripts of interest from the microarray studies of symptomatic and 
late-stage SOD1G93A were differentially expressed in neonatal astrocytes in culture, 
RNA was extracted from NTg and SOD1G93A astrocytes and qPCR performed (Figure 
4.4). qPCR was performed on RNA from astrocytes that had been maintained in 
isolation (mono-culture) and those that had been co-cultured with motor neurons (co-
culture). Transcripts were chosen from the significant transcripts in microarray 
validation involved in the immune response (Ccl6 and C1qb), lysosome (Ctss and Hexa), 
lipid processing (Lpl), stress response (Atf3) and extracellular matrix (Timp1) (Section 
3.8).  
None of the tested transcripts was significantly differently expressed in SOD1G93A 
astrocytes versus NTg controls in either mono-cultured or co-cultured conditions. For 
mono-cultured astrocytes, C1qb and Ctss showed a trend towards the direction of 
regulation on the microarrays of symptomatic and late-stage SOD1G93A astrocytes, 
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whilst for co-cultured astrocytes C1qb and Timp1 showed a trend in the same direction 
as the arrays.  
 
Figure 4.4 qPCR of transcripts called significant in microarray validation. a) qPCR of selected 
transcripts from microarray validation in mono-cultured astrocytes. n = 5 NTg and n=4 
SOD1G93A. b) qPCR of selected transcripts from microarray validation in astrocytes co-cultured 
with motor neurons. No transcripts were differentially expressed in either mono- or co-
cultured astrocytes. For co-cultures n = 4 NTg and n = 3 SOD1G93A. Error bars = SEM. SOD1G93A 
have been normalised to respective NTg controls. 
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4.4 Treatment of microglia with astrocyte conditioned medium – expression of M1 
and M2 markers 
Due to the increased expression of genes involved in the immune response in the 
microarray data from symptomatic and late-stage SOD1G93A astrocytes (Section 3.6.4), 
the effect of SOD1G93A astrocytes upon microglial phenotype was investigated. 
Microglia transition from an M2 “non-inflammatory” phenotype to an M1 “classically 
activated” phenotype during disease progression in the SOD1G93A mouse (Liao et al., 
2012) and given the differential expression of multiple chemokines in the symptomatic 
and late-stage SOD1G93A gene lists the hypothesis was generated that: SOD1G93A 
astrocytes are able to modulate microglial phenotype. This was tested by taking 
astrocyte-conditioned medium (ACM) from SOD1G93A and NTg astrocytes for treatment 
of NTg microglia, which were then assayed for markers of M1 and M2 microglia by 
qPCR. As in section 4.2, this experiment was run with mono-cultured and co-cultured 
astrocytes to see if astrocytes required activation by motor neurons to elicit an effect. 
No significant difference was seen between NTg and SOD1G93A for the expression of 
the M1 markers nitric oxide synthase 2 (Nos2) and cyclo-oxygenase 2 (Cox2) or for the 
M2 marker arginase 1 (Arg1) in either mono- or co-cultured astrocytes (Figure 4.6). In 
addition the M2 marker Ym1 was assayed by qPCR but was not expressed at a high 
enough level to provide robust results via qPCR. To confirm these results, the medium 
of both astrocytes, and microglia that had been treated with ACM, were assayed for 
the presence of M1- or M2-polarising cytokines using flow cytometry. Cytokines tested 
were the pro-inflammatory cytokine IL1β, the “anti-inflammatory” cytokine IL10 and 
two chemoattractant cytokines: monocyte chemoattractant protein 1 (MCP1 a.k.a. 
CCL2) and keratinocyte chemoattractant (KC). In astrocyte media, none of the tested 
cytokines was significantly different in concentration between NTg and SOD1G93A 
astrocytes, for either mono-cultured or co-cultured cells (Figure 4.6). This situation was 
the same for media from microglia that had been treated with ACM (Figure 4.7). When 
the cytokine profiles from both sets of cells were compared (Figure 4.9), it was 
observed that microglia secrete higher amounts of IL1β and IL10 into the media, which 
reached significance for Il1β in microglia treated with NTg-cc astrocyte media and for 
IL10 in microglia treated with NTg-mono astrocyte media. MCP1 and KC were 
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expressed at much higher levels than IL1β and IL10 in both astrocytes and microglia 
and showed similar levels of expression between the two cell types. 
 
 
 
 
Figure 4.5 qPCR for the M1 markers Cox2 and Nos2 and the M2 marker Arg1 in microglia 
treated with media from NTg and SOD1G93A astrocytes in monoculture (mono) and astrocytes 
co-cultured with motor neurons (cc). None of the tested genes were significantly different 
between disease and control astrocytes. One-way ANOVA with Tukey post-hoc test.. Error bars 
= S.E.M. NTg mono and NTg cc: n=3. SOD1G93A mono and SOD1G93A cc: n=4. 
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Figure 4.6 Presence of different cytokines in media from NTg and SOD1G93A astrocytes in 
monoculture (mono) or co-cultured (cc) with motor neurons. None of the cytokines tested was 
significantly different between disease and control astrocytes. One-way ANOVA with Tukey 
post-hoc test. n=4 NTg mono and NTg cc, n=3 SOD1G93A mono and SOD1G93A cc. Error bars = 
S.E.M. 
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Figure 4.7 Presence of different cytokines in media from NTg microglia treated with NTg and 
SOD1G93A astrocytes in monoculture (mono) or co-cultured (cc) with motor neurons. None of 
the cytokines tested was significantly different between disease and control astrocytes. One-
way ANOVA with Tukey post hoc test. n=3 NTg mono and NTg cc, n=4 SOD1G93A mono and 
SOD1G93A cc. Error bars = S.E.M. 
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Figure 4.8 Comparison of cytokine expression between mono-cultured and co-cultured NTg 
and SOD1G93A astrocytes (green bars) and NTg microglia (red bars) that have been treated with 
ACM from said astrocytes. Microglia show a trend for higher secretion of IL1β and IL10 
compared to astrocytes for all conditions which reaches significance for IL1β (NTg-cc) and IL10 
(NTg-mono), whereas levels of MCP1 and KC are comparable. Independent samples t-test. 
Error bars = S.E.M. ** = p≤0.01, *** = p≤0.001.  
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4.5 Up-regulation of lysosomal function in symptomatic and late-stage astrocytes 
To confirm that the increased expression of lysosomal transcripts seen by qPCR 
validation (Section 3.8) was carried through to a functional up-regulation, an enzymatic 
activity assay was carried out for β-hexosaminidase (β-hex). The α- and β-subunits of 
β-hex are increased in expression at both symptomatic and late-stage disease in the 
microarray study (α-subunit (Hexa): 90d: +2.26, 120d: +2.38; β-subunit (Hexb): 90d: 
+2.54, 120d: +2.97). Hexa and Hexb showed a significantly increased expression and a 
trend for increased expression respectively when analysed by qPCR (Section 3.8 and 
Figure 3.12). To assess β-hex activity in different locations of the nervous system, 
sections of tissue were cut from the lower cord (~lumbar), upper cord (~thoracic) and 
motor cortex. As a control, tissue was collected from ≥120 day old mice over-
expressing the wild-type human form of SOD1 (SOD1WT). As an additional control β-
galactosidase (β-gal) activity, which was not differentially expressed at either 
symptomatic or late-stage, was assayed in lumbar cord.  
β-hex activity was found to be significantly increased in SOD1G93A compared to SOD1WT 
(855.3 ± S.D. 82.67) and NTg (90d: 819.8 ± S.D. 85.41 , 120d: 984.6 ± S.D. 223.1) in 
upper spinal cord sections at late-stage disease whilst showing a trend towards 
increased activity at the symptomatic time-point (90d: 1232 ± S.D. 139.2, 120d: 2442 ± 
S.D. 419.4) (Figure 4.5a). Similarly, in lower cord, β-hex activity was significantly 
increased in SOD1G93A compared to SOD1WT (1045 ± S.D. 162.6) and NTg (90d: 921.7 ± 
S.D. 329.1, 120d: 677.3 ± S.D. 403.4) at late-stage in lumbar cord whilst showing a 
trend towards increased activity at the symptomatic time-point (90d: 1167 ± S.D. 247, 
120d: 2303 ± S.D. 620.1) (Figure 4.5b). In the motor cortex, there was no significant 
difference between any of the groups (Figure 4.5c). There was also no significant 
difference in the lower spinal cord between any of the groups for β-gal activity, which 
was also much lower than that seen for β-hex, reinforcing the findings of the 
microarray analysis.  
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Figure 4.9 Assay of β-hexosaminidase (β-hex) activity in homogenates of upper cord, lower 
cord and motor cortex. a) In upper cord, there was a trend towards higher β-hex activity at 
symptomatic stage and β-hex activity was significantly higher in SOD1G93A than either NTg or 
SOD1WT in late-stage SOD1G93A mice (SOD1WT, 90d NTg and 90d SOD1G93A: n=3, 120d NTg and 
120d SOD1G93A: n=4). b) In lower cord there was a trend towards higher β-hex activity in 
symptomatic SOD1G93A spinal cord and a significantly higher activity in late-stage SOD1G93A mice 
compared to NTg and SOD1WT mice (n=3 for all groups). c) In the motor cortex no difference 
was seen for β-hex activity between any group. (n=3 for all groups except NTg 120d n=4). d) 
No difference was observed between any group for the control enzyme β-galactosidase (n=3 
all groups). 90d = symptomatic, 120d = late-stage. ** = p≤0.01, **** = p≤0.0001 vs NTg 
control, ## = p≤0.01, #### = p≤0.0001 vs SOD1WT (one-way ANOVA with Tukey post-hoc t-test). 
Error bars = S.E.M. 
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4.6 Increased phagocytosis in SOD1G93A astrocytes 
Transcripts for phagocytosis were enriched in the microarray data of both 
symptomatic and late-stage SOD1G93A astrocytes (Section 3.6). To investigate this 
further, an assay was adapted from the method used by Sargsyan et al. (2011) to 
investigate SOD1G93A microglial phagocytosis, which measured the amount of Cy3-
labelled NSC34 cell debris taken up by astrocytes over a period of 48 hours. Astrocytes 
were observed with large accumulations of NSC34 cell debris within them (Figure 
4.10a). To confirm that NSC34 debris had been phagocytosed, the assay was 
performed upon coverslips and visualised using confocal microscopy (Figure 4.10b). 
This confirmed the presence of red debris in the same plane as GFAP staining, as 
observed in the y/z and x/z planes. Taken together this increased the confidence in 
astrocyte phagocytosis occurring under these experimental conditions. The assay was 
analysed using the InCell 2000 analyser and the average amount of debris per cell 
quantified from 9 fields of 5 wells per cell line (number of cell lines NTg =3 SOD1G93A = 
3). The values for SOD1G93A astrocytes in each experiment were normalised to their 
respective NTg controls. The results of three experiments show a significantly larger 
amount of NSC34 debris is phagocytosed per cell in SOD1G93A astrocytes versus NTg 
controls (204.83% ± S.D. 36.6 vs. 100% ± S.D. 17.84) (Figure 4.10c).  
Riluzole is currently the only drug used in the treatment of ALS and prolongs life by 2-3 
months (Miller et al., 2007). Apart from its effects in reducing excitotoxicity in disease, 
other effects are unknown. Therefore riluzole was added to the phagocytosis assay at 
a concentration of 25µM to assess whether it has an effect upon phagocytic activity of 
astrocytes. The results show that whilst riluzole had no significant effect upon NTg 
controls, there was a trend towards a decrease in amount of debris phagocytosed per 
cell in SOD1G93A astrocytes treated with riluzole. However, this result was not 
significantly different to non-treated SOD1G93A astrocytes and SOD1G93A astrocytes 
treated with DMSO only.  
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Figure 4.10 Phagocytosis of Cy3-labelled NSC34-cell debris by NTg and SOD1G93A astrocytes. 
a) Astrocytes were labelled with GFAP (green) and imaged using the InCell at x63 
magnification. Some cells contained large accumulations of NSC34 cell debris (red). b) Confocal 
microscopy confirmed that NSC34 debris were located in the same plane as GFAP staining 
suggesting that it is inside the cell rather than on the surface. Crosshairs indicate location of 
y/z and x/z planes. Within these planes the green and red staining are seen in close 
localisation. c) Mean debris area per cell in SOD1G93A astrocytes was normalised to NTg 
controls. A significant increase (> 2-fold) in debris area per cell was observed in SOD1G93A 
astrocytes versus control. * = p≤0.05, independent samples t-test. n=3. Error bars = S.E.M. 
Scale bars = 25µm. 
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Figure 4.11 Mean debris area per cell in NTg and SOD1G93A astrocytes treated with Cy3-labelled 
NSC34 cell debris alone or in combination with DMSO or riluzole (25µM). Apart from 
difference in phagocytosis of Cy3-labelled NSC34 cell debris previously seen, no significant 
difference was observed between groups in NTg or SOD1G93A astrocytes upon treatement with 
Riluzole or DMSO. * = p≤0.05, one way ANOVA with Tukey’s post-hoc test. Error bars = S.E.M. n 
= 3 per group. 
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4.7 Altered distribution of markers of cholesterol metabolism in late-stage 
SOD1G93A astrocytes 
At late-stage disease, several transcripts involved in cholesterol synthesis were 
dysregulated in SOD1G93A astrocytes versus NTg controls (Section 3.6.6). To investigate 
whether cholesterol synthesis genes were affected at the protein level, 
immunohistochemistry (IHC) was performed for 3-hydroxy-3-methylglutaryl-CoA 
reductase (HMGCR), an important enzyme in the first steps of cholesterol synthesis, 
and Sterol regulatory element binding protein 2 (SREBP2) which is the master 
regulator of cholesterol synthesis and is involved in activating transcription of genes 
such as HMGCR. SREBP2 is normally located at the endoplasmic reticulum (ER) where it 
is sequestered until low cholesterol concentrations occur. This triggers the SREBP-
cleavage activating protein (SCAP) to transport SREBP2 to the Golgi where it is 
processed to its active form and can proceed to the nucleus to activate genes involved 
in cholesterol synthesis (Brown and Goldstein, 1997). 
Staining for HMGCR in the lumbar spinal cord of late-stage mice showed no difference 
in HMGCR expression or distribution between NTg and SOD1G93A. For SREBP2, a change 
in the staining intensity of this protein was seen between the NTg and SOD1G93A spinal 
cords (Figure 4.12). In NTg spinal cord cells with the morphology of motor neurons 
(dashed areas in Figure 4.13) stained negatively for SREBP2, whilst in SOD1G93A cells 
with motor neuronal morphology were positive for SREBP2. In addition the SOD1G93A 
spinal cord also contained cells with the morphology of astrocytes throughout the grey 
matter with SREBP2 outlining the processes of these cells (arrowhead in Figure 4.13). 
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Figure 4.12 Staining for HMGCR in late stage NTg and SOD1G93A spinal cord. HMGCR showed no 
difference between the NTg and SOD1G93A condition, apart from the clear motor neuronal 
staining in the NTg cord that was absent in the SOD1G93A cord due to neuronal loss. Scale bar = 
100µm. Images representative of 3 animals per genotype. 
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Figure 4.13 Staining for SREBP2 in late stage NTg and SOD1G93A spinal cord. SREBP2 staining is 
altered in staining intensity between the NTg and SOD1G93A condition. In NTg cord, negative 
staining is seen in areas with the morphology of motor neurons (dashed areas) whereas in the 
SOD1G93A cord positive staining is seen in neurons (arrow) and in structures resembling 
astrocyte processes (arrowhead). Scale bar = 100µm. Images representative of 3 animals per 
genotype. 
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4.8 Discussion 
4.8.1 The use of neonatal SOD1G93A astrocyte cultures for modelling symptomatic 
and late-stage disease processes 
The first objective for in vitro studies of SOD1G93A astrocytes was to assess if these cells 
replicated some of the features of symptomatic and late-stage astrocytes seen in the 
array studies. Genes already validated as significantly differentially expressed upon the 
arrays were tested by qPCR in mono-cultured astrocytes and astrocytes co-cultured 
with motor neurons (Figure 4.4). None of the genes tested reached significance in 
either the mono- or co-cultured conditions, and only two genes per condition were 
differentially expressed in the direction indicated on the arrays. These results might 
seem surprising. However, in this model system astrocytes may not be stimulated by 
the factors secreted from other cell types in vivo leading to differences in gene 
expression between the cultured cells and those used in the arrays. In addition, co-
cultures were performed for three days before collection of medium and RNA. This 
may not have been sufficient time for motor neuronal stress, and consequent gene 
expression changes in co-cultured astrocytes, to occur. Finally, neonatal cells may not 
have been exposed to mutant SOD1 long enough to replicate all of the features of 
adult SOD1G93A astrocytes. 
4.8.2 Astrocyte-conditioned medium did not activate microglia in vitro 
Given the microarray findings of increased immune response transcripts in SOD1G93A 
astrocytes, it was decided to investigate whether astrocytes could modulate microglial 
phenotype in vitro. Microglia are seen to progress from an M2 (or non-activated) 
phenotype characterised by secretion of “anti-inflammatory” cytokines at the start of 
disease to an M1 (classically activated) phenotype characterised by increased secretion 
of pro-inflammatory cytokines and reactive oxygen species towards the end-stage of 
disease in the SOD1G93A mouse (Liao et al., 2012). Cultures of astrocytes obtained from 
neonatal SOD1G93A mice have previously been shown to reproduce many of the gene 
expression changes seen in spinal cord of adult SOD1G93A mice during the progressive 
phase of disease (Phatnani et al., 2013). It is therefore surprising that cultured 
astrocytes, with or without the presence of motor neurons, did not alter the 
expression of the M1 markers Cox2 or Nos2 or the M2 marker Arg1 (Figure 4.6). This is 
  154 
in agreement with the qPCR data from mono and co-cultured astrocytes which did not 
replicate the significant differences in gene expression seen in the microarrays of in 
vivo astrocytes (Figure 4.4). When assayed for the presence of modulatory cytokines 
there was no significant difference in the levels of IL1β, IL10, MCP or KC in astrocyte 
medium or in the medium of microglia treated with astrocyte medium (Figure 4.7 and 
Figure 4.8). Concordant with their increased immune role, microglia showed a trend 
for increased production of the cytokines IL1β and IL10 over astrocytes, which passed 
significance after treatment with NTG-cc medium (IL1β) and NTG-mono medium (IL10) 
(Figure 4.9).  
Astrocyte-conditioned medium was obtained after three days of mono- or co-culture, 
which may not have been enough time for a sufficient level of modulatory factors to 
build up, and therefore future studies should focus upon extending the amount of time 
before which medium is collected. Ferraiuolo et al. (2011a), in their previous study of 
pre-symptomatic SOD1G93A astrocytes, co-cultured motor neurons and astrocytes for 
14 days before which revealed the perturbation in lactate release suggested from their 
microarrays. Therefore the duration and type of stimulus must be optimised further to 
investigate astrocyte effects upon microglia. 
In contrast to the previously mentioned study by Phatnani et al. (2013) showing that 
neonatal astrocytes reproduce the gene expression characteristics of adult SOD1G93A 
spinal cord, Benkler et al. (2013) showed that neonatal SOD1G93A astrocytes are 
characterised by a lack of supportive function and are unable to respond to activating 
factors. If neonatal astrocytes are unable to respond to activating factors this may be 
the reason for them not modulating microglial phenotype in the current experiments. 
Data from Chiu et al. (2013) suggest it may be too simplistic to use a few markers to 
define the phenotype of microglia. Their data show that microglia in ALS do not occupy 
either the M1 or the M2 ends of the spectrum but have a distinct phenotype unique to 
the disease process occurring around them in which they express both 
neuroprotective and neurotoxic factors simultaneously. Adult murine microglial 
cultures are now optimised (Frakes et al., 2014) and further efforts should be made to 
optimise the culture of adult astrocytes for future co-culture investigations. The use of 
these cell types and a secretome-mapping approach may prove more useful in 
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answering the question of whether astrocytes are involved in microglial phenotype 
modulation. 
4.8.3 Lysosomal up-regulation is present in symptomatic and late-stage SOD1G93A 
mice 
Several lysosomal transcripts were increased in expression in both the symptomatic 
and late-stage astrocyte gene expression profiles. The activity of total β-
hexosaminidase (β-hex) was therefore assayed, as the Hexa (encoding the α-subunit) 
and Hexb (encoding the β subunit) transcripts were up-regulated in SOD1G93A 
astrocytes at both time-points on the arrays with HexA significantly increased and 
HexB showing a trend for increased expression by qPCR. Two β-hex isoenzymes exist, 
HexA and HexB, which hydrolyse GM2 gangliosides. HexA is a heterodimer of an α and 
β subunit whilst Hex B is a homodimer of two β subunits (Mahuran, 1995). The 
increase in total β-hex activity seen in symptomatic and late-stage SOD1G93A spinal 
cord validates the up-regulation seen in the microarray analyses at these time-points. 
A caveat of the experiments performed here is the use of whole spinal cord 
homogenate in the assay. This means that the increased activity of β-hex cannot be 
ascribed to a particular cell type. Chiu et al. (2013) found that lysosomal transcripts 
were increased in expression in SOD1G93A microglia using deep sequencing, and 
localised Ctsb and Ctss expression to microglia using immuno-staining. However, the 
levels of microglial marker transcript expression on the arrays is low in comparison to 
those of astrocytes (Section 3.4). A previous study by Fukada et al. (2007) has found 
Cathepsin H expression to be increased in the spinal cord of the Leu126delTT mouse 
model of ALS. This increased expression was localised to both astrocytes and microglia. 
In addition Cathepsin B expression has been localised to GFAP+ astrocytes in 
symptomatic SOD1G93A mouse spinal cord (Wootz et al., 2006). This suggests that both 
types of glial cell are activated in the same way during disease progression.  
4.8.4 Phagocytosis is increased in SOD1G93A astrocytes 
Several transcripts were increased in expression in SOD1G93A astrocytes that suggested 
an increased phagocytic activity (Table 3.12). Sargsyan et al. (2011) have previously 
shown that SOD1G93A microglia phagocytose significantly less Cy3-labelled NSC34 cell 
debris compared to NTg controls. Using the same assay as Sargsyan et al. (2011), 
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SOD1G93A astrocytes phagocytose significantly more NSC34 debris than NTg controls, 
reinforcing the up-regulation seen in the microarray analysis. This assay also provides 
evidence for the purity of the arrays and the assigning of these immune transcripts to 
astrocytes, as astrocyte cultures were ≥95% pure (Figure 4.1) and only cells that were 
GFAP+ were measured. 
Astrocyte phagocytosis of apoptotic cell debris is protective to co-cultured neurons 
(Loov et al., 2012), therefore the increased phagocytic ability of SOD1G93A astrocytes 
might be a protective mechanism if it exists in vivo. In contrast to Sargsyan et al. 
(2011), Frakes et al. (2014) showed SOD1G93A microglia were more toxic to co-cultured 
neurons and that they attacked and phagocytosed neuronal debris. Given the differing 
findings of Sargsyan et al. (2011) and Frakes et al. (2014) this may mean that either 
astrocytes are able to compensate for reduced microglial phagocytosis in the diseased 
spinal cord or that both cell types work in concert in phagocytosing increased amounts 
of debris. To answer this question, future experiments could use SOD1G93A mice with 
GFP-tagged motor neurons, with subsequent immunohistochemical analysis of GFP-
labelled debris within astrocytes and microglial cells.  
Riluzole is currently the only therapy approved for the treatment of ALS. Its known 
mechanisms of action include reduction of excitotoxic damage to neurons via 
inhibition of neurotransmitter release and modulation of Na+ and K+ currents 
(Bellingham, 2011). Little is known about the effect of riluzole upon astrocytic 
behaviour, therefore we sought to see if there was an effect of riluzole upon 
phagocytic ability of SOD1G93A and NTg astrocytes (Figure 4.11). Riluzole had no effect 
upon the phagocytosis of NSC34 debris in NTg astrocytes. In contrast phagocytosis of 
NSC34 debris by SOD1G93A astrocytes was significantly decreased in the presence of 
riluzole. This decrease was not significantly different to the decrease observed when 
SOD1G93A astrocytes were treated with DMSO alone, therefore further replicates will 
need to be added to assess whether this observation is robust. If phagocytosis of 
cellular debris is protective as previously suggested by Loov et al. (2012), these data 
may suggest that Riluzole has a detrimental effect by reducing astrocyte phagocytosis, 
which may be a contributing factor to the relatively short extension of lifespan 
observed with riluzole treatment. Future therapies would therefore need to look at 
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combinatorial approaches that might preserve protective behaviours that are 
negatively affected by riluzole treatment. 
Astrocytes in culture have been found to engulf cells via a classic non-professional 
phagocyte mechanism involving the proteins Megf10 and Crk (Loov et al., 2012). Other 
proteins thought to be involved in non-professional phagocytosis are Dock180, Elmo, 
Gulp1, and abca1 (Kinchen et al., 2005). Only Crk (120d: -2.07) and Elmo2 (120d: -2.48) 
are differentially expressed in the microarray data of SOD1G93A astrocytes and in the 
opposite direction than expected given the increased phagocytic ability of SOD1G93A 
astrocytes seen in vitro. However, transcripts for recognition of IgG are increased in 
expression, such as Fcgr1, Fcgr2b and Fcgr3 (Appendix 3). IgG removed from serum of 
ALS patients and injected into healthy mice is seen to localise to motor neurons 
(Engelhardt et al., 2005), and thereby might promote phagocytosis by astrocytes. The 
effect of IgG upon astrocyte phagocytosis needs to be investigated further, however 
this might signify a difference in the behaviour of in vivo and in vitro astrocytes, 
whereby the array data shows phagocytosis to operate by recognition of opsonin-
bound debris in vivo and the data of Loov et al. (2012) shows it to operate by 
recognition of markers of apoptotic cells in vitro. Regardless, these data demonstrate 
and add to the growing evidence of astrocyte phagocytosis and its importance in the 
CNS. 
4.8.5 Cholesterol synthesis is dysregulated in late-stage SOD1G93A astrocytes 
In addition to functional studies that investigated the reactive phenotype of 
astrocytes, immunohistochemistry was performed to investigate the down-regulation 
of many transcripts involved in cholesterol processing in the late-stage SOD1G93A data 
(Section 3.6.6). Genes involved in cholesterol processing are key in other 
neurodegenerative diseases such as Alzheimer’s disease (AD) which features 
polymorphisms in APOE (up-regulated in late-stage SOD1G93A astrocytes by 5.23-fold) 
and also ACAT1 (Acat2 is -2.23 at late-stage) as risk factors (Liu et al., 2010). Niemann-
Pick Disease, which is a lysosomal storage disorder characterised by 
neurodegeneration, features a defect in the ability of the lysosome to process 
sphingosine and a subsequent accumulation of cholesterol (Vanier, 2014). In ALS, 
cholesterol esters and the sphingolipid sphingomyelin are increased in the spinal cord 
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of sALS patients versus controls (Cutler et al., 2002). A side effect of increased 
intracellular lipid concentrations may operate in SOD1-ALS with regard to misfolding of 
SOD1; the A4V mutation, which is the most common variant in American SOD1-ALS 
cases (Cudkowicz et al., 1997), confers an increased propensity for SOD1-misfolding 
when in increasing concentrations of fatty acids (Kim et al., 2005).  
Given the increased phagocytic and lysosomal activity demonstrated here, it is 
tempting to suggest that increased cholesterol accumulates in the cell through 
phagocytosis of cell debris. Much cholesterol is contained within the cell membranes 
of this debris, along with sphingolipids such as gangliosides, which are broken down by 
the concomitant increase in activity of β-hexosamindase. Poirier et al. (1993) showed 
that after damage to the rat entorhinal cortex, the cholesterol synthesis of the nearby 
hippocampal tissue was significantly decreased by 8-days post-lesion and that the 
hippocampal APOE content was significantly increased by this timepoint. This is 
consistent with the pattern seen within the late-stage SOD1G93A microarray data in 
which cholesterol synthesis genes are decreased in expression whereas ApoE 
expression is increased. Increased APOE activity might function to redistribute excess 
astrocytic cholesterol to neurons, and future study should focus upon confirming the 
increased expression of APOE at the protein level. The increased motor neuronal and 
astrocytic staining of SREBP2 seen in late-stage SOD1G93A lumbar spinal cord (Figure 
4.12b) may be due to these increased cholesterol levels inhibiting the processing and 
movement of SREBP2 to the nucleus. Indeed the staining for SREBP2 appears to be 
located throughout the cytoplasm of motor neurons and the processes of astrocytes 
rather than the nucleus. To investigate this further, cholesterol measurements of the 
spinal cord need to be performed in order to confirm an increased cholesterol content 
in SOD1G93A vs NTg controls. In addition, in vitro studies should be performed to 
investigate whether increased extracellular cholesterol leads to cytoplasmic SREBP2 
localisation in astrocytes and if the SOD1G93A mutation affects this. 
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CHAPTER 5 
RESULTS 
Gene expression profiling of astrocytes from SOD1-
ALS patients 
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5 Gene expression profiling of astrocytes from SOD1-ALS patients  
5.1 Introduction 
Microarray analysis was performed upon ~1500 astrocytes laser captured from the 
ventral horn of the lumbar spinal cord of 3 SOD1-ALS cases and 6 non-ALS controls. 
The ALS cases consisted of: 34/92 (age 40, female), 37/04 (age 60, female) and 49/94 
(age 66, female) with a mean age of 55.33 ± S.D. 13.61. The control group consisted of 
2JK3 (age 71, male), 2JK4 (age 80, female), 2JK7 (age 54, female), 135.34 (age 89, 
female), 2JK10 (age 82, male), 20/07 (age 77, male) with a mean age of 75.5 ± S.D. 
12.08. 
5.2 RNA amplification and fragmentation 
RNA quality was assessed immediately after laser capture, following amplification and 
following fragmentation steps of the microarray preparation procedure (Figure 5.1). 
Amplification effectively increased the amount of RNA for use in array analysis (Table 
5.1) and fragmentation effectively produced shorter species of RNA with a smaller 
spread in sequence length, thereby increasing the likelihood of binding to the 
complementary 25mer probe sequences on the GeneChips. 
Table 5.1 RNA yields of samples used in microarray analysis of human SOD1-ALS and control 
astrocytes following 1-round and 2-round amplification. 
Sample Disease 
status 
RNA yield 1st round 
amplification 
RNA yield 2nd round 
amplification 
135.34 Control 57.64 1032.05 
2JK4 Control 83.92 714.15 
2JK7 Control 78.07 856.95 
20/07 Control 80.47 1389.3 
2JK10 Control 82.12 1721.89 
2JK3 Control 65.15 958.91 
49/94 SOD1-ALS 68.19 882.34 
37/04 SOD1-ALS 69.2 501.32 
34/92 SOD1-ALS 73.53 1813.72 
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5.3 Quality control of human astrocyte GeneChips 
As in the mouse analysis (Chapter 3) GeneChips were first subjected to quality control 
analysis in Bioconductor (Figure 5.2). Three SOD1-ALS cases and six controls were run 
on the arrays. It is apparent in Figure 5.2 that the three SOD1-ALS cases possess higher 
percentage present calls as a group than the 6 controls (SOD1 mean: 46.94 range: 
46.41-47.57; Control mean: 33.99 range: 14.92-46.33). Meanwhile, average 
background values were consistent across all chips (SOD1 mean: 28.95 range = 28.07-
30.39; Control mean: 28.03 range: 26.77-31.65). 
When the percentage present calls of each of the GeneChips was individually assessed, 
two GeneChips, 2JK3 and 2JK7, possessed lower percentage present values than the 
rest of the group. 2JK3 is more than a factor of three-fold outside the experiment 
average chip intensity (blue band in Figure 5.2) and has a percentage present call much 
lower than the other GeneChips (14.92%). Likewise 2JK7 is only just within the scale 
factor viewed as acceptable by Affymetrix and also has a low percentage present call 
(24.89%). The lower percentage present calls of 2JK3 and 2JK7 indicate errors in the 
hybridisation process for these samples. In addition to lower percentage present calls, 
RNA degradation analysis showed 2JK3 and 2JK7 to have lower mean intensity values 
than the rest of the GeneChips for probesets at the 3’ end of target transcripts. This is 
also indicative of less efficient hybridisation for these two samples. NUSE analysis of 
2JK3 and 2JK7 showed both samples to have a larger spread of values compared to the 
rest of the samples and the mean of 2JK3 to be close to 1.1, indicative of low quality 
(Figure 5.4). Finally, RLE analysis confirmed 2JK3 and 2JK7 as lower quality samples due 
to the larger spread of values and the mean for these samples not being centred 
around zero (Figure 5.5). 
Due to the results of the quality control analysis indicating a lower level of 
hybridisation for 2JK3 and 2JK7, the decision was made to remove these GeneChips 
from all subsequent analyses. Removal of 2JK3 and 2JK7 resulted in a more similar 
mean and range of percentage present calls to the SOD1-ALS GeneChips (control 
mean: 41.03 range: 34.04-46.33). NUSE and RLE plots also revealed that removal of 
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2JK3 and 2JK7 resulted in a more uniform set of GeneChips for further analysis (Figure 
5.6).  
The resulting 3 SOD1-ALS and 4 control GeneChips were processed using the PUMA 
package. All GeneChips showed similar distributions of intensity values prior to and 
following normalisation using the MMGMOS algorithm (Figure 5.7) and consequently 
differential expression analysis was performed. 
 
 
 
Figure 5.1 Representative picochip (a) and nanochip (b and c) results for LCM-RNA post-LCM 
(a), post-amplification (b) and post fragmentation (c). Fragmentation of cDNA was successful in 
creating a smaller and tighter distribution of RNA species which were detected before 30 
seconds (c). Graphs are representative of all 7 samples.  
 
a) POST-LCM b) POST-AMPLIFICATION 
c) POST-FRAGMENTATION 
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Figure 5.2 Quality control of microarray chips for SOD1-ALS and control astrocytes pre-
normalisation performed in Bioconductor using the simpleaffy package. Chips are listed on the 
left, percentage present call is in red, average background is in blue to the right of chip ID. The 
scale factor graph to the right of each chip represents the signal intensity for each chip. The 
blue strip represents the range where the individual average chip intensities are within three-
fold of the overall chip intensity. The GeneChips “2JK3” and “2JK7” are inconsistent with the 
rest of the analysed GeneChips both in terms of percentage present call and also in scale 
factor. On the far right of the figure are triangles and circles indicating the ratio of 5’ ACTIN to 
3’ ACTIN and 5’GAPDH to 3’GAPDH respectively as a measure of RNA degradation; where red 
indicates a value above the recommended ratio. 34/92 (SOD1) and 2JK4 (Control) both contain 
an ACTIN 3’-5’ ratio that is beyond the bounds of the graph and therefore a triangle is not 
shown for these samples.  
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Figure 5.3 RNA degradation plot for all GeneChips initially run in the analysis of human SOD1 
astrocytes versus controls. The mean intensity of each probe within a probeset from the most 
5’ to the most 3’ is given. GeneChips 2JK3 and 2JK7 are again of lower quality showing lower 
mean intensity values at the 3’ end than GeneChips from the other samples. This indicates a 
lower amount of RNA hybridisation has taken place for these GeneChips. 
 
Figure 5.4 Normalised Unscaled Standard Error (NUSE) plot for human SOD1-ALS and control 
astrocytes. Lower quality GeneChips have a standard error greater than one and show as 
higher on the plot. An average level of 1.1 (dotted line) indicates a low quality array. The NUSE 
plot shows 2JK7 and 2JK3 to be lower quality arrays than the rest of the analysed GeneChips. 
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Figure 5.5 Relative Log Expression (RLE) plot of human SOD1-ALS and control astrocytes. The 
more variable a GeneChip is from the median, the larger its spread of values on the RLE plot. 
GeneChips should be centred around zero and possess a similar spread. The RLE plot reinforces 
the findings from previous analyses in that 2JK7 and 2JK3 are identified as outliers in terms of 
quality.  
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Figure 5.6 NUSE and RLE plots for astrocytes from SOD1-ALS patients and controls following 
removal of 2JK3 and 2JK7. All GeneChips now fall below 1.1 on the NUSE plot and show a 
similar spread of values on the RLE indicating that they are of a similar quality. 
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Figure 5.7 Density plot of log intensity values for astrocytes from SOD1-ALS patients and 
controls prior to (a) and following (b) normalisation. a) Before normalisation step the seven 
arrays showed a similar distribution in intensity values indicating a similar level of 
hybridisation. b) After the normalisation step all seven arrays are still very similar in their 
distribution of intensity values indicating that normalisation has not created differences 
between chips. 
 
b) 
a) 
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5.4 Enrichment of cellular markers on human arrays 
As in the analysis of mouse arrays markers of different cell types were assessed for 
expression level to give an estimate of cellular enrichment in the initial LCM samples 
(Figure 5.8). Again, an enrichment of markers for astrocytes and oligodendrocytes is 
seen, with the two highest expression levels belonging to GFAP (astrocyte) and MBP 
(oligodendrocyte). In comparison, markers of neurons, microglia, endothelia and 
pericytes are much lower than astrocytic and oligodendrocyte markers. 
 
Figure 5.8 Markers of different cell types were analysed by MMGMOS expression level across 
the arrays used in analysis of human SOD1 and control astrocytes. The GeneChips are enriched 
for markers of astrocytes and oligodendrocytes. 
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5.5 Differential gene expression analysis results 
As described in Methods 2.2.4.4 transcripts identified as differentially expressed due to 
gender were excluded from the SOD1-ALS versus control analysis. From the initial list 
of 1455 differentially expressed probesets, this left a total of 1231 differentially 
expressed probesets in human SOD1-ALS astrocytes compared to controls, with 769 of 
those up-regulated and 462 down-regulated. On Affymetrix GeneChips, certain 
transcripts have multiple probesets for detection. Thus, of these 1231 probesets 1132 
corresponded to unique differentially expressed transcripts, of which 719 were up-
regulated and 413 were down-regulated.  
5.6 Gene enrichment analysis of differentially expressed transcripts in human 
SOD1-ALS astrocytes 
The Database for Annotation, Visualisation and Integrated Discovery (DAVID) was used 
to assess enrichment of differentially expressed transcripts for particular gene 
annotations (Table 5.2). When all transcripts were analysed together, the top-ranked 
category housed genes that encode proteins involved in nuclear import, such as four 
members of the Importin family (karyopherin alpha 1, karyopherin alpha 2, 
karyopherin alpha 6, importin 11). Also enriched in the list containing all transcripts 
were genes involved in purine biosynthesis (ranked 2, 4 and 5) and gene silencing 
(ranked 3 and 6), though the latter two categories contained fewer genes than other 
enriched clusters. 
The gene list was divided into up- and down-regulated transcripts and each list 
interrogated separately. Within the up-regulated transcripts, a large group of 52 genes 
involved in protein transport was the most significantly enriched category, which also 
included within it the majority of genes from the nuclear import category. The nuclear 
import genes were second-ranked in the up-regulated transcripts. In common with the 
all genes analysis (Table 5.2a), transcripts involved in purine biosynthesis (ranked 3, 5 
and 7) and gene silencing (ranked 4 and 6) are also enriched within the up-regulated 
data set (Table 5.2b). Transcripts common between the purine biosynthesis categories 
include ATP synthases present within the mitochondrial F1 complex (ATP5B +1.22 and 
ATP5A1 +1.42) and there is also increased expression of ATPases (ATP8B4 +4.72, 
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ATP13A3 +1.79, ATP2A2 +1.45, ATP8A1 -4.23) including those present within the 
lysosome (ATP6V1C1 +1.64) and plasma membrane (ATP2B4 +1.25). Although the fold-
changes for some of these transcripts are very low, this may suggest an increased 
energy requirement in SOD1-ALS astrocytes. The miRNA category includes transcripts 
encoding two eukaryotic translation initiation factors (EIF2C4 +1.51 and EIF2C3 +2.30), 
two probesets for trinucleotide repeat containing 6 (TNRC6A +1.57 and +1.44), RNA 
binding motif protein 3 (RBM3 +2.02) and a zinc finger domain containing protein 
(ZCCHC11 +1.28). EIF2C4 and EIF2C3 encode argonaute proteins which bind miRNAs 
and play a role in gene silencing, whilst TNRC6A encodes a protein (GW182) that 
associates with argonaute proteins and mRNA during gene silencing and is important 
in preserving miRNA stability (Yao et al., 2012). Differential expression of factors 
involved in miRNA stability suggests miRNA differential expression in addition to the 
mRNA differential expression currently under investigation. 
 For down-regulated transcripts (Table 5.2c) the top ranked categories were ovulation 
cycle process and sex differentiation, despite gender correction having been 
performed. These categories contained genes such as vascular endothelial growth 
factor a (VEGFA -2.00), leptin receptor (LEPR -1.78) and progesterone receptor (PGR -
3.66). Such genes have a variety of roles additional to those in female sexual 
differentiation, therefore these categories were not investigated further. Down-
regulated transcripts were also enriched for haemoglobin transcripts and transcripts 
involved in focal adhesion (ranked 4 and 5), as well as 3 categories related to 
programmed cell death (ranked 6, 7 and 9) which included transcripts involved in both 
the positive and negative regulation of this process. 
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Table 5.2 Functional annotation clustering of transcripts differentially expressed (p≤0.05) in SOD1-ALS astrocytes compared to control. Transcripts were 
analysed using the DAVID functional annotation clustering tool with highest stringency settings. The top 10 enriched categories ranked by DAVID 
enrichment score within a) all genes, b) up- and c) down-regulated categories are summarised below. Each cluster consisted of multiple similar annotations 
and has been given a summarised cluster term. The number of genes is listed along with the proportion of those genes within the full gene list of 
differentially expressed transcripts. The most significant cluster term within the cluster is listed along with its p-value. Finally the DAVID enrichment score is 
given, which is calculated by summarising the significance of enriched annotations within each cluster, the higher the enrichment score the more significant 
the enrichment of that cluster within the dataset. Full details of all clusters is contained within Appendices 12-14. 
a) All transcripts 
 Summarised Cluster Term # genes % of gene 
list 
Most significant cluster term p (most sig 
term) 
DAVID 
Enrichment score 
1 Nuclear import 14 1.24 GO:0006606~protein import into nucleus 0.002 2.49 
2 Purine ribonucleoside triphosphate 
metabolic process 
14 1.24 GO:0009206~purine ribonucleoside 
triphosphate biosynthetic process 
0.007 1.90 
3 Gene silencing by RNA 6 0.53 GO:0016441~posttranscriptional gene silencing 0.008 1.83 
4 Purine ribonucleotide metabolic 
process 
15 1.33 GO:0009152~purine ribonucleotide 
biosynthetic process 
0.013 1.63 
5 Nitrogen compound catabolic process 9 0.80 GO:0009166~nucleotide catabolic process 0.012 1.59 
6 Regulation of translation, ncRNA-
mediated 
3 0.27 GO:0035278~gene silencing by miRNA, negative 
regulation of translation 
0.033 1.47 
7 Primary active transmembrane 
transporter activity 
13 1.15 GO:0042626~ATPase activity, coupled to 
transmembrane movement of substances 
0.036 1.31 
8 Isoprenoid biosynthetic process 3 0.27 GO:0035238~vitamin A biosynthetic process 0.021 1.29 
9 Cyclic nucleotide catabolic process 4 0.35 GO:0009214~cyclic nucleotide catabolic process 0.004 1.28 
10 Positive regulation of cell death 36 3.18 GO:0043065~positive regulation of apoptosis 0.059 1.20 
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b) Up-regulated transcripts 
 Summarised Cluster Term # genes % of gene 
list 
Most significant cluster term p (most sig 
term) 
DAVID 
Enrichment score 
1 Protein localisation 52 7.14 GO:0015031~protein transport 2.10E-04 3.18 
2 Protein localisation in nucleus 12 1.65 GO:0006606~protein import into nucleus 6.20E-04 3.07 
3 Nitrogen compound catabolic process 8 1.10 GO:0009166~nucleotide catabolic process 0.004 2.08 
4 Gene silencing 5 0.69 GO:0035195~gene silencing by miRNA 0.004 1.72 
5 Ribonucleoside triphosphate 
metabolic process 
10 1.37 GO:0006754~ATP biosynthetic process 0.009 1.66 
6 Cytoplasmic mRNA processing body 3 0.41 GO:0035278~gene silencing by miRNA, negative 
regulation of translation 
0.015 1.54 
7 Ribonucleotide biosynthetic process 11 1.51 GO:0009152~purine ribonucleotide 
biosynthetic process 
0.019 1.53 
8 Regulation of interleukin-1 production 4 0.55 GO:0032731~positive regulation of interleukin-
1 beta production 
0.017 1.47 
9 Chromosome segregation 6 0.82 GO:0000070~mitotic sister chromatid 
segregation 
0.014 1.44 
10 Amino acid activation 6 0.82 GO:0043039~tRNA aminoacylation 0.036 1.42 
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c) Down-regulated transcripts 
 Summarised Cluster Term # genes % of gene 
list 
Most significant cluster term p (most sig 
term) 
DAVID 
Enrichment score 
1 Ovulation cycle process 9 2.18 GO:0022602~ovulation cycle process 6.83E-05 4.05 
2 Sex differentiation 11 2.66 GO:0048608~reproductive structure 
development 
5.34E-04 3.06 
3 Negative regulation of biosynthetic 
process 
25 6.05 GO:0010558~negative regulation of 
macromolecule biosynthetic process 
0.001 2.43 
4 Oxygen carrier 4 0.97 GO:0005833~hemoglobin complex 0.002 2.27 
5 Cell-substrate junction 8 1.94 GO:0005925~focal adhesion 0.007 2.07 
6 Regulation of cell death 29 7.02 GO:0042981~regulation of apoptosis 0.014 1.83 
7 Negative regulation of cell death 16 3.87 GO:0043066~negative regulation of apoptosis 0.014 1.82 
8 Negative regulation of transcription 20 4.84 GO:0016481~negative regulation of 
transcription 
0.014 1.80 
9 Positive regulation of cell death 18 4.36 GO:0043065~positive regulation of apoptosis 0.018 1.75 
10 Haemopoiesis  12 2.9 GO:0030097~hemopoiesis 0.018 1.52 
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5.7 Disruption of nucleocytoplasmic transport in SOD1-ALS astrocytes 
The most enriched category in the all transcripts analysis and in the analysis of up-
regulated transcripts is involved in the localisation and import of proteins into the 
nucleus (Table 5.3). This category is also more enriched than any of the down-
regulated categories after the exclusion of the sexual differentiation clusters. The 14 
significant probe set IDs within the nuclear import category corresponded to 12 
transcripts due to multiple significant probesets for BCL6 and RERE. The majority of 
transcripts (9 of 12) are increased in expression. Several members of the karyopherin 
family are present: KPNA1, KPNA2, KPNA6 and IPO11. The products of these genes are 
involved in the localisation of proteins which contain nuclear localisation signals, such 
as transcription factors, to the nuclear envelope (Cautain et al., 2014). Other 
transcripts directly involved in nucleocytoplasmic transport include nucleoporin 
205kDa (NUP205) which encodes a protein that is a structural component of the 
nuclear pore (Cautain et al., 2014) and RPAIN which also encodes a protein that 
localises other proteins to the nuclear pore (Jullien et al., 1999). 
The SOD1-ALS group and the control group have different mean ages (Section 5.1). 
This could provide a confounding variable which may lead to differential expression of 
genes. Therefore, to test that these transcripts of interest were not differentially 
regulated due to the confounding variable of age, a Pearson’s R statistic was 
calculated. Of the 12 transcripts, 3 transcripts (BCL6, RERE, and RPAIN) were found to 
significantly correlate with age. 
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Table 5.3 Transcripts linked to nucleocytoplasmic transport that are differentially expressed in 
SOD1-ALS astrocytes compared to controls. R2 values of MMGMOS expression value versus age 
are given with P value Pearson’s R statistic, notice that most transcripts show a non-significant 
correlation with age. 
Gene Full Name FC R2 P 
BCL6 B-cell CLL/lymphoma 6 +1.88* 0.75 0.012 
FYB FYN binding protein (FYB-120/130) +1.97 0.20 0.32 
IPO11 importin 11 -9.78 0.38 0.14 
JAK2 Janus kinase 2 +2.06 0.33 0.18 
KPNA1 karyopherin alpha 1 (importin alpha 5) +2.29 0.26 0.24 
KPNA2 karyopherin alpha 2 (RAG cohort 1, importin 
alpha 1); karyopherin alpha-2 subunit like 
+1.62 0.41 0.12 
KPNA6 karyopherin alpha 6 (importin alpha 7) +1.74 0.39 0.14 
MCM3AP minichromosome maintenance complex 
component 3 associated protein 
+1.43 0.39 0.14 
NUP205 nucleoporin 205kDa +1.47 0.52 0.067 
RERE arginine-glutamic acid dipeptide (RE) repeats -1.97* 0.63 0.033 
RPAIN RPA interacting protein +1.33 0.61 0.038 
SPTBN1 spectrin, beta, non-erythrocytic 1 -1.43 0.32 0.19 
TGFB2 transforming growth factor, beta 2 +1.47 0.48 0.083 
TMCO6 transmembrane and coiled-coil domains 6 +3.65 0.28 0.22 
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5.8 Pathway enrichment analysis reveals decreased expression of tight junction 
transcripts in SOD1-ALS astrocytes 
To investigate if pathways of genes were enriched within the dataset, an enrichment 
analysis was performed to identify the presence of differentially expressed genes 
within pathways stored in the Kyoto Encyclopaedia of Genes and Genomes (KEGG) 
(Table 5.4). This showed enrichment of pathways such as adherens junction and the 
complement cascade in the up-regulated transcripts.  However, by far the most 
significant enrichment by p-value was that for transcripts involved in tight junctions in 
the down-regulated gene list. Other enriched categories within the down-regulated 
transcripts include transendothelial migration and VEGF signalling, which in 
conjunction with a down-regulation of tight junction components might indicate a 
dysregulation of the blood brain barrier (BBB). 
Table 5.4 Enrichment of transcripts within pathways stored on the Kyoto Encyclopaedia of 
Genes and Genomes (KEGG). DAVID was used to analyse differentially expressed transcripts in 
SOD1-ALS astrocytes for their presence in canonical pathways. Transcripts were split into up- 
and down-regulated lists prior to analysis. The most significant enrichment within a pathway 
was seen for transcripts involved in the tight junction. 
Term Count % p-value 
Fold 
Enrichment 
Up-regulated transcripts 
    
Adherens junction 6 1.33 0.032 3.34 
One carbon pool by folate 3 0.66 0.054 7.84 
Glycerophospholipid metabolism 5 1.11 0.074 3.12 
Epithelial cell signaling in Helicobacter pylori 
infection 
5 1.11 0.077 3.07 
Complement and coagulation cascades 5 1.11 0.077 3.07 
Glycosaminoglycan degradation 3 0.66 0.080 6.27 
Down–regulated transcripts 
    
Tight junction 11 3.45 2.61E-04 4.13 
Focal adhesion 10 3.13 0.017 2.50 
Leukocyte transendothelial migration 7 2.19 0.026 3.02 
Pathways in cancer 13 4.08 0.029 1.96 
Renal cell carcinoma 5 1.57 0.051 3.51 
VEGF signaling pathway 5 1.57 0.061 3.32 
Adherens junction 5 1.57 0.063 3.28 
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Tight junctions are inter-cellular junctions that restrict the flow of ions and water 
between cells. These junctions are particularly important in the endothelium of the 
blood brain barrier (BBB) where they act to restrict the entry of unwanted pathogens 
or substances. Some of the principle components of tight junctions are the occludin, 
claudin, junctional adhesion molecule (JAM) and zona occludens proteins (Gonzalez-
Mariscal et al., 2008) of which transcripts for all four are down-regulated in SOD1-ALS 
astrocytes (Table 5.5 and Figure 5.9). Other down-regulated transcripts encoding 
proteins with important roles in tight junction and BBB integrity include the cortactin 
and the epsilon isoform of protein-kinase C. Of the 11 transcripts in Table 5.4 only TJP2 
and CDC42 were seen to significantly correlate with age of sample. 
Table 5.5 Transcripts belonging to the KEGG pathway “Tight junction” within SOD1-ALS 
astrocytes. Members of the principle tight junction components Claudin, Occludin, JAM and 
Zona occludens are all represented within the genelist. R2 values of MMGMOS expression 
value versus age are given with P value Pearson’s R statistic. Of the 11 transcripts, only CDC42 
and TJP2 are significantly correlated with age. 
Gene Full name Fold 
change 
R2 age P 
CDC42 cell division cycle 42 (GTP binding protein, 
25kDa); cell division cycle 42 pseudogene 2 
-1.56 0.83 0.0042 
CLDN5 claudin 5 -2.40 0.28 0.22 
CTTN cortactin -1.77 0.29 0.21 
EPB41 erythrocyte membrane protein band 4.1 
(elliptocytosis 1, RH-linked) 
-2.02 0.16 0.38 
F11R F11 receptor (junctional adhesion molecule 1) -6.11 0.156 0.38 
JAM2 junctional adhesion molecule 2 -2.07 0.50 0.074 
OCLN occludin pseudogene; occludin -2.22 0.47 0.087 
PARD3 par-3 partitioning defective 3 homolog (C. 
elegans) 
-1.74 0.27 0.23 
PRKCH protein kinase C, eta -1.72 0.56 0.052 
PTEN phosphatase and tensin homolog; phosphatase 
and tensin homolog pseudogene 1 
-1.30 0.41 0.12 
TJP2 tight junction protein 2 (zona occludens 2) -2.39 0.70 0.018 
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Figure 5.9 Components of the  tight junction dysregulated in SOD1-ALS astrocytes. DAVID was 
used to identify enrichment of transcripts within pathways stored in the Kyoto Encyclopaedia 
of Genes and Genomes (KEGG). Red stars indicate where corresponding transcripts have been 
identified as down-regulated in the microarray of SOD1-ALS astrocytes. Image obtained from 
KEGG (www.genome.jp/kegg). 
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5.9 qPCR validation 
As with the mouse microarray analysis (Section 3.8) qPCR was used to validate the 
findings of the arrays in terms of the direction of differential regulation and the genes 
of interest identified in the arrays. To validate the nucleocytoplasmic transport 
category karyopherin alpha 6 (KPNA6) was tested for differential expression. The 
majority of genes chosen were involved in BBB and tight junction integrity and 
included: the tight junction genes CLDN5 and JAM2; transforming growth factor β 
(TGFB) and transforming growth factor β receptor 1 (TGFBR1) which are involved in 
astrocyte-endothelial crosstalk at the BBB (Abbott et al., 2006); and endothelial PAS-
domain containing protein 1 (EPAS1) which is a transcription factor important in 
vascular development and protection of  endothelial cells against stress (Duan et al., 
2014). Also included for validation were: gap junction channel 1 (GJC1), due to the 
importance of gap junctions in astrocyte-astrocyte interactions; and chitinase 3-like 1 
(CHI3L1) which had the highest positive fold-change on the arrays. Of the genes tested 
for validation, only CHI3L1 showed a significant correlation with age of sample (R2 = 
0.93 p = 0.0005). As shown in Figure 5.10, all genes tested showed differential 
expression in the direction indicated on the microarrays with five of the eight genes 
tested showing a significant difference in expression level (p≤0.05). 
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Figure 5.10 qPCR validation of transcripts identified as differentially regulated by microarray analysis of astrocytes from SOD1-ALS and controls. * = p≤0.05, 
** = p≤0.01 vs. control, Independent samples t-test, error bars = S.E.M.  
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5.10 Comparison to SOD1G93A mouse astrocyte microarray analyses 
The gene list from human SOD1-ALS-related astrocytes was compared to the gene-lists 
from the three stages of disease in the SOD1G93A mouse model to look for common 
patterns of dysregulation (Table 5.6). A small number of genes overlapped with the 
pre-symptomatic (11) and symptomatic (2) stages which increased to 37 common 
transcripts with the late-stage gene-list. 
Of the shared genes at all time points, only one gene is present at multiple time-points: 
nel-like 1 (NELL1), which is up-regulated in human SOD1-ALS astrocytes but down-
regulated in symptomatic and late-stage disease in the SOD1G93A mouse model. NELL1 
encodes a secreted protein with growth factor properties that is seen to be important 
in both neural and skeletal development (Zhang et al., 2010). Of the shared genes 
between the human gene list and all mouse time-points combined: 38 are up-
regulated and 13 down-regulated in human astrocytes whereas 14 are up-regulated 
and 37 are down-regulated in mouse astrocytes. Fourteen genes are in agreement in 
terms of direction of differential expression between the two analyses. These include 
genes that encode proteins involved in GTP binding (GNAS, CDC42, SEPT7), 
ribonucleotide binding (EPHA5, GNAS, CDC42, RUNX1, SEPT7) and proteins containing 
transmembrane regions (ELOVL5, EPHA5, GPR160, CNNM4, MS4A7).  
Table 5.6 Genes in common between the human SOD1-ALS astrocytes and pre-symptomatic, 
symptomatic and late-stage SOD1G93A astrocytes. + = up-regulated, - = down-regulated. Up- 
and down-regulated genes have been coloured red and blue respectively. 
Gene Full name Human FC Mouse FC 
Pre-symptomatic time-point 
BUB3 budding uninhibited by 
benzimidazoles 3 homolog 
(yeast) 
-1.18 +4.01 
CNNM4 cyclin M4 +1.78 +3.3 
FAM184B family with sequence similarity 
184, member B 
+1.50 -2.73 
GNAS GNAS complex locus -2.14 -2.79 
GPR160 G protein-coupled receptor 160 +2.27 +3.23 
JAK2 Janus kinase 2 +2.06 -2.57 
KIF3A kinesin family member 3A +1.46 -2.16 
LEF1 lymphoid enhancer-binding 
factor 1 
-1.88 +3.67 
RUNX1 runt-related transcription 
factor 1 
-1.95 -2.31 
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Gene Full name Human FC Mouse FC 
SOCS4 suppressor of cytokine 
signaling 4 
+1.21 +2.71 
TYMS thymidylate synthetase +9.45 +2.05 
UBE3A  ubiquitin protein ligase E3A +1.27 -2.18 
Symptomatic time-point 
MS4A7 
membrane-spanning 4-
domains, subfamily A, member 
7 
+2.73 +2.20 
NELL1 NEL-like 1 (chicken) +3.52 -2.18 
Late-stage time-point 
ACSL6 acyl-CoA synthetase long-chain 
family member 6 
+3.55 -2.59 
ANG angiogenin, ribonuclease, 
RNase A family, 5 
-1.68 +2.76 
ARIH2 ariadne homolog 2 (Drosophila) +1.60 +2.33 
ARL4C ADP-ribosylation factor-like 4C +2.19 -2.17 
ATPAF1 ATP synthase mitochondrial F1 
complex assembly factor 1 
+2.02 -3.37 
B4GALT5 UDP-Gal:betaGlcNAc beta 1,4- 
galactosyltransferase, 
polypeptide 5 
+1.70 -2.11 
C3 similar to Complement C3 
precursor; complement 
component 3; hypothetical 
protein LOC100133511 
+2.51 +9.44 
CDC42 cell division cycle 42 (GTP 
binding protein, 25kDa); cell 
division cycle 42 pseudogene 2 
-1.56 -2.24 
CPSF6 cleavage and polyadenylation 
specific factor 6, 68kDa 
+1.37 -2.13 
ELOVL5 ELOVL family member 5, 
elongation of long chain fatty 
acids (yeast) 
-2.50 -2.13 
EPHA5 EPH receptor A5 -1.89 -2.06 
EXOC8 exocyst complex component 8 +1.37 -2.55 
GRIA3 glutamate receptor, ionotropic, 
AMPA3 (alpha 3) 
+1.56 -2.05 
GRM5 glutamate receptor, 
metabotropic 5 
+3.07 -2.00 
KANK4 KN motif and ankyrin repeat 
domains 4 
-1.50 -2.32 
KIF3A kinesin family member 3A +1.46 -2.53 
MAPK9 mitogen-activated protein 
kinase 9 
+1.63 -2.68 
MEIS2 Meis homeobox 2 +1.34 -2.06 
NECAP1 NECAP endocytosis associated 
1 
+1.51 -2.86 
NELL1 NEL-like 1 (chicken) +3.52 -2.87 
NRIP3 nuclear receptor interacting 
protein 3 
+2.95 -2.41 
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Gene Full name Human FC Mouse FC 
OGT O-linked N-acetylglucosamine 
(GlcNAc) transferase (UDP-N-
acetylglucosamine:polypeptide-
N-acetylglucosaminyl 
transferase) 
+1.44 -2.28 
OPA1 optic atrophy 1 (autosomal 
dominant) 
+1.40 -2.86 
PAK1 p21 protein (Cdc42/Rac)-
activated kinase 1 
+2.48 -2.70 
PCYT1A phosphate cytidylyltransferase 
1, choline, alpha 
+1.53 +2.33 
PDXP pyridoxal (pyridoxine, vitamin 
B6) phosphatase 
+2.36 -2.18 
RPL27 ribosomal protein L27 -1.36 +2.04 
RPL34 ribosomal protein L34 -1.28 +2.72 
RRM2B ribonucleotide reductase M2 B 
(TP53 inducible) 
+1.37 -2.43 
SEPT7 Septin 7 -1.65 -2.31 
SGIP1 SH3-domain GRB2-like 
(endophilin) interacting protein 
1 
+2.50 -2.66 
SCL9A6 solute carrier family 9 
(sodium/hydrogen exchanger), 
member 6 
+1.81 -2.23 
SNX13 sorting nexin 13 +1.38 -2.41 
TAX1BP1 Tax1 (human T-cell leukemia 
virus type I) binding protein 1 
+1.66 -2.02 
TCS22D1 TSC22 domain family, member 
1 
-1.59 2.34 
UHMK1 U2AF homology motif (UHM) 
kinase 1 
+1.42 -3.16 
YTHDC2 YTH domain containing 2 +1.56 -2.84 
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5.11 Comparison to SOD1-ALS motor neuron analysis 
The list of transcripts differentially expressed in SOD1-ALS astrocytes was compared to 
a previous analysis of SOD1-ALS motor neurons performed by Kirby et al. (2011). From 
a total gene list size of 1231 and 1170 transcripts for astrocytes and motor neurons 
respectively, 22 differentially expressed transcripts were shared between the two cell 
types (Table 5.7). Of these transcripts, 14 were differentially expressed in the same 
direction and 8 were differentially expressed in opposite directions. The shared gene 
groups represent common themes seen throughout the analysis of SOD1G93A 
astrocytes (Chapter 3) and human SOD1-ALS astrocytes; three transcripts are involved 
in ion channel activity (CLIC5, KCNN3 and SCN2A), three are involved in regulation of 
transcription (NAA16, RBM15, and TAF11) and three are involved in ATP binding 
(ATP8B4, FPGT andPDXK).  
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Table 5.7 Transcripts differentially expressed in both SOD1-ALS astrocytes and motor neurons. 
+ = up-regulated, - = down-regulated. Up- and down-regulated genes have been coloured red 
and blue respectively. 
Gene 
Symbol 
Gene.Name Astro FC MN FC 
APOC1 apolipoprotein C-I +2.32 +6.09 
ATP8B4 ATPase, class I, type 8B, member 4 +4.72 -2.97 
CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) +17.22 +4.70 
CLIC5 chloride intracellular channel 5 -1.46 +2.89 
FPGT TNNI3 interacting kinase; fucose-1-phosphate 
guanylyltransferase 
+4.02 +2.45 
INA internexin neuronal intermediate filament protein, 
alpha 
+5.63 +4.49 
KCNN3 potassium intermediate/small conductance calcium-
activated channel, subfamily N, member 3 
+2.03 +2.73 
LOC729799 SEC14-like 1 (S. cerevisiae); SEC14-like 1 pseudogene -1.39 -2.99 
NAA16 NMDA receptor regulated 1-like -2.04 -2.79 
NPHP4 nephronophthisis 4 +4.61 -2.08 
PDXK pyridoxal (pyridoxine, vitamin B6) kinase -1.43 -3.90 
PKP4 plakophilin 4 -3.39 -4.10 
PTEN phosphatase and tensin homolog; phosphatase and 
tensin homolog pseudogene 1 
-2.10 +7.92 
PTPRB protein tyrosine phosphatase, receptor type, B -1.97 +2.84 
RBM15 RNA binding motif protein 15 +1.30 -3.41 
RHAG Rh-associated glycoprotein -2.22 +3.74 
SCN2A sodium channel, voltage-gated, type II, alpha subunit +4.76 +2.94 
SLCO4C1 solute carrier organic anion transporter family, 
member 4C1 
-2.09 +4.47 
SNRPN small nuclear ribonucleoprotein polypeptide N; 
SNRPN upstream reading frame 
+3.27 +5.26 
SRRM1 serine/arginine repetitive matrix 1 +1.41 +2.03 
TAF11 TAF11 RNA polymerase II, TATA box binding protein 
(TBP)-associated factor, 28kDa 
+1.63 +3.70 
ZMYM3 zinc finger, MYM-type 3 +1.43 +4.09 
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5.12 Discussion 
The data here represent the first microarray analysis of astrocytes from human SOD1-
ALS spinal cord. The analysis of RNA from human astrocytes and subsequent gene 
expression profiling is more challenging than that performed previously for murine 
astrocytes (Chapter 3). The increased post mortem interval for human tissue versus 
mouse before LCM can lead to greater RNA degradation. In addition, there is increased 
variability due to factors such as: differing ages of human samples, gender of human 
samples and increased genetic heterogeneity of humans versus mice. Sample quality 
appears to have been compromised for two of the control samples (2JK3 and 2JK7) 
used in the analysis of SOD1-ALS astrocytes. This is evidenced by inefficient 
hybridisation upon the GeneChips, thereby causing these samples to be outliers in 
terms of array quality (Figures 5.2-5.5). Removal of these GeneChips gave a more 
consistent set of samples for subsequent analysis (Figure 5.6). The SOD1-ALS and 
control groups also differed in terms of mean age, therefore a Pearson’s R statistic was 
calculated for each gene of interest to identify those affected by this confound. Lastly, 
to counteract any gender bias from the different gender composition of each group, an 
analysis of male versus female GeneChips was performed and the resultant 
differentially expressed genes excluded from the SOD1-ALS versus control gene list. 
The result is a list of 1231 probesets with which to proceed to further analysis 
(Appendix 11). 
As with the microarray analysis of LCM-captured SOD1G93A astrocytes, an enrichment 
was seen for transcripts highly expressed by astrocytes and oligodendrocytes (Figure 
5.8). Transcripts of other cell types were not enriched within the dataset, which is 
reinforced by the low level of overlap between the SOD1-ALS astrocyte gene list and 
the gene-list of LCM-captured SOD1-ALS motor neurons from Kirby et al. (2011) (Table 
5.7). In conclusion, LCM has successfully been used to capture astrocyte material from 
human spinal cord and functional experiments using astrocytes will be used to confirm 
attribution of array data to astrocytes. 
Results of enrichment analyses show enrichment of genes involved in 
nucleocytoplasmic transport, purine biosynthesis and gene silencing (Table 5.2). In 
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addition pathway analysis shows an enrichment of down-regulated transcripts 
involved in the tight junction which together with transcripts involved in VEGF 
signalling and leukocyte transendothelial migration indicate a potential perturbation of 
the blood brain barrier (Table 5.4, Table 5.5 and Figure 5.9). 
5.12.1 Nucleocytoplasmic transport disruption in SOD1-ALS astrocytes 
Microarray analysis of human SOD1-ALS astrocytes has shown a dysregulation of genes 
involved in protein transport, particularly transport of proteins into the nucleus (Table 
5.2). The gene group particularly affected is the Karyopherin (a.k.a. Importin alpha) 
gene group, with KPNA1, KPNA2, KPNA6 and IPO11 all significantly up-regulated in 
disease. This group of genes codes for proteins that localise other proteins such as 
transcription factors to the nuclear pore complex, allowing entry to the nucleus 
(Cautain et al., 2014). A transcription factor identified as being protective against 
oxidative stress and currently of high interest in ALS is nuclear factor erythroid 2-
related factor 2 (Nrf2). Nrf2 is expressed more highly in astrocytes than neurons (Kraft 
et al., 2004), where antioxidant response element (ARE) genes are down-regulated in 
ALS (Kirby et al., 2005), and when over-expressed in astrocytes Nrf2 was seen to 
significantly delay disease onset and extend survival time in an ALS-mouse model 
(Vargas et al., 2008a). Under normal conditions, Nrf2 is stopped from entering the 
nucleus and turning on antioxidant response (ARE) genes by being bound to its 
inhibitor Keap1. Importin alpha 7 (KPNA6) is seen to interact with Keap1, allowing the 
nuclear import of Keap1 and removal of Nrf2 from the nucleus, and when over 
expressed in the NIH 3T3 fibroblast cell line KPNA6 was seen to reduce Nrf2 activity 
(Sun et al., 2011). KPNA6 is increased in human SOD1 astrocytes in our microarray 
analysis, which may be a reason for the observed reduction in Nrf2 activity. KPNA6 was 
tested for validation by qPCR, however it was not confirmed as differentially 
expressed. Therefore, nucleocytoplasmic transport was not investigated further using 
functional studies.  
5.12.2 Blood-brain-barrier (BBB) and blood-spinal-cord-barrier (BSCB) disruption in 
ALS 
BBB dysfunction in ALS is seen in both animal models and human patients. Increased 
leakage of Evans blue, a dye which binds to albumin, was observed in both cervical and 
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lumbar spinal cord of the SOD1G93A mouse at early and late-stage disease (Garbuzova-
Davis et al., 2007b). Ultra-structure analysis using electron microscopy upon these 
animals showed high levels of oedema in the neuropil of the spinal cord and swelling 
of the mitochondria within endothelial cells whilst the tight junctions appeared to 
remain intact (Garbuzova-Davis et al., 2007a). In contrast, in the SOD1G37R and 
SOD1G85R models of ALS there is a significant loss of the tight junction transcripts 
Claudin-5, Occludin and ZO1 in vessels of the anterior horn coupled to a decreased 
rate of blood flow and an increased leakage of IgG, all of which preceded motor 
neuron loss (Zhong et al., 2008, Miyazaki et al., 2011).  This work is reinforced by 
Nicaise et al (2009a), who found decreased levels of Occludin and ZO1 mRNA in the 
SOD1G93A rat spinal cord only once disease symptoms had begun. Leakage of Evans 
blue was significantly higher in the brainstem and spinal cord of symptomatic rats over 
wild-type and pre-symptomatic and there was also evidence of IgG, IgM and 
Hemosiderin deposition. Magnetic resonance imaging (MRI) has shown living SOD1G93A 
rats have higher leakage of Gd-DTPA, a marker of BBB permeability, in the brain 
(Andjus et al., 2009). Astrocytes in the SOD1G93A rat exhibit swollen end feet when 
observed using electron microscopy, providing evidence of damage to the entire 
neurovascular unit (Nicaise et al., 2009a). Aquaporin-4, a water channel protein 
expressed on astrocyte endfeet, was significantly up-regulated at both the mRNA and 
protein level in the grey matter of the SOD1G93A rat model at end stage (Nicaise et al., 
2009b) and exhibits increased immuno-staining in the trigeminal nuclei, motor cortex 
and glia limitans of the same model (Bataveljic et al., 2012). 
Leonardi et al (1984) were the first to notice heightened levels of IgG and albumin 
within the CSF of ALS patients. In the cervical spinal cord of both sALS and fALS 
patients there is a significant leakage of haemoglobin and significantly increased 
erythrocyte extravasation from the capillaries (Winkler et al., 2013). This increased 
permeability could be due to decreased endothelial tight junction expression; Henkel 
et al (2009) found significantly decreased levels of the tight junction transcripts 
Occludin and ZO1 within ALS patients with earlier (under 57 years) onset of disease. As 
in the SOD1 animal models an astrocytic defect is seen in ALS patients, with 
detachment of endfeet from endothelial cells (Miyazaki et al., 2011) consistent with an 
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increase in collagen deposition around capillaries seen by electron microscopy 
(Garbuzova-Davis et al., 2012).  
Despite the aforementioned evidence for BBB and BSCB disruption in ALS, this area 
remains controversial. Although MRI scans of the SOD1G93A rat show leakage of Gd-
DTPA, MRI of ALS patients has not revealed significant micro-haemorrhages 
(Verstraete et al., 2010). IgG from ALS patients localises to motor neurons when 
injected intraperitoneally (Engelhardt et al., 2005), suggesting that IgG leakage may be 
due to its inherent ability to cross the BBB rather than an increase in barrier leakiness. 
Further, excision of SOD1G37R solely in endothelia of the SOD1G37R mouse by Cre-lox 
mediated excision led to a significant decrease in IgG leakage compared to diseased 
animals, however the disease onset and duration was not affected (Zhong et al., 2009). 
Lastly, the immunostaining performed in the study by Miyazaki et al. (2011) is not 
conclusive of endfoot detachment, although the electron microscopy studies 
performed by Garbuzova-Davis et al. (2007a, 2012) do support astrocyte end-foot 
disruption.  
In this analysis of SOD1-ALS astrocytes, all of the main components of tight junctions, 
such as claudins, occludin, junctional adhesion molecules and zona occludens, have 
been identified as down-regulated (Table 5.4), reinforcing previous findings of 
decreased tight junction gene expression (Zhong et al., 2008, Henkel et al., 2009, 
Miyazaki et al., 2011). CLDN5 and JAM2 were confirmed as differentially expressed by 
qPCR (Figure 5.10). The tight junction genes, with the exception of TJP2 are not 
affected by the confounding variable of age (Table 5.5). Even if age were a 
confounding variable in this analysis, evidence points to an increased permeability of 
the BBB with age and a mislocalisation of tight junction proteins (Bake et al., 2009), 
suggesting that if age were affecting tight junction expression in this analysis, then it 
should be lower in the controls than in the SOD1-ALS group. Tight junction genes are 
classically associated with endothelial cells, however the levels of endothelial 
transcripts upon the arrays is low suggesting low endothelial cell contamination (Table 
5.3), and the tight junction proteins Occludin and Zona occludin 1 have been detected 
in astrocytes (Simpson et al., 2010). The finding that genes involved in focal adhesions 
are also enriched within the down-regulated gene list (Table 5.3) also adds weight to a 
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disruption of BBB integrity due to the finding that blockade of interactions with the 
ECM result in a decrease in Claudin-5 expression of endothelial cells (Osada et al., 
2011). In addition, other transcripts that could affect tight junction formation are 
dysregulated, such as Protein kinase C ε-isoform (PRKCH) which is reported to increase 
tight junction formation (Yoo et al., 2003). There is differential expression of 
transcripts involved in signalling to endothelia, such as VEGFA which increases BBB 
permeability (Gavard and Gutkind, 2006) and TGFB2 and its receptor TGFBR2. The 
TGFβ signalling pathway is specifically enriched within astrocytes in comparison to 
oligodendrocytes and neurons (Cahoy et al., 2008) thereby increasing confidence in a 
disrupted astrocyte-endothelial interaction in SOD1-ALS.  
Further experiments are necessary to address the abovementioned controversy 
existing in ALS as to the involvement of BBB/BSCB disruption in disease pathogenesis. 
To date there have been no studies of astrocyte-endothelial co-cultures using cells 
derived from ALS patients, despite this interaction being a vital part of the 
neurovascular unit.  
5.12.3 Discrepancies between mouse and human arrays 
The microarrays performed for the symptomatic and late-stage SOD1G93A astrocytes 
and those performed for human SOD1-ALS astrocytes do not overlap greatly. The 
common themes identified in the mouse analysis of lysosome and immune up-
regulation and down-regulated ion homeostasis are not present within the human 
gene-list, whilst the tight junction category is not present within the mouse data. 
When the pre-symptomatic data from Ferraiuolo et al. (2011a) is included it can be 
seen that the late-stage SOD1G93A astrocytes share the most dysregulated genes with 
the human SOD1-ALS astrocytes (Table 5.5). This is likely due to the fact that the late-
stage mouse astrocyte and end-stage human astrocyte are closer to each other in 
terms of disease stage. However, though 37 genes are shared between late-stage 
SOD1G93A astrocytes and human SOD1-ALS astrocytes, only 9 transcripts show 
differential expression in the same direction. If all mouse lists are combined, only 14 
transcripts show differential expression in the same direction.  
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The low amount of overlap between the two datasets demonstrates that key 
differences exist between the mouse model and human forms of SOD1-related ALS. In 
addition to the aforementioned differences between the mouse and human studies 
with regard to post mortem interval, age, gender and genetic heterogeneity, there may 
also be differences due to the type of SOD1 mutation present. For example, the mouse 
model contains the human SOD1 gene with a mutation at position G93A (p.G94A), 
whereas the cases used in the human microarray study consisted of two patients with 
mutations at I113T (p.I114T) and one case with a mutation at E100G (p.E101G). 
Different mutations in SOD1 are known to confer different disease courses (Turner and 
Talbot, 2008). In the SOD1G93A mouse model mutant-SOD1 is expressed at 11-fold 
higher than endogenous levels with a disease onset of 3-4 months and a duration of 1-
2 months. However another commonly used model, containing a mutation at G85R 
(p.G86R) features an endogenous-level of mutant-SOD1 expression and a disease 
onset at 8-14 months and duration of just half a month (Turner and Talbot, 2008). In 
human SOD1-ALS the A4V mutation leads to short survival compared to the G37R, 
G41D and G93C mutations (Cudkowicz et al., 1997) and the D90A mutation which 
leads to a slow disease progression (Andersen et al., 1995). Such heterogeneity in 
disease course caused by mutations in the same gene could explain the lack of 
similarity between the human and mouse gene-lists shown here.  
Another reason for the lack of similarity seen between the two sets of astrocyte data is 
the use of GFAP as a marker of astrocytes in the human analysis and ALDH1L1 in the 
mouse analysis. GFAP is associated with a reactive astrocyte phenotype, and was not 
used in the mouse analysis as ALDH1L1 had been identified as a pan-astrocyte marker 
(Cahoy et al., 2008) that would lead to a gene-list not biased by reactive astrocytes. 
Conversely, in human tissue ALDH1L1 was not a robust marker of astrocytes as seen by 
Waller et al. (2012), and GFAP lead to more easily identifiable cells for capture. 
Consequently the human LCM material has a higher enrichment of GFAP compared to 
the mouse (Figure 5.8 and Figure 3.9) and thus the use of different populations of 
astrocytes may contribute to the differences in gene expression seen here.  
 
  192 
CHAPTER 6 
RESULTS 
Functional studies of human SOD1-ALS astrocytes 
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6 Functional studies of human SOD1-ALS astrocytes 
6.1 Introduction 
Astrocytes from human SOD1-ALS patients showed differential expression of 
transcripts involved in the tight junction complex and factors that might affect the 
vasculature (Section 5.5, Chapter 5). Given this, it was hypothesised that astrocytes in 
SOD1-ALS are involved in the BBB and BSCB (hereafter referred to simply as “BBB”) 
breakdown observed in animal models and patients (Zhong et al., 2008, Henkel et al., 
2009). To investigate this, astrocytes derived from human fibroblasts of controls and 
patients with ALS were co-cultured with human umbilical vein endothelial cells 
(HUVECs) to measure the effect of co-culture upon barrier properties. In addition, 
motor neurons were added to cultures to recreate a more accurate astrocyte 
phenotype. 
6.2 Cultures used for human functional studies 
It has recently been shown that mouse embryonic fibroblasts can be directly 
converted, i.e. rather than reprogrammed back to an iPS state, to a neural precursor 
cell (NPC) that can be differentiated into neurons, astrocytes and oligodendrocytes 
using either the four classical iPS factors Oct4, Sox2, Klf4 and c-Myc with subsequent 
NPC-stimulating growth factors (Kim et al., 2011) or with the three factors Foxg1, Sox2 
and Brn2 (Lujan et al., 2012). This work was built upon by Meyer et al. (2013) who used 
the method of Kim et al. (2011) to reprogramme adult human fibroblasts from control 
and ALS patients to NPCs with subsequent differentiation to neurons, astrocytes and 
oligodendrocytes. The astrocytes, hereafter referred to as i-astrocytes, recapitulate the 
toxic phenotype towards motor neurons observed in animal models of ALS. Using this 
technique, i-astrocytes were produced by Dr Kathrin Meyer (Nationwide Children’s 
Hospital, Columbus OH, U.S.A.) for use in astrocyte-endothelial co-cultures. After 
possession of i-astrocytes had been taken, the cells were stained for the astrocyte 
markers CD44 and S100b, with nearly all cells showing as CD44 and S100b positive. 
To study the effect of i-astrocytes upon endothelia, primary human umbilical vein 
endothelial cells (HUVECs) were cultured for use in the culture cell model of the BBB. 
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HUVECs were stained for the endothelial markers Claudin-5 and CD31 which again 
showed nearly 100% of cells to be stained positively for these markers (Figure 6.2). 
Claudin-5 staining showed a high degree of localisation to the periphery of the cells 
indicating tight junction formation and confirming these cells as a model for tight 
junction integrity in further experiments. 
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Figure 6.1 Human i-Astrocytes stained with anti-CD44 (green) and anti-S100b (red) with nuclei 
stained with Hoescht (white). Magnification = 20X. Scale bar = 50µm.  
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Figure 6.2 Human umbilical vein endothelial cells stained for the endothelial markers Claudin-5 
(green) and CD31 (red). Nuclei stained for Hoescht (white), magnification = 20X, scale bar = 
50µm. 
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6.3 Co-culture of HUVECs and i-astrocytes and BBB permeability measurements 
HUVECs were co-cultured with i-astrocytes on either side of a transwell membrane. To 
ensure a more accurate astrocyte phenotype, transwells were placed into a 24-well 
plate which contained mouse wild-type motor neurons on the bottom of each well. At 
day 3 of triple co-culture, transendothelial electrical resistance (TEER) measurements 
were made across the membrane to assess ion permeability and thus tight junction 
integrity (Figure 6.3a). TEER measurement involves the placement of an electrode on 
each side of the barrier, and measurement of the voltage required to reach 10 µA of 
current, thus TEER is a way of assessing the ionic flow across the membrane. High tight 
junctional coupling would lead to low ionic permeability and therefore a high 
resistance measurement whereas low tight junctional coupling would allow more ions 
to flow between cells and thus a lower resistance measurement. In addition to tight-
junctional coupling, confluence of cell monolayers also influences TEER readings. 
Therefore, in addition to measurement of the BBBs, measurements were also taken for 
wells containing astrocytes-only in the absence of HUVECs such that any variation in 
astrocyte confluence which might affect barrier measurements could be subtracted, 
and the resultant measurements are hereby termed delta (Δ) measurements. 
Following TEER measurement, another test of barrier permeability was performed 
using 4kDa dextrans conjugated to FITC. Dextrans were placed into the top chamber 
and left for two hours, at which point aliquots were made from the bottom chamber 
and the fluorescence of these aliquots measured on a plate-reader. A highly 
permeable barrier would show greater fluorescence in the bottom chamber than a 
barrier with low permeability. This measurement is different to TEER in that it is testing 
barrier permeability to macromolecules, thus differences in dextran transport should 
either be due to large scale cell death and holes within the monolayer, or increased 
endocytosis and trans-cellular transport of the dextrans. As in the TEER measurements, 
the BBB values were corrected for the values from astrocyte-only controls wells. 
Three separate experiments were performed, using two SOD1 i-astrocyte lines and one 
sALS i-astrocyte line. The reason for inclusion of the sALS line was to test whether 
results obtained were applicable to the wider sporadic ALS population. For each 
experiment, one control and one ALS i-astrocyte line were co-cultured with HUVECs 
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simultaneously. Experiments 1 (SOD1-ALS) and 2 (sALS) were conducted in the Kaspar 
Laboratory at Nationwide Children’s Hospital, Ohio, U.S.A. using FACS-sorted murine 
GFP-expressing motor neurons for stimulation of i-astrocytes. Experiment 3 was 
performed at The University of Sheffield, U.K. using murine motor neurons prepared 
from E13.5 embryos using density-gradient centrifugation. Due to limitations in the 
amount of motor neurons obtained from a primary motor neuron preparation versus 
FACS sorted motor neurons, the experimental conditions in experiment 3 were 
repeated in duplicate rather than in triplicate as in experiments 1 and 2. 
The results of the three experiments were combined to give an average of ALS BBB 
versus control BBB TEER readings (Figure 6.3). Values were normalised to mono-
cultured HUVECs in each experiment before data were combined. TEER readings were 
found to be significantly different between monocultured HUVECs and HUVECs co-
cultured with control or ALS i-astrocytes (p=0.0061). HUVECs cultured in BBBs 
containing ALS i-astrocytes had significantly lower relative TEER readings (123.51 ± S.D. 
33.2) than either control i-astrocytes (205.02 ± S.D. 26.95) or monocultured HUVECs 
(100 ± S.D. 14). In contrast, although significant differences were seen between groups 
for dextran permeability (p=0.0166), this difference lay between monocultured 
HUVECs and co-cultured HUVECs, and a significant difference was not seen between 
control (63.45 ± S.D. 10.89) and ALS BBBs (67.85 ± S.D. 8.99) (Figure 6.4b).  
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Figure 6.3 Average TEER readings and dextran permeability measurements for HUVECs 
cultured in monoculture or with control i-astrocytes or ALS i-astrocytes in BBBs. The ALS BBBs 
consist of two SOD1-ALS lines and one sALS line of i-astrocytes. a) TEER readings for HUVECs 
cultured in ALS BBBs were significantly lower than monocultured HUVECs or HUVECs cultured 
in control BBBs. HUVECs cultured in ALS BBBs showed a trend for increased TEER 
measurements over monocultured HUVECs which did not reach significance. b) Dextran 
permeability was significantly lower than monocultured HUVECs for HUVECs cultured in either 
control or ALS BBBs. Values from 3 independent experiments normalised to respective HUVEC 
controls. BBB values represent measurements corrected for astrocyte-only recordings. * = p ≤ 
0.05, ** = p ≤ 0.01 vs. monocultured HUVECs. # = p ≤ 0.05 vs control BBB (one-way ANOVA 
with Tukey post-hoc test). Error bars = S. E. M.  
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6.4 Identification of EPAS1 for transduction of HUVECs and i-astrocytes 
Due to the decreased TEER readings seen for HUVECs co-cultured in ALS BBBs 
compared to controls (Figure 6.3) transcripts on the microarrays were investigated for 
their applicability to rescue this deficit via a gene-therapy approach. Transcription 
factors were investigated rather than individual tight junction genes due to the 
potential to act upon an entire pathway of genes which might influence barrier 
integrity.  
Endothelial PAS domain protein 1 (EPAS1), which encodes the protein known as 
Hypoxia-inducible factor 2α (HIF2α), is a transcription factor decreased in expression 
by 1.61-fold in SOD1-ALS astrocytes and present within annotation cluster 10 
(haemopoiesis) in the enrichment analysis of down-regulated transcripts (Table 5.1c, 
Chapter 5). This cluster was first investigated due to its relationship to the vasculature 
and thus the BBB. Gruber et al. (2010) found that postnatal ablation of Epas1 led to a 
disrupted blood-testis-barrier in mice and a trend for decreased expression of tight 
junction transcripts. Additionally, HIF2α expression in astrocytes drives the expression 
of erythropoietin (EPO) (Chavez et al., 2006), which is able to protect against VEGF-
mediated endothelial permeability (Martínez-Estrada et al., 2003).  
EPAS1 was highly expressed in comparison to other differentially expressed 
transcription factors (Figure 6.4) and possessed the third largest range between the 
highest expression level in control and the lowest expression level in disease. Only two 
other transcription factors had larger ranges, Staphylococcal nuclease and tudor 
domain containing 1 (Snd1) and TSC22 domain family, member 1 (Tsc22d1). SND1 is a 
part of the RNA-induced silencing complex (RISC) involved in microRNA processing and 
is shown to be increased in expression in cancer (Tsuchiya et al., 2007) and was 
therefore disregarded for use in an overexpression study. TSC22D1 encodes the 
protein TGFβ-stimulated clone 22 (TSC22) which acts as a tumour suppressor (Yoon et 
al., 2012). Another transcription factor, homeodomain interacting protein kinase 2 
(HIPK2), had five probe sets differentially expressed between SOD1-ALS and control 
astrocytes. HIPK2, like TSC22D1, encodes a protein with tumour suppressor function 
that interacts with p53 and also has a repressive effect upon the anti-oxidant 
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transcription factor HIF1α (Nardinocchi et al., 2009). The transcription factor ZNF595 is 
not reported to have any effects upon BBB function, MECOM encodes a protein 
involved in leukaemia (Jolkowska and Witt, 2000), LEF1 knockout has been shown to 
not affect tight junction expression or TEER readings in keratinocytes (Fehrenschild et 
al., 2012) and LHX6 which is involved in interneuron development (Liodis et al., 2007). 
In conclusion, none of the other down-regulated transcription factors present upon 
the arrays at a robust concentration was as well supported in the literature as EPAS1 
for manipulation of BBB properties. 
  
 
Figure 6.4 The top 10 down-regulated transcription factors by expression level in the 
microarray analysis of SOD1-ALS astrocytes vs. controls. Transcripts have been ranked by range 
between highest expression level and lowest expression level. Multiple probesets were 
differentially expressed for the transcription factor Hipk2. Epas1 was highly expressed and had 
a large range between control and disease samples. 
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6.5 Effect of LvEPAS1 transduction upon tight junction gene expression 
To assess the affect of EPAS1 over-expression upon tight junction formation, EPAS1 
was cloned and put into a lentiviral vector. EPAS1 sequencing showed one nucleotide 
substitution in the EPAS1 sequence: a G→A substitution at position 129 encoding a 
silent mutation. Lentivirus was used to transduce HUVECs with the EPAS1 gene (hereby 
designated (LvEPAS1) at at multiplicity of infection (MOI) of 20. To control for the 
transduction process, lentiviral transduction of HUVECs with green fluorescent protein 
(LvGFP) was also performed at 20 MOI. Both types of transduced cell were compared 
by qPCR to non-transduced (non-trans) controls for the expression of EPAS1 and tight 
junction genes CLDN5, ZO2, OCLN, and JAM2 as well as transforming growth factor 
beta 2 (TGFB2) (Figure 6.5). Transduction with LvEPAS1 led to significantly increased 
EPAS1 expression in HUVECs relative to non-trans and LvGFP transduced controls 
(p=<0.0001). In terms of tight junction transcripts: CLDN5 expression was significantly 
increased over non-trans and LvGFP transduced cells (p=0.02); as was ZO2 (p=0.0038); 
OCLN expression was significantly decreased in LvGFP HUVECs versus non-trans 
HUVECs suggesting that lentiviral transduction has a negative effect upon this 
transcript (p=0.02 between groups), and JAM2 expression was significantly increased 
in LvEPAS1 HUVECs versus non-trans controls but was not significantly different to 
LvGFP control cells (p=0.02 between groups). In addition TGFB2, the protein of which 
modulates astrocyte-endothelial interactions at the BBB (Abbott et al., 2006), was 
investigated and found to be significantly increased in LvEPAS1 HUVECs compared to 
non-trans and LvGFP controls (p=0.0009).  
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Figure 6.5 HUVECs transduced with Lv-EPAS1 were assayed by qPCR for expression of tight 
junction transcripts and modulators of BBB permeability. * = p ≤ 0.05, ** = p ≥ 0.01, *** = p 
≥0.001 vs non-transduced control.  # = p ≥ 0.05, ## = p ≥ 0.01, ### = p ≥0.001 vs Lv-GFP control 
(one-way ANOVA with Tukey post-hoc test). Data represent three technical replicates. Error 
bars = S.E.M. 
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6.6 Transduction of i-astrocytes with LvEPAS1 and treatment of HUVECs with 
astrocyte conditioned medium 
In light of the promising results for CLDN5 and ZO2 expression in LvEPAS1-transduced 
HUVECs, i-astrocytes were transduced with LvEPAS1 and medium collected (iACM) to 
see if EPAS1 over-expression in i-astrocytes led to factors being secreted that modified 
HUVEC gene expression. Comparisons were made to media taken from the same cell-
lines without EPAS1 transduction. As a control, HUVECs were treated with just 
medium, and gene expression values for each cell-line were normalised to this control. 
HUVECs were treated with iACM for 24 hours and then assayed by qPCR for the 
expression of the four tight junction transcripts CLDN5, ZO2, OCLN and JAM2 (Figure 
6.6). Media from four i-astrocyte cell lines was used: the two control lines AG and 209, 
and two SOD1-ALS lines p91 and 295. The sALS line 009 was not included in this 
experiment due to limited sample material.  
Media from the control i-astrocyte line AG led to a trend for decreased expression of 
CLDN5 in HUVECs compared to media only controls, with a trend for decreased CLDN5 
expression in AG-EPAS1 iACM treated HUVECs. Conditioned media from the second 
control i-astrocyte cell-line 209, whether transduced or not, also led to trend for 
decreased CLDN5 expression in HUVECs. For HUVECs treated with iACM from the 
SOD1-ALS i-astrocyte line p91 there was again a trend for decreased expression of 
CLDN5 which reached significance for p91-EPAS1 iACM, whilst the second SOD1-ALS i-
astrocyte line 295 also showed a trend for decreased expression of CLDN5. 295-EPAS1 
iACM-treated HUVECs had significantly lower CLDN5 expression compared to those 
treated with just media or 295 iACM. In contrast to CLDN5 expression, the expression 
of ZO2 was not affected by treatment of HUVECs with any of the conditioned media.  
For OCLN, AG induced a trend for decreased expression in both non-transduced and  
EPAS1-transduced conditions. Similarly, expression of OCLN in HUVECs treated with 
iACM from 209 was not significantly different from media alone, however treatment 
with iACM from 209-EPAS1 led to a significant decrease in OCLN expression versus 
media alone and 209 iACM. OCLN showed a small non-significant decrease in 
expression in p91 and p91-EPAS1 treated HUVECs. In HUVECs treated with medium 
from 295 there was a significant decrease in OCLN expression versus media. In contrast 
  205 
to all other tested lines, OCLN expression was actually significantly higher in HUVECs 
treated with 295-EPAS1 iACM compared to 295 iACM. 
The expression of JAM2 in HUVECs was significantly increased upon treatment with 
media from AG over media alone but not upon treatment with AG-EPAS1 media, whilst 
JAM2 expression was not significantly altered from media alone in either 209 or 209-
EPAS1 treated HUVECs. In contrast to iACM taken from EPAS1-transduced control i-
astrocyte lines, JAM2 expression was significantly increased over both media and non 
transduced p91 iACM when HUVECs were treated with iACM from p91-EPAS1. As with 
p91, HUVECs treated with iACM from 295-EPAS1 showed significantly higher 
expression of JAM2 over media and 295-iACM. The increased expression of JAM2 in 
HUVECs treated with EPAS1 SOD1-ALS i-astrocytes is in direct contrast to the effect of 
EPAS1 overexpression in control i-astrocytes, media from which led to a decreased 
expression of JAM2 in HUVECs compared to media from non-transduced control i-
astrocytes.  
In summary, CLDN5 expression appears reduced in HUVECs treated with iACM 
regardless of transduction by LvEPAS1, whilst LvEPAS1 transduction appears to have a 
different effect upon JAM2 expression between control and disease cell lines. The 
expression of ZO2 and OCLN appears variable dependent upon the cell-line used and 
shows no consistent effect of media from LvEPAS1-astrocytes upon the expression of 
these genes. 
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Figure 6.6 Tight junction transcript expression in HUVECs treated with conditioned medium 
from control or SOD1-ALS i-astrocytes which were either non-transduced or transduced with 
LvEPAS1. Three technical repeats per cell line. * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001 vs. 
HUVECs cultured in media alone. # = p ≤ 0.05, ## = p ≤ 0.01, ### = p ≤ 0.001 vs. HUVECs 
treated with respective non-transduced i-astrocyte conditioned medium (one-way ANOVA 
with Tukey post-hoc test). Error bars = S. E. M.  
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6.7 Co-culture of i-astrocytes and HUVECs and effect of transduction with LvEPAS1 
HUVECs and i-astrocytes were transduced by LvEPAS1 and placed together in 
transwells to assess whether there was an effect upon HUVEC tight junction integrity 
using TEER and dextran permeability measurements. All different combinations of 
transduction were tested, resulting in transwells containing transduced i-astrocytes 
with non-transduced HUVECs, non-transduced i-astrocytes with transduced HUVECs or 
both cell types transduced. As previously (Section 6.3), three separate experiments 
were performed, with experiments 1 (SOD1-ALS) and 2 (sALS) being performed at the 
Kaspar Laboratory at Nationwide Children’s Hospital, Ohio, U.S.A. and experiment 3 
(SOD1-ALS) being performed at The University of Sheffield, U.K. 
The transduction of monocultured HUVECs with LvEPAS1 (HUVECEPAS1) showed a trend 
for increased TEER and also showed a significant decrease in dextran-permeability 
(Figure 6.7). Similarly, the transduction of HUVECs with LvEPAS1 and co-culture with 
non-transduced control i-astrocytes (Astro/EndoEPAS1) led to a significant increase in 
TEER over transwells containing non-transduced control i-astrocytes and HUVECs. The 
significant difference between control Astro/Endo and disease Astro/Endo transwells 
was still seen in the Astro/EndoEPAS1 culture condition. AstroEPAS1/Endo and 
AstroEPAS1/EndoEPAS1 conditions were only repeated twice but show minimal differences 
between control and disease transwells for both TEER and dextran readings. No 
significant differences were observed for any of the transduction combinations in 
terms of dextran readings. 
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Figure 6.7 TEER reading and Dextran permeability of HUVECs co-cultured with control and ALS 
i-astrocytes under different LvEPAS1 transduction conditions. a) TEER readings of HUVEC-only 
controls and transwells containing either HUVECs-only, i-astrocytes-only or both cell types 
transduced with Lv-EPAS1 (as denoted by superscript text). EPAS1 overexpression increased 
TEER readings in control Astro/EndoEPAS1 transwells relative to non-transduced Astro/Endo 
transwells. b) Dextran permeability measurements of the cultures used in a).  EPAS1 
overexpression decreased the permeability of HUVECs cultured alone but did not significantly 
decrease the permeability of any of the transwell cultures relative to non-transduced 
Astro/Endo co-cultures. All experiments had n=3 apart from AstroEPAS1/Endo and 
AstroEPAS1/EndoEPAS1 which had n=2. Values are normalised to non-transduced HUVECs after 
subtraction of astrocyte only-control values. * = p ≤ 0.05 , *** = p ≤ 0.001. ## = p ≤ 0.01 vs 
Astro/Endo. One-way ANOVA with Sidak’s multiple comparisons test. Error bars = S. E. M.  
a) 
b) 
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6.8 Discussion 
This study shows the first evidence of endothelial function being disrupted by i-
astrocytes obtained from patients with SOD1 and sporadic ALS. When HUVECs were 
co-cultured with control and ALS i-astrocytes, the delta value, corresponding to the 
transwell resistance once astrocyte-only values had been subtracted, was significantly 
higher in control transwells versus ALS transwells (Figure 6.3). Delta values were used 
instead of total resistance values due to the heterogeneous nature of the i-astrocytes; 
monolayer tightness and density was variable between cell lines. TEER readings are 
affected by confluence of monolayers, thus it was therefore necessary to subtract 
values obtained from astrocyte-only control wells.  
The lower TEER readings observed for transwells containing ALS i-astrocytes could be 
through a lack of supportive factors, an increase in toxic factors, or an alteration of 
signalling to the endothelia. The i-astrocytes produced by this method have previously 
been shown to decrease viability of co-cultured motor neurons compared to those co-
cultured with control i-astrocytes (Meyer et al., 2013). Toxic factors such as lead 
acetate and malathion are capable of inducing decreased transwell TEER readings and 
expression of tight junction proteins (Balbuena et al., 2010a, Balbuena et al., 2010b). 
Therefore it may be possible that as yet unidentified factors are being secreted by i-
astrocytes that are toxic to endothelial cells. 
It is more likely however that there is an altered signalling between ALS i-astrocytes 
and endothelia. This is due to the observation that dextran permeability is similar 
between control and ALS transwells (Figure 6.3). If toxicity were occurring, one would 
expect disruption to endothelia to occur on a large enough scale to allow greater 
solute permeability. The fact that a disruption is seen only in the TEER readings, which 
represent the ionic permeability of the barrier, suggests that a more subtle effect is 
operating at the level of the tight junction. Astrocytes are able to signal to endothelia 
through a variety of signalling factors such as prostaglandins and cytokines such as IL1β 
and TGFβ (Abbott et al., 2006). Perhaps the increased expression of transcripts for 
factors such as TGFB2, validated previously by qPCR (Figure 5.10, Chapter 5), can 
explain the increased permeability of ALS transwells versus controls.  
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Upon the finding that i-astrocytes from ALS patients are less supportive/disrupted in 
signalling to HUVECs compared to those from controls, a gene therapy approach was 
investigated to see whether this defect could be rescued. Transcription factors 
decreased in expression in the human microarrays were investigated for their 
applicability in modulating the properties of the BBB (Figure 6.4). EPAS1 was identified 
as a highly expressed transcription factor that has the potential to regulate tight 
junction transcripts (Martínez-Estrada et al., 2003, Chavez et al., 2006, Gruber et al., 
2010). This study has identified EPAS1 as a transcription factor which when over-
expressed at the transcript level leads to an increased expression of tight junction 
transcripts such as CLDN5 and ZO2 and the BBB modulator TGFB2 in HUVECs. Claudin-5 
and ZO2 are intimately linked in the cell; ZO1 and ZO2 are scaffolding proteins which 
localise to the intra-cellular side of the plasma membrane and are vital for correct 
localisation of tight junction proteins and, in particular, the polymerisation of Claudin 
proteins (Umeda et al., 2006). The linkage of EPAS1 with tight junction gene expression 
also reinforces previous work which found a trend for decreased tight junction 
expression in response to EPAS1 deletion (Gruber et al., 2010). In contrast to CLDN5 
and ZO2, the expression of OCLN and JAM2 was not significantly different to non-
transduced or LvGFP-transduced controls, meaning that other factors may have to be 
investigated for the manipulation of these genes. Functionally, EPAS1 over-expression 
led to increased TEER readings and significantly decreased permeability to dextrans in 
HUVEC monolayers (Figure 6.7).  
The choice of EPAS1 for over-expression studies was also based upon the previous 
observation that HIF2α, the protein encoded by EPAS1, drives EPO expression in 
astrocytes during hypoxic conditions and that EPO is a factor important in maintaining 
barrier integrity (Martínez-Estrada et al., 2003, Chavez et al., 2006). In contrast to 
these studies, over-expression of EPAS1 in astrocytes appeared to decrease tight 
junction transcript expression in HUVECs treated with iACM (Figure 6.6). The one 
robust effect of LvEPAS1 transduction upon iACM-mediated tight junction expression 
was for JAM2 which was increased in expression when treated with media from 
LvEPAS1 transduced i-astrocytes. Thus it appears that factors secreted by LvEPAS1-
astrocytes can up-regulate JAM2 whilst LvEPAS1-HUVECs feature up-regulation of 
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CLDN5 and ZO2. Further study should focus upon increasing the number of cell lines 
used to see if the effects observed are consistent.  However, the experiments 
described here highlight the differing behaviour of the two cell types upon 
transduction. 
In the transwell co-culture experiments (Figure 6.7), transduction of HUVECs alone and 
co-culture with i-astrocytes in Astro/EndoEPAS1 transwells increased TEER readings 
relative to the levels seen in Astro/Endo conditions, which reached significance for the 
control transwells. This also appears to be the case for AstroEPAS1/EndoEPAS1 transwells, 
although more replicates will be needed to confirm this finding. This suggests that 
expression of EPAS1 in the two cell types may lead to different or synergistic effects 
upon BBB integrity. If future therapeutic strategies were to use viral delivery of 
transgenes or RNAi to the BBB then the differing reactions of all BBB cell types should 
be thoroughly investigated.  
Future studies could also look at whether EPAS1 over-expression in i-astrocytes leads 
to an increased expression of TGFB2 as it does in HUVECs here (Figure 6.5). TGFB2 
increases HUVEC permeability when applied exogenously (Ishihara et al., 2008), and 
may be a contributing factor to the increased permeability of AstroEPAS1/Endo 
transwells relative to AstroEPAS1/EndoEPAS1 transwells. Alternatively, HIF2α has also 
been shown to affect the transcription of VEGF in the absence of HIF1α (Shinojima et 
al., 2007). VEGF is also able to increase endothelial permeability (Gavard and Gutkind, 
2006, Argaw et al., 2012), and thus over-expression of EPAS1 could lead to increased 
VEGF production by astrocytes. In support of this, HIF1α has recently been shown to 
be unstable in sALS fibroblasts during hypoxia, leading to significantly lower levels of 
HIF1α protein compared to control fibroblasts (Raman et al., 2014). If this is also the 
case in the SOD1 and sALS astrocytes used here, the subsequent over-expression of 
HIF2α could therefore drive the transcription of VEGF.  In summary, the applicability of 
EPAS1 for gene therapy of the observed TEER deficit in ALS transwells has not yet been 
proven, and requires further investigation to clarify these interesting pilot data. As an 
alternative to the gene therapy approach, future strategies could investigate the use of 
factors such as glycerophosphoinositol (GPI) or dexamethasone, which have been 
found to increase TEER in a similar in vitro BBB model (Cucullo et al., 2004). 
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6.8.1 The contribution of endothelia in the transwell co-culture requires further 
investigation 
The contribution of the endothelial cells in the transwells should not be overlooked as 
they are also capable of modulating astrocyte properties. Endothelia treated with 
ammonia had increased translocation of NFκB to the nucleus and conditioned medium 
taken from these cells induced swelling of astrocytes (Jayakumar et al., 2012). Perhaps 
endothelia secrete factors to ALS i-astrocytes that exacerbate the situation, or perhaps 
the use of wild-type endothelia here dampened the effect of ALS i-astrocytes. Li et al 
(2013) have recently shown that fibroblasts can be converted to endothelia through a 
similar direct conversion method as used for the i-astrocytes in this study.  Therefore a 
valuable future study would be to use ALS endothelia in co-culture with i-astrocytes to 
see if the effects are exaggerated when both cell types are diseased. 
6.8.2 Attribution of tight junction transcript expression to astrocytes 
Future studies should be designed to confirm whether the tight junction transcripts 
identified as down-regulated in the microarrays of SOD1-ALS versus control astrocytes 
are truly dysregulated in astrocytes in ALS or are due to expression by contaminating 
endothelial cells from LCM-capture. OCLN and ZO2 expression has previously been 
seen in astrocytes (Simpson et al., 2010), however CLDN5 has not. Although the level 
of contaminating transcripts for endothelial cells is very small relative to those of 
astrocyte transcripts, three of the transcripts used to identify endothelia (vWF, FLT1 
and CLDN5) are differentially expressed between the controls and SOD1-ALS cases 
(Figure 5.8, Chapter 5).  
The majority of signal upon the microarrays is from astrocytes, due to GFAP being used 
as a marker during LCM and the high expression levels of astrocyte transcripts. 
However the intricate inter-twining of non-neuronal cells in the spinal cord, especially 
astrocytes which contact the vasculature and neurons with their processes, means that 
a small amount of contaminating signal from other cell types is inevitable. Rather than 
disregard the enrichment of tight junction transcripts as contamination, one could 
hypothesise that the decrease in tight junction transcripts in SOD1-ALS cases is due to 
either a) astrocyte toxicity towards endothelia and subsequent loss of contaminating 
endothelial cells in ALS-LCM samples or b) astrocyte-mediated down-regulation of 
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tight junction transcripts in ALS and a consistent level of endothelial contamination in 
LCM samples from ALS and controls. The results presented here support the latter 
hypothesis; astrocyte-conditioned medium is able to influence tight junction transcript 
expression, whilst HUVECs co-cultured with i-astrocytes derived from ALS fibroblasts 
show a significantly lower level of TEER than those cultured with i-astrocytes from 
control fibroblasts. Finally, the lack of a difference between control and ALS transwells 
with regards to dextran permeability indicates that endothelial cell death death 
resulting from i-astrocyte toxicity is not occurring. Signalling between the different 
components of the blood brain barrier in ALS and its effect upon disease progression 
therefore merits further investigation. 
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CHAPTER 7 
Discussion 
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7 Discussion 
This project used microarray technology to address the hypothesis that gene 
expression profiling of murine SOD1G93A astrocytes will identify dysregulated gene 
expression that reveals the contribution of astrocytes to motor neuron death 
throughout the disease process. Though this hypothesis was fairly broad, microarray 
technology is itself a hypothesis generation tool. Thus, the microarray analysis of 
SOD1G93A astrocytes generated the subsequent hypotheses that the immune response, 
lysosome and cholesterol pathways are dysregulated in symptomatic and/or late-stage 
SOD1G93A astrocytes. Similarly, microarray technology was used to address the 
hypothesis that astrocytes in SOD1-ALS human subjects possess dysregulated gene 
expression that reveals the contribution of astrocytes to motor neuron death. Through 
identification of the differential expression of tight junction transcripts on the arrays, it 
was hypothesised that SOD1-ALS astrocytes contribute to the BBB breakdown that is 
seen in ALS mouse models and patients. These hypotheses, generated at the transcript 
level, could then be tested at the functional level using tissue and in vitro studies. In 
this way, the initial hypotheses have been answered: microarray profiling of murine 
SOD1G93A and human SOD1-ALS astrocytes did reveal dysregulated gene expression 
and led to functional experiments that revealed phenomena that may affect survival of 
motor neurons. 
7.1 Similarities of these findings to other neurodegenerative conditions 
Non-cell autonomy is now recognised as a key feature in neurodegenerative disease. 
The data here show that a multitude of processes within astrocytes are being 
dysregulated during ALS progression in the SOD1G93A mouse and within human SOD1-
ALS astrocytes (Figure 7.1). Some of the astrocyte behaviours seen in this study and in 
ALS are common to other neurodegenerative diseases. For example, reactive 
astrogliosis is also a key feature of Alzheimer’s disease (AD) and Parkinson’s disease 
(PD) (Beach and McGeer, 1988, Sacino et al., 2014). Reactive astrocytes are even seen 
in the spinal cord of these patients (Samantaray et al., 2013), which is not the main 
region of pathology for these diseases.  
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Figure 7.1 The changing phenotype of astrocytes during disease progression in the SOD1G93A 
mouse. Key dysregulated gene categories are shown from the pre-symtptomatic, symptomatic 
and late-stages of disease. 
  
The data in the current study of murine astrocytes suggest that this reactive 
phenotype contains protective elements, at least in the symptomatic phase of disease 
before the pathology becomes overwhelming. It is now generally accepted that 
astrocytes become reactive as a defence response for the protection of neurons 
(Rodriguez-Arellano et al., 2015). This would make sense in ALS, where an increased 
number of astrocytes could clear excess glutamate and ROS. In contrast to ALS, AD and 
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PD, mouse models of the neurodegenerative disorder Huntington’s disease (HD) 
feature no increase in astrogliosis at symptom onset (Tong et al., 2014), and it would 
be interesting to see if stimulation of astrocyte proliferation in HD models is 
neuroprotective. 
If gliosis and neuro-inflammation are largely protective strategies in ALS, this may be 
the reason why anti-inflammatory therapies have had limited effect on disease 
progression. For example, many anti-inflammatory treatments have shown promise in 
the SOD1G93A mouse which have not translated to humans. The inhibition of cyclo-
oxygenase 2 (COX2), which is involved in the synthesis of pro-inflammatory cytokines, 
with the drug celecoxib significantly enhanced survival time by 25% in the SOD1G93A 
mouse (Drachman et al., 2002). However, the use of this drug in human ALS showed no 
effect upon disease progression (Cudkowicz et al., 2006). Minocycline is a drug which 
inhibits microglial activation and inflammation which has also been trialled in ALS. 
Presymptomatic administration of minocycline to mSOD1 mice delayed the onset of 
neurodegeneration and extended survival time by 5 weeks when administered in high 
doses in food (Kriz et al., 2002) and around 16% when given in lower doses via intra-
peritoneal injection (Van Den Bosch et al., 2002). However minocycline actually 
seemed to worsen disease outcomes in humans, as demonstrated by a faster decline 
in the ALSFRS-R (Gordon et al., 2007). Therefore, inflammation may be a feature of the 
mouse model which is either not important in human disease, or plays a positive role 
in disease pathophysiology. 
Increased activity of lysosomal enzymes was also a key feature of the symptomatic and 
late-stage SOD1G93A astrocytes. One contributing factor for this in ALS may be that one 
of the two identified proteins contained within bunina bodies is the lysosomal cysteine 
protease inhibitor Cystatin C (Okamoto et al., 2008), thereby removing a source of 
lysosomal inhibition. Lysosomal dysfunction is also seen in other neurodegenerative 
diseases. Similar to the findings here of increased lysosomal activity, lysosomal content 
of vulnerable neurons in human AD cases is increased around two to eight-fold over 
age-matched controls (Cataldo et al., 1996) and increased lysosomal staining of 
astrocytes is seen in human AD brain compared to controls (Kobayashi et al., 2002). In 
contrast, the treatment of dopaminergic neurons with 1-methyl-4-phenyl-1,2,3,6-
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tetrahydropyridine (MPTP), which models PD, features a depletion of lysosomes within 
dopaminergic neurons (Dehay et al., 2010). Restoration of lysosomes through 
treatment with rapamycin proved protective against MPTP exposure, providing 
evidence that increased lysosomal function may be neuroprotective.  
Lysosomal dysfunction in neurodegenerative disease is of particular interest due to the 
lysosome being the end-point for the process of autophagy, which is the cellular 
process for degradation of macromolecules, organelles and protein aggregates. Protein 
aggregation is particularly pertinent in repeat expansion disorders such as 
Huntington’s disease, in which large increases in lysosomes are seen, possibly in 
response to decreased lysosomal enzyme activity (Cortes and La Spada, 2014). Coupled 
with defective loading of autophagosomes, this leads to decreased turnover of 
misfolded mutant huntingtin protein. Thus, in ALS, which features aggregated proteins 
in all genetic subtypes, and also features C9ORF72-ALS with a repeat-expansion 
component, lysosomal function is likely to be of importance.  
In terms of the reduced expression of cholesterol transcripts in late-stage SOD1G93A 
astrocytes (Chapter 4), it is interesting that HD also features dysfunctional metabolism 
of cholesterol with lower activation of SREBP2 and reduction in cholesterol synthesis 
genes (Leoni and Caccia, 2015). In AD, it has been known for some time that the 
APOE4 allele confers an increased susceptibility to AD development (Strittmatter et al., 
1993). APOE4 encodes an isoform of apoliprotein E, which is important in the transport 
of cholesterol from astrocytes to neurons, and confers a different domain structure 
and stability than the APOE2 and APOE3 alleles (Zhong and Weisgraber, 2009). 
Meanwhile in PD, there is less clear-cut evidence for cholesterol playing a role in 
neuronal death (Martin et al., 2014). The data from the current study add to the 
limited evidence of dysregulation of cholesterol pathways currently present in the ALS 
field. However, the occurrence of this process in other neurodegenerative diseases 
warrants its further investigation in ALS. 
For human SOD1-ALS astrocytes, the microarray study led to the hypothesis that 
astrocytes are involved in the BBB breakdown seen in ALS. This is also suggested in 
other neurodegenerative conditions. For example in PD, increased reactive gliosis is 
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seen with subsequent release of pro-inflammatory cytokines which can disrupt the 
BBB (Cabezas et al., 2014). In AD, Aβ damages endothelium via stimulation of 
superoxide production (Thomas et al., 1996). This is particularly interesting given the 
increased amount of ROS produced by astrocytes and microglia in SOD1-ALS and also 
given the fact that provision of SOD1 rescued the endothelial damage caused by Aβ 
(Thomas et al., 1996). 
7.2 Comparative analyses of mouse and human data 
As already discussed in section 5.12.3, it was interesting that there was little overlap of 
the mouse and human gene expression data. However, large differences in gene 
expression are seen between cells of the same type in different locations in the CNS 
(Doyle et al., 2008). Perhaps the different locations of picked astrocytes, lumbar spinal 
cord in the mouse study versus cervical spinal cord in the human cases, could be one 
reason for the different outcomes of the two studies, or perhaps there is a more 
fundamental difference in astrocyte behaviour between mouse and man. 
Human astrocytes are known to be more complex than murine astrocytes e.g. by 
possession of more processes and a faster rate of calcium-wave conduction (Oberheim 
et al., 2009). This is thought to be linked to the enhanced cognitive abilities of humans 
compared to mice, and murine memory and learning is improved when glial restricted 
precursors are implanted into the mouse brain (Han et al., 2013). In addition, multiple 
different subtypes of astrocyte are observed in human brain that are not present in 
rodent brain (Oberheim et al., 2009). This difference in astrocyte complexity means 
that the lack of overlap between the human and mouse datasets is not surprising. In 
addition variation between the human and mouse arrays will be influenced by the 
factors mentioned in Chapter 5 section 5.12.3 such as post mortem interval, age, 
gender, genetic heterogeneity of humans versus mice, type of SOD1 mutation, over-
expression of mSOD1 in the mouse model and the use of different markers of 
astrocytes for LCM. 
7.3 Discrepancies between mouse models and human disease 
The SOD1G93A mouse model has allowed many of the pathological mechanisms of ALS 
to be elucidated and has proved invaluable in this study where it has allowed study of 
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pre-symptomatic and symptomatic disease, something that is not possible in human 
SOD1-ALS. However, although the mSOD1 models of ALS recapitulate human disease 
pathology and progression, no therapies have successfully transitioned from the 
mSOD1 mouse to the clinic. It may be that the low percentage of SOD1-ALS cases, only 
20% of fALS and therefore only 2% of cases overall, will mean that most trials using 
large numbers of patients are likely to fail, as any effects identified in the mouse model 
could be SOD1-specific. It is therefore important for the ALS community to generate 
models using the other known ALS-causative mutations, the most important of these 
being C9ORF72 and TDP-43 related ALS.  
C9ORF72-related ALS accounts for around 40% of fALS and up to 7% of sALS, meaning 
that if a good model could be made, there may be more successful translation from 
model to clinic. Progress is occurring on this front, as recently a tetracycline-inducible 
mouse model which produces C9ORF72 RNA containing 80 GGGGCC repeats has been 
created (Hukema et al., 2014). Three hypotheses exist for the pathogenicity of 
C9ORF72 containing repeat expansions: 1) expanded C9ORF72 mRNA sequesters RNA 
binding proteins and leads to abnormal splicing events, 2) expanded C9ORF72 upon 
one allele leads to haploinsufficiency, and 3) the dipeptide repeat proteins (DPR) 
encoded by the expansion cause toxicity through formation of protein aggregates 
(Walsh et al., 2014). The inducible mouse model of Hukema et al. (2014) contains 
ubiquinated inclusions in the nucleus of striatal neurons and in the neuropil but does 
not show expression of DPR proteins commonly associated with C9ORF72-ALS, 
meaning that it is a good model to study the mechanisms of RNA toxicity in isolation. 
No cell loss is observed in this model after 12 weeks of C9ORF72 induction, suggesting 
that it may be the DPRs that mediate the toxic effect. In support of this, generation of 
drosophila lines carrying stop codons in the C9ORF72 expansion, thereby removing 
DPR production, did not suffer ocular degeneration, whereas ocular degeneration did 
occur when expanded C9ORF72 did not contain stop codons (Mizielinska et al., 2014). 
The use of TDP-43 models has proven problematic due to the fact that over-expression 
of wild-type human TDP-43 in mice is toxic (Stallings et al., 2010). Thus comparisons 
between mutant TDP-43 models and a wild-type TDP-43 control model are difficult to 
make. Knockout of TDP-43 is embryonic lethal in mice (Wu et al., 2010), however 
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partial knockout mouse models in which TDP-43 is knocked out of motor neurons have 
demonstrated ALS-like pathology (Wu et al., 2012b). These data show that wild-type 
TDP-43 has both the propensity to misfold and that its normal function is vital for the 
survival of the cell.  
As shown in the current study, even when studying the same disease-causing gene, 
there is a marked difference between the mouse and human gene expression 
signatures. As previously mentioned in Chapter 1, different mutations in SOD1 can 
cause very different disease progressions. As more causative genes are being found, it 
is becoming increasingly apparent that ALS is a spectrum of disorders leading to a 
common endpoint, so it may be that astrocytes play different roles in each ALS sub-
type, and corresponding therapies will need to take this into account. 
7.4 Toxicity or loss of support 
As mentioned in Chapter 1, one of the main questions regarding astrocyte biology in 
ALS is that of whether astrocytes are toxic to motor neurons or whether their 
supportive function is compromised. Certainly there is evidence for both of these 
phenomena occurring in vitro. The evidence presented in the two microarray studies 
conducted here upon astrocytes that were as close to in vivo as possible, seems to 
show that a loss of supportive function makes up a larger component of astrocyte 
behaviour than toxicity. It is postulated that the immune function and lysosomal up-
regulation detected in symptomatic SOD1G93A astrocytes may actually be a protective 
function, allowing the phagocytosis and recycling of neuronal debris. Similarly, the 
putative disruption of the BBB by astrocytes seen in the human study is not a direct 
toxic effect of these cells upon neurons. Furthermore, the disruption in ion 
homeostasis observed in symptomatic and late-stage astrocytes indicates that one of 
the main supportive roles, that of homeostatic regulation of the external environment, 
has been severely impaired in disease. The data accumulated from the microarray 
analyses of the pre-symptomatic, symptomatic and late-stage disease in the SOD1G93A 
mouse appear to show, amongst many dysregulated processes, a progressive loss of 
support for neurons, beginning with decreased lactate secretion and continuing with 
problems in ion homeostasis and cholesterol biosynthesis (Figure 7.1). 
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This is not to say that there is no toxicity of astrocytes toward motor neurons in ALS or 
other neurodegenerative disorders. In AD, delivery of the peptide inhibitor VIVIT to 
astrocytes using adeno-associated virus interfered with the pro-inflammatory “nuclear 
factor of activated T-cells” pathway leading to decreased astrogliosis, improved 
cognition, synaptic function and lower Aβ levels (Furman et al., 2012). Thus, astrocytes 
do have the capacity to be damaging to neuronal function. Similar to the M2 to M1 
microglial switch in ALS, perhaps astrocytes could be said to transition from an A2 
(supportive) to an A1 (reactive) phenotype during disease progression, where an 
increase in reactivity occurs in parallel to a decrease in supportive function. 
7.5 Future work 
To provide more evidence for the observed phenomena in the mouse and human array 
studies, more functional studies need to be performed, particularly in the area of 
cholesterol processing in SOD1G93A mice. For example, it is widely known that motor 
neurons co-cultured with SOD1G93A astrocytes show lower viability than those co-
cultured with wild-type cells. It would be interesting to use GFP-motor neurons co-
cultured with SOD1G93A astrocytes to see if phagocytosis of neuronal debris occurs in 
vitro and whether this phagocytosis leads to cytoplasmic localisation of SREBP2, as 
proposed in Chapter 6. At the moment it is unanswered as to whether phagocytosis is 
the reason for decreased cholesterol processing transcripts in astrocytes, or whether 
there is a more fundamental problem with cholesterol homeostasis.  
Microarray experiments are great hypothesis generation tools. However the sheer 
number of hypotheses that can be generated given the list of differentially expressed 
genes can sometimes mean that interesting phenomena are left uninvestigated. A key 
feature of the murine astrocyte arrays that has not been functionally investigated is 
that to do with K+ homeostasis. Astrocytes are key in K+ buffering of the interstitial 
fluid (Kofuji and Newman, 2004) and a simple validation of whether astrocytes carrying 
the SOD1G93A mutation are defective in K+ buffering capacity could be performed by 
measuring K+ in the medium of astrocytes in vitro. With relevance to the differential 
expression of ion homeostasis genes seen in the mouse study, the potassium channel 
Kir4.1 is lost from astrocytes in mouse models of Huntington’s disease, leading to 
elevated extracellular K+ levels and neuronal death.  This was rescued by viral delivery 
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of Kir4.1 (Tong et al., 2014). Thus K+ buffering of ALS astrocytes is an important 
mechanism for investigation. 
Another feature of the array analyses which warrants further investigation is the 
differential expression of mitochondrial or ATP-biosynthesis transcripts. Mitochondrial 
transcripts are dysregulated in murine presymptomatic SOD1G93A astrocytes and a 
dysregulation of ATP-biosynthetic transcripts is observed in human SOD1-ALS 
astrocytes here. This is a common theme amongst neurodegenerative disorders, with 
both AD (Liang et al., 2008) and PD (Duke et al., 2007) featuring differential expression 
of mitochondrial transcripts. Interestingly, the AD study using laser-captured neurons 
showed a decreased expression of mitochondrial transcripts, whereas the PD study 
using whole tissue and the present study of human SOD1-ALS astrocytes saw an 
increased expression of mitochondrial transcripts. In SOD1-ALS motor neurons, there is 
an equal split between increased and decreased transcripts involved in the electron 
transport chain (Kirby et al., 2011). It would therefore be interesting in future to 
investigate cell-specific mitochondrial dysfunction beyond the transcript level during 
disease progression. 
In the human microarray study, the use of a new method to produce i-astrocytes 
through direct conversion of fibroblasts allowed the hypothesis that SOD1-ALS 
astrocytes are involved in BBB disruption to be tested using in vitro BBB models. This 
study has shown for the first time that ALS i-astrocytes induce higher permeability in 
endothelial monolayers in comparison to control i-astrocytes. The use of i-astrocytes 
will be beneficial for future research, as it means that the problems associated with 
transitioning between mouse disease to human disease will be removed. There is also 
the opportunity to create new lines of i-astrocytes from AD and PD fibroblasts to 
investigate BBB dysfunction in these diseases. The use of gene therapy to attempt 
rescue of monolayer integrity was successful in one patient line but unsuccessful in the 
following two lines tested. However, the data generated from the microarray study 
mean that more candidate genes could be identified in future to study alteration of 
BBB properties. 
  224 
Finally, although efforts have been made here to compare the pre-symptomatic, 
symptomatic and late-stage motor neuron datasets of Ferraiuolo et al. (2007) to the 
corresponding astrocyte datasets, this has been done in an observational fashion. It 
would therefore be interesting to conduct a more thorough bioinformatic analysis of 
the two datasets to extract correlating networks of genes between the two cell-types. 
Corresponding efforts should also be made to compare the human SOD1-ALS motor 
neurons analysed by Kirby et al. (2011) to the human SOD1-ALS astrocytes used here. 
Such comparisons could be a powerful way of elucidating non-cell autonomous effects 
of astrocytes upon neurons and also of the signals that motor neurons are sending 
towards astrocytes. Finally, these datasets can be compared to a human C9ORF72-ALS 
astrocyte dataset already generated at the Sheffield Institute of Translation 
Neuroscience (SITraN) to elucidate sub-type specific mechanisms of disease. 
7.5.1 ALS should be considered in the context of age 
This study, in combination with data from pre-symptomatic SOD1G93A astrocytes 
(Ferraiuolo et al., 2011a), has provided an image of astrocyte behaviour at multiple 
different time-points of the disease process (Figure 7.1). However, due to the 
aggressive nature of the disease course in SOD1G93A mice, the late-stage of the disease 
was at 120 days, which is still relatively early in the mouse life. This ignores one of the 
main risk factors for ALS: age. The risk of ALS increases up to a peak risk at ~75 years 
old (Al-Chalabi and Hardiman, 2013), therefore it is important in future studies that the 
interactions of age and disease be studied more carefully. This could be done by using 
a more slowly-progressing mouse model such as the SOD1G85R model (Bruijn et al., 
1997). Alternatively, a rapidly ageing mouse model, such as senescence accelerated 
mice (SAMs) (Shimada and Hasegawa-Ishii, 2011) could be crossed with an ALS mouse 
to study the interaction between the rapid ageing process and the ALS disease process. 
SAMs even come in different strains possessing different aspects of ageing, such as 
osteoporosis in SAMP6 mice or reduction of neuronal dendritic arbour and synaptic 
number in SAMP10 mice, meaning interaction of ALS with different aspects of ageing 
could be investigated. It would be interesting to study what processes in ageing lead to 
increased susceptibility to ALS, as this might reveal opportunities for preventative 
therapies. With reference to astrocytes, it is known that the expression of different 
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cellular markers changes with age in mice, suggesting that astrocytes undergo a 
phenotypic shift during the ageing process (Rodriguez et al., 2014). Also of note, the 
expression of inflammatory genes increases with age (Berchtold et al., 2008), and given 
the neuro-inflammation observed in ALS this could have an intensifying effect. 
Specifically with regard to the BBB disruption seen in the human microarray study, 
ageing by itself is seen to lead to BBB breakdown (Marques et al., 2013). This provides 
a further reason why BBB disruption did not show up in the late-stage mouse array 
study. In addition, perhaps the in vitro BBB model used in the human study, in which 
fibroblasts were de-differentiated to a neural precursor cell, removed some of the age-
related behaviour that these astrocytes might exhibit in vivo. In addition these cells 
were co-cultured with neonatal endothelia, and therefore this BBB model may not 
have accurately modelled the ageing neurovascular unit. Perhaps in vivo during ALS 
the combination of ageing and disrupted astrocyte-endothelial signalling leads to a 
greater disruption of the BBB than can be studied in vitro. Such questions could be 
answered if mouse models were created that combined the two phenomena. 
At the end of a chromatid there is a stretch of non-coding DNA nucleotides known as a 
telomere, which protects the coding-DNA from damage. During replication, telomeres 
are not fully replicated and so become shortened with each cell division (Harley et al., 
1990). Upon loss of telomere caps in human fibroblasts by expression of a truncated 
dominant negative form of the telomere capping factor TRF2, DNA damage occurs 
which leads to cell-cycle arrest and cellular senescence (d'Adda di Fagagna et al., 
2003). Oxidative stress is shown to damage telomeres leading to senescence (Kurz et 
al., 2004), which is particularly interesting given that SOD1-ALS contains an oxidative 
stress component. In addition, lysosomal content of cells increases with senescence 
(Kurz et al., 2000), which is seen in the SOD1G93A astrocytes at symptomatic and late-
stage disease in the current study. Finally, TGFβ secretion induces cell senescence in 
nearby cells in a paracrine fashion (Hubackova et al., 2012), and is increased in the 
human SOD1-ALS astrocytes in the current study. Therefore the following hypothesis 
has been formed about SOD1-ALS: SOD1-ALS is a disease caused by an accelerated 
ageing mechanism. Astrocytes would play a major part in this paradigm through 
oxidative stress of nearby cells, TGFβ secretion and an accelerated loss of supportive 
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function. Recently, telomere length has been found to be shorter in the leukocytes of 
sALS patients versus controls (De Felice et al., 2014). Future studies should investigate 
whether markers of ageing are increased in CNS cell-types in SOD1-ALS relative to 
controls and whether interference with key features of ageing astrocytes might prove 
beneficial. 
7.6 Concluding remarks  
In conclusion, this thesis presents the first study in which the gene expression of 
astrocytes has been mapped throughout the disease course in the SOD1G93A mouse 
model of ALS. This has identified common themes amongst the three disease stages, 
but also characteristics that change with disease progression. This could have powerful 
consequences upon future therapies, as the stage of disease will need to be taken into 
account so that the correct treatment is used for the phenotype of the cells being 
treated. In addition, astrocytes have been shown to interact with endothelia in human 
SOD1-ALS, possibly leading to BBB disruption. Lastly, a new hypothesis that SOD1-ALS 
contains an accelerated ageing mechanism has been formed, in which astrocytes could 
play a major part. These data highlight the myriad roles that astrocytes can play in 
disease and provide further evidence of ALS as a disease of more than just motor 
neurons. 
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